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CHAPTER I  
 
INTRODUCTION 
 
Overview 
The past decade has ushered in an era of personalized medicine with the growing ability to 
customize care and optimize patient response to therapy. In 2010, a New England Journal of 
Medicine Perspective shared a vision of “steering patients to the right drug at the right dose at 
the right time” (Hamburg & Collins 2010). Improved understanding of genetic and molecular 
characteristics of cancerous cells has opened the door to creating selective biological vehicles 
designed to bind specifically to malignant tissue. Often, these tissue-specific agents can be paired 
with radioactive elements to create powerful diagnostic and therapeutic tools. Cell-targeting 
carriers labeled with photon-emitting radionuclides enable disease diagnosis and localization 
with nuclear medicine imaging techniques. Likewise, tumor-targeting agents can concentrate 
cytotoxic radiation in diseased tissue through the emission of short-ranged charged particles. 
The use of radiopharmaceuticals as a systemic treatment modality has a unique 
distinguishing feature compared to other methods of personalized treatment, such as 
chemotherapy, that target diseased tissue through molecular mechanisms. The capability of 
imaging radionuclides permits quantification of patient pharmacokinetics for use in treatment 
planning to optimize the delivered dose. This high level of individualized dosage differs greatly 
from chemotherapy that is administered based on body weight and a maximum tolerated dose 
determined in clinical trial. Thus, cancer treatment using targeted radionuclides offers two levels 
of personalized medicine. The “right drug” is achieved by selecting the appropriate 
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radiopharmaceutical based on the specificity of cancer cell biology and receptor expression. The 
“right dose” is administered by individualized treatment planning through the use of a tracer 
amount for pre-assessment of uptake and retention. 
Despite the prospect for highly individualized therapy using targeted radionuclides, 
dosimetry is not routinely employed as a clinical tool to optimize patient treatment. Instead, most 
patients receive similar amounts of radioactivity based on the maximum activity to deliver 
sufficient dose to diseased tissue while avoiding toxicity in normal tissue determined in clinical 
trials. The conservative “fixed activity” approach to treatment results in only a small percentage 
of patients receiving optimal care and largely under-dosing the majority of those treated. This is 
in stark contrast compared to other radiation oncology therapies that routinely employ 
individualize treatment plans. For external beam therapy, the radiation energy is selected based 
on tumor depth for maximum dose deposition and the beam is contoured to specifically match 
the shape of the tumor. Furthermore, real-time patient imaging during treatment permits dynamic 
planning as tumor shape and position change.  
The lack of an established, widely adopted treatment planning method in targeted 
radionuclide therapy is due, in part, to the complexity of the procedure and also because early 
attempts failed to demonstrate a relationship between delivered dose and patient outcome. 
However, recent developments offer improved quantification of pharmacokinetics and new 
approaches to modeling radiobiological response. These advances offer promise for patient-
specific dosimetry and the ability to relate dose to important biological end points, namely tumor 
control and toxicity. Many efforts have been made towards making individualized treatment a 
clinical reality. These include the development of accurate techniques for activity quantification 
and applications capable of performing complex dose calculations by Monte Carlo (MC) 
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simulation and other voxel-level dose estimation methods. One facet of patient-specific 
dosimetry that requires attention is the ability to quickly and accurately define patient anatomy 
necessary for modeling tissue composition in MC simulations and calculating absorbed doses to 
organ and tumor volumes. The current methods include using a standard anthropomorphic 
phantom that may differ drastically from the actual patient morphology or the creation of a 
patient-specific model from imaging data through time-consuming manual and semi-automatic 
segmentation. A different approach to modeling patient anatomy that is both accurate and fast 
must be established in order for patient-specific dosimetry to be clinically efficient. 
Objectives 
The goal of the research described in this dissertation is to explore the use of deformable 
anthropomorphic phantoms as a way to produce patient-specific anatomical models for dose 
assessment in targeted radionuclide therapy. This research was motivated by the development of 
standard phantoms consisting of Non-Uniform Rational B-Splines (NURBS) surfaces (Segars 
et al. 2001, Segars et al. 2010). The phantom organs are easily transformed by manipulating the 
control points that define their shape to generate models with varying anatomy. This research 
project is of interest because the quick adaption of an existing body model to an individual 
patient, without having to perform time-consuming image-based manual segmentation of 
anatomical structures, allows patient-specific dosimetry to be completed in a time-frame more 
favorable with the clinical treatment schedule. It is our aim that the development of a real-time 
application to create patient models for organ and tumor identification in conjunction with 3D 
dose estimates through MC simulation will facilitate the effort to replace current “fixed activity” 
treatment protocols with personalized plans.  
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This work is divided into two separate parts. The first project focuses on the development 
and validation of a voxel-based Monte Carlo simulation application for dose calculation. Our 
objective is to construct a dosimetry code that is capable of modeling the decay scheme of any 
type of radionuclide in order to be widely-applicable to current and future therapies. The second 
part is to develop an application to create patient-specific 3D models from deformable NURBS 
phantoms. These models will serve as input to the dosimetry application to accurately define 
patient anatomy and designate tissue properties in the simulation. We will then test the 
effectiveness of this method by performing patient-specific dosimetry in clinical studies. The 
specific aims are defined as followed: 
1. To develop and validate a 3D dosimetry application using the Geant4 Monte Carlo 
toolkit. Geant4 provides an easy and comprehensive method of modeling any radionuclide 
through the use of the built-in radioactive decay module. The toolkit is also very flexible for 
defining the simulation geometry and scoring energy transferred to tissue at the voxel level. The 
dosimetry application produces 3D dose distributions that show tumor dose non-uniformities and 
permit radiobiological modeling.  
2. To develop a patient-specific deformable model application including a Graphical 
User Interface (GUI) to display the NURBS surfaces and patient Computed Tomography 
(CT) images for easy user manipulation. The deformable model application has the ability to 
perform many different manipulations of the NURBS surfaces that define the phantom body 
contour and internal organs. These methods include simple transformations such as translation, 
rotation, and scaling as well as more complex algorithms for vector field transforms and surface 
reshaping to fit a set of points. These algorithms provide the user with a robust toolkit for easily 
creating a patient-specific model using a standard phantom as a template. 
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3. To assess accuracy of patient models created by modification of a NURBS-based 
standard phantom by comparing them to manually segmented image data. The accuracy of 
the patient models is assessed using a variety of different metrics, including comparing total 
organ volumes, calculating a distance map between organs, and computing the percent volume 
overlap of a specific organ. The data used in this study represents patients of different sizes, 
genders, and ages, which provides a measure of the robustness and flexibility of the deformable 
models program.  
4. To demonstrate the utility of the dosimetry and deformable models techniques 
through application to clinical studies. The use of data from patient studies will establish the 
clinical viability of our dosimetry application and serve as an additional validation of our 3D 
dose assessment by comparing results to an established dosimetry method. 
Outline 
The work of this dissertation is organized into five major chapters. Chapter 2 begins with an 
introduction to clinical treatment applications using open source radioactivity. The chapter 
continues with a discussion of the methodology of determining dose from internal emitters and 
the role of anthropomorphic phantoms in internal dosimetry. The chapter concludes with a 
summary of research findings that serve as motivation for performing patient-specific dosimetry 
for these patients and advancements made in the field. 
Chapter 3 focuses on the creation and validation of the Voxel-based Internal Dosimetry 
Application (VIDA), a toolkit using MC simulation and a custom exponential fitting tool to 
perform patient-specific imaged-based dosimetry. The material in this chapter is an extension of 
an article, “VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using 
Geant4”, published in Cancer Biotherapy and Radiopharmaceuticals (Kost et al. 2015). 
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Chapter 4 summarizes the method for creating a patient-specific anatomical model based on 
a standard NURBS phantom. The introduction section includes background on NURBS surfaces 
and the advantages for using them as a primitive for realistic modeling of the human body. The 
chapter continues with a discussion the Phantom Morphus software application and its 
algorithms that deform the NURBS surfaces of a reference phantom to match patient anatomy 
from CT imaging. The chapter also contains a study using high-resolution CT imaging that 
investigated the accuracy of identifying volumes of interest from the individualized NURBS 
model compared to manual and semiautomatic segmentation methods and an analysis of the 
impact of using deformable models for 3D dose assessment with VIDA. 
Chapter 5 describes a clinical application of patient-specific dosimetry using the methods 
defined in Chapters 3 and 4. Individualized dosimetry was performed for two non-Hodgkin 
lymphoma (NHL) patients treated with a 
131
I-labeled monoclonal antibody using multiple hybrid 
Single Photon Emission Computed Tomography (SPECT)/CT scans. The chapter presents results 
of voxel-level doses using organ maps created from conventional segmentation methods and 
from a patient-specific NURBS model. The chapter also includes a comparison of the results 
with doses calculated with another 3D dosimetry code that serve as additional validation of 
VIDA. 
Finally, Chapter 6 summarizes the results of the previous chapters and discusses the clinical 
value of using patient-specific NURBS phantoms for dose assessment and treatment planning for 
radionuclide therapy. This chapter also outlines future advancements that can be made to expand 
the method for deforming NURBS phantoms into individualized models and the additional steps 
required to release the created dosimetry application to the broader nuclear medicine community. 
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CHAPTER II  
 
BACKGROUND 
 
Patient-specific dosimetry involves determining the amount, rate and distribution of internal 
doses from ionizing radiation based on individual anatomy and biokinetics. Internal dose 
assessment is not performed using direct measurements, but instead on theoretical calculations 
dependent on a number of principles, including fundamental physical processes of radioactivity 
and particle interactions, the biological response to radiation, pharmacokinetics of treatment 
agents, nuclear medicine imaging techniques for the detection and treatment disease, and 
computational simulation of dose deposition in models of the human body. 
This chapter is organized into five sections. The first section contains an overview of clinical 
aspects of radionuclide therapy. The following section provides a brief overview of the two main 
approaches to internal dosimetry, namely fixed-geometry and 3D imaged-based methods. The 
third section discusses the historical development of anthropomorphic phantoms. These 
phantoms define anatomical structures and their tissue compositions necessary for dose 
calculations. The remaining sections focus on the motivation for performing patient-specific dose 
calculations and a summary of research developments that make personalized dosimetry viable 
in the clinical setting. For readers unfamiliar with basic physical concepts relating to nuclear 
medicine and internal dosimetry such as radioactive decay, particle interactions and absorbed 
dose, a review is included in Appendix A. The methodology behind nuclear medicine imaging 
techniques, including SPECT and Positron Emission Tomography (PET), is summarized in 
Appendix B. A brief overview of MC methods is found in Appendix C. 
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Clinical Overview of Targeted Radionuclide Therapy 
Targeted radionuclide therapy
1
 (TRT) employs locally, regionally or generally administered 
unsealed radioactive sources to selectively deliver radiation to tumors or target organs. 
Successful treatment depends on the sufficient uptake and prolonged retention of the 
radiopharmaceutical in the target region while limiting the toxicity to normal tissue. This 
specificity is achieved by selecting appropriate radionuclides that emit short range electrons 
through beta decay. As a cancer treatment, TRT combines the advantage of target selectivity 
from external beam therapy and the benefit of whole body treatment similar to chemotherapy. 
The systemic nature of TRT makes it an attractive treatment choice by simultaneously targeting 
primary tumor sites and distant metastatic disease that may be undetectable by diagnostic 
imaging.  
Historically, TRT has exploited the human body’s natural tendency for concentrating 
specific elements in certain tissue, such as iodine uptake in the thyroid or phosphate and 
strontium accumulation in bone. Many efforts have focused on developing a so called “magic 
bullet” with a mechanism for specific binding to target tissue. Progress has been made in the 
form of radioimmunotherapy (RIT) by combining immunotherapeutic and radiation mechanisms 
to target cancer cells that express specific antigens. Peptide receptor radionuclide therapy 
(PRRT) aims to target tumor cells with bioengineered radiopeptides that bind to specific 
membrane receptors with high affinity. Selective internal radionuclide therapy (SIRT) employs 
radioactive microspheres that are selectively delivered to tumors in the liver via the hepatic 
                                               
1 The use of unsealed radioactive source in cancer treatment has historically been known by a variety of names 
including isotope treatment, targeted radionuclide therapy, radiopharmaceutical therapy, internal radionuclide 
therapy, and more recently, molecular radiotherapy. There may be some nuances in each of these names, e.g. 
molecular radiotherapy is used to describe treatment with radioactive agents that interact with molecular sites and 
receptors. However, the vast majority of literature in this field employs the term targeted radionuclide therapy. 
Hence, in this work, any treatment relating to unsealed radiopharmaceuticals will be referred to as such. 
9 
 
artery. Table II.1 summarizes common therapeutic radionuclides including their decay properties 
and treatment indications. Comprehensive reviews of TRT for cancer treatment can be found in 
the literature (e.g. Brans et al. 2007, Ersahin et al. 2011). 
Table II.1: Common radionuclides and treatment indications. Mean energies are reported for beta 
decay emissions. 
Radionuclide Half Life 
Key Emissions 
Treatments 
γ (keV) β- (MeV) 
131
I 8.02 d 365 0.192 Benign and malignant thyroid disorders  
B-cell non-Hodgkin lymphoma 
Neuroendocrine tumors 
90
Y 64.1 h — 0.934 B-cell non-Hodgkin lymphoma 
Neuroendocrine tumors 
Microspheres for liver metastases 
111
In 2.80 d 171 
245 
— Neuroendocrine tumors 
Imaging analogue for 
90
Y 
177
Lu 6.73 d 208 0.149 Neuroendocrine tumors 
89
Sr 50.5 d — 0.585 Bone metastases 
153
Sm
 
46.5 h 103 0.640 
0.710 
0.810 
Bone metastases 
166
Ho 26.8 h 80.6 0.651 
0.694 
Multiple myeloma 
Microspheres for liver-related disease 
188
Re 16.9 h 155 0.795 Microspheres for hepatocellular 
carcinoma, colorectal cancer and 
neuroendocrine tumors 
 
Radioiodine Therapy 
The first application of targeted radionuclide therapy began in the 1940’s with the use of 
radioiodine (
131
I) for the treatment of hyperthyroidism (Graves’ disease) and malignant thyroid 
conditions (Frantz et al. 1944, Hertz & Roberts 1946). Radioactive iodine is a natural choice for 
treatment due to its tendency to concentrate in thyroid tissue, with minimal or no adverse effects 
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on normal tissue including radiosensitive red marrow. Radioiodine decays with both beta and 
gamma emissions. The primary beta emission has an approximate maximum range in tissue of 2 
mm, concentrating large doses to the thyroid. The detectable photon provides a method for 
characterizing the activity uptake in diseased and normal tissue.  
Neuroendocrine tumors such as neuroblastoma and phaeochromocytoma can also be treated 
with radioiodine. Neuroblastoma is extremely radiosensitive and external beam therapy provides 
good control of local disease; however dose constraints of total body irradiation limit its success 
for systemic treatment. Targeted therapy with radioiodinated metaiodobenzylguanidine (
131
I-
mIBG) exploits the active uptake pathway for noradrenaline expressed in tumors of neural crest 
origin (Meller 1997). 
131
I-mIBG therapy is most effective in treating small metastases due to the 
limited penetration range of 
131
I beta particles, and is mostly utilized as a secondary treatment for 
patients with metastatic disease that exhibit poor response to chemotherapy. Other studies 
(Mukherjee et al. 2001, Prvulovich et al. 1998) have shown that 
131
I-mIBG also has potential to 
treat metastatic carcinoid tumors in patients with advanced disease. 
Bone-Seeking Therapies 
Bone-seeking radionuclides offer an alternative palliative treatment for painful bone 
metastases. Skeletal tissue is a common place for metastatic disease with the majority of cases 
linked to prostate or breast cancer (Ersahin et al. 2011). External beam radiotherapy has been 
successful in treating both localized tumor sites and widely disseminated disease using half or 
total body irradiation. However, this approach can be very toxic and TRT may be equally 
effective but better tolerated (Chatal & Hoefnagel 1999). The most frequently used radionuclides 
for metastatic bone disease are 
89
Sr
 
and 
153
Sm. 
89
Sr is a pure beta emitter and acts as calcium 
analogue with preferential uptake in the skeleton. Treatment with 
153
Sm is administered as a 
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molecule linked to a calcium salt (EDTMP) that has an affinity for skeletal tissue exhibiting 
increased bone turnover (Bauman et al. 2005). A novel bone-targeted therapy using the alpha 
emitter 
223
Ra has been approved to treat metastatic castration-resistant prostate cancer. 
223
Ra 
dichloride mimics calcium in the body and binds to areas of increased bone turnover as found in 
metastases. Energetic alpha particles have a very short range in tissue (< 100 μm), resulting in 
high linear energy transfer and cytotoxic DNA double-strand breaks (Bruland et al. 2006). The 
short range of alpha particles also offers the advantage of reduced dose to bone marrow 
compared to beta particles emitted by 
89
Sr
 
and 
153
Sm. 
Bone-seeking radiopharmaceuticals can also be used to treat multiple myeloma as a 
preparative regimen to high-dose chemotherapy and peripheral blood stem cell transplantation 
(Breitz et al. 2006). Tetraphosphonate molecules radiolabeled with 
166
Ho localize on bone 
surfaces. 
166
Ho is primarily a beta emitter with maximum energy of 1.85 MeV corresponding to a 
pathlength of 8.7 mm in soft tissue and 3.8 mm in bone, concentrating radiation in the skeleton 
while sparing normal tissue. The short physical half live of 
166
Ho (27 hours) permits delivery of 
high-dose chemotherapy and reinfusion of preserved peripheral blood stem cells within 6–10 
days, offering an advantage over high-dose therapy with longer lived radionuclides such as 
131
I 
or 
90
Y (Breitz et al. 2006). 
Radioimmunotherapy  
RIT for B-cell NHL is an attractive treatment option because lymphoma cells are inherently 
sensitive to radiation. Moreover, approximately 90 percent of patients with follicular lymphoma 
present with disseminated disease and cannot be cured with external-beam radiotherapy to 
localized sites (Kaminski et al. 2005). Several radiolabeled monoclonal antibodies have been 
developed that selectively bind to CD20 antigen on the surface of normal and malignant B cells 
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(see Figure II.1). The CD20 antigen is an ideal target for immunotherapy of B-cell NHL because 
it is expressed in most cases of NHL and on normal B lymphocytes but not on stem cells, plasma 
cells, or nonhematopoietic tissues (Witzig et al. 2002). When labeled with 
131
I (
131
I-tositumomab, 
drug name Bexxar) or 
90
Y (
90
Y ibritumomab tiuxetan, drug name Zevalin) and administered 
systemically, the antibody can deliver cytotoxic doses of radiation to all sites of disseminated 
disease. 
90
Y-labeled antibodies may provide better response when treating bulky, poorly 
vascularized tumors and tumors with heterogeneous antigen expression. 
90
Y delivers higher beta 
energy radiation than 
131
I (2.3 MeV vs. 0.6 MeV) and can penetrate soft tissue up to 5 mm 
compared to the 1 mm range of 
131
I. Furthermore, as a nearly pure beta-emitter, 
90
Y ibritumomab 
tiuxetan can be administered on an outpatient basis without the need for patient isolation due to 
radiation safety concerns (Witzig et al. 2002). 
 
Figure II.1: Radiolabeled anti-CD20 monoclonal antibody targets cancerous NHL B-cells. 
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Peptide Receptor Radionuclide Therapy  
PRRT has been investigated by several clinical trials as targeted treatment for 
neuroendocrine tumors. Therapy with radiopeptide exploits the overexpression of somatostatin 
receptors in a restricted number of tumor types. Somatostatin analogues were first labeled with 
111
In in the form of 
111
In-DTPA
0
-octreotide and used mainly for tumor imaging. Initial treatment 
studies were performed by administering high activities of this radiopeptide with encouraging 
results (Valkema et al. 2002). However, 
111
In is not an ideal radionuclide for PRRT because of 
its small particle range and therefore short tissue penetration (Kwekkeboom et al. 2003). Another 
radiolabeled somatostatin analogue 
90
Y-DOTA
0
-Tyr
3
-octreotide was developed specifically for 
radiotherapy. As a pure beta emitter, 
90
Y offers the advantage of delivering targeted dose to 
receptor-positive tissue while sparing normal tissue. However, the use of 
90
Y must be paired with 
an imaging tracer counterpart for dosimetry calculations. The imaging tracer may not be 
chemically identical but must yield comparable radiopharmacokinetics and biodistribution. 
Recently a new analogue DOTA
0
-Tyr
3
-octreotate has been developed with a ninefold higher 
affinity for the somatostatin receptor subtype 2 as compared with DOTA
0
-Tyr
3
-octreotide 
(Kwekkeboom et al. 2003). Octreotate has been labeled with the beta and gamma-emitting 
radionuclide 
177
Lu for therapy, offering several benefits over 
111
In and 
90
Y labeled radiopeptides. 
Studies indicated that the concentration of 
177
Lu-octreotate was comparable to 
111
In-octreotide 
for normal tissue but was up to fourfold higher for tumors. The increased tumor uptake obtained 
with 
177
Lu-octreotate results in higher absorbed doses to malignant cells with similar doses to 
organs at risk for toxicity. 
177
Lu-labeled peptides offer the advantage of having a lower 
maximum beta energy (0.49 MeV) and penetration range (2 mm) compared to 
90
Y which may be 
important when targeting small tumors. 
177
Lu also decays via gamma emission allowing for 
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activity quantification and dosimetry calculations using the therapeutic agent. A clinical 
investigation of the use of 
177
Lu-DOTA
0
-Tyr
3
-octreotate for treatment of inoperable, 
somatostatin receptor positive gastro-entero-pancreatic neuroendocrine tumors is currently 
ongoing. 
Selective Internal Radiation Therapy 
Radiolabeled microspheres selectively treat primary or metastatic liver tumors through 
infusion into the hepatic artery. This treatment, known as SIRT, is based on observation that liver 
tumors larger than 2 cm in diameter receive more than 80% of their blood supply from the 
hepatic artery (Giammarile et al. 2011). Conversely, normal liver parenchyma receives the 
majority of its blood from the portal vein. The use of microspheres provides a highly specific 
treatment with upwards of 90% of the radioactivity localized in the liver. 
90
Y embedded in resin or glass microspheres is the most popular radionuclide for SIRT. Fat 
droplets of iodized esters of poppy seed oil are also used by substituting stable iodine (
127
I) with 
radioiodine. Microspheres containing 
166
Ho and 
188
Re are also used. With the exception of 
90
Y, 
these radionuclides emit gamma photons that can be imaged, permitting patient-specific dose 
estimates from SPECT (Burrill et al. 2011, Shcherbinin et al. 2014). 
Internal Dose Calculations 
Internal dose assessment requires the determination of the total energy absorbed per unit 
mass of tissue for volumes of interest (i.e. whole organs, tumors, or voxels). The absorbed dose 
from internal sources is dependent on the type of particles emitted, their energies, and the tissues 
with which they interact. Absorbed dose calculations also require measurement of the uptake and 
retention of radiopharmaceuticals administered to the patient. Two approaches to internal dose 
calculations, fixed-geometry and 3D image-based dosimetry, are described in this section. 
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Fixed-Geometry Dosimetry 
The conventional method for estimating absorbed dose from internal sources was 
standardized in the 1960’s by the Medical Internal Radiation Dose (MIRD) committee of the 
Society of Nuclear Medicine (Loevinger & Berman 1976, Loevinger et al. 1988). The MIRD 
approach divides the dose calculation into the physical factors that determine the fractional 
energy of emitted particles absorbed by the tissue and the biodistribution of activity in the body. 
The method calculates the radiation dose to a target organ from radioactivity in one or more 
source organs based on absorbed fractions derived from a fixed geometry using a standard 
anatomical model.  
Fixed geometry dosimetry using the MIRD schema separates the components of absorbed 
dose in a target volume into three distinct quantities. The dose is dependent on (1) the amount of 
activity as a function of time in the source organ, (2) the energy emitted per disintegration in the 
source organ and (3) the fraction of emitted energy absorbed by the target organ. 
Cumulated Activity 
Dose delivered by a source organ to a target organ is a function of the amount of activity in 
the source organ and the time the activity is present. The product of these values characterizes 
the number of total disintegrations in a source volume. This quantity, called cumulated activity 
(Ãs), is determined by integrating the time-activity curve for a particular source organ (see 
equation II.1). 
 ?̃?𝑠 = ∫ 𝐴𝑠(𝑡)𝑑𝑡
∞
0
= 𝐴0∫ 𝑓𝑠(𝑡)𝑑𝑡
∞
0
 II.1 
The number of disintegrations in the source region depends on both the spatial and temporal 
distribution of the radionuclide within the body. Clinically, this value is obtained from a time-
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sequence of nuclear medicine scans after injection of the radiopharmaceutical. These data are 
modeled as a sum of exponential functions (see equation II.2), with effective clearance rates 
dependent on the physical and biological half-lives of the source. 
 𝑓𝑠(𝑡) = 𝑓1𝑒
−(𝜆1+𝜆𝑝)𝑡 + 𝑓2𝑒
−(𝜆2+𝜆𝑝)𝑡 +⋯+ 𝑓𝑁𝑒
−(𝜆𝑁+𝜆𝑝)𝑡 II.2 
The terms f1…fN represent the fractional uptake of administered activity within the first to 
N
th
 components of the source region, λ1… λN represent the biological clearance rates for the 
corresponding N components and λp is the physical decay constant of the radioactive source 
(Stabin 2008b). 
Energy Emitted Per Disintegration 
The mean energy emitted per disintegration (Δi), also known as the equilibrium absorbed 
dose constant, is a product of both the average energy of the i
th 
emission and the relative 
frequency of the emission per decay. The equilibrium absorbed dose constant is a physical 
property of the radionuclide and may be obtained from standard dosimetry tables. For sources 
that have multiple emissions in their decay scheme, the total mean energy per transition must be 
calculated as the sum of the mean energies for all particles emitted. The product of the mean 
energy emitted per disintegration and the cumulated activity serves as an expression for the total 
energy emitted by the i
th 
emission for the time radioactivity is present in the source organ. 
Absorbed Fraction 
The final quantity in the MIRD schema for absorbed dose calculations is the absorbed 
fraction (ϕi). The absorbed fraction accounts for the emission type and particle energy as well as 
the geometrical factors relating the source to the target tissue. This value represents fraction of 
the total energy emitted in a source region that is absorbed in the target organ. The target 
receiving the energy can be the region emitting the radiation (self-dose) or other organs 
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throughout the body (cross-organ dose). For non-penetrating radiation (see Figure II.2a), most 
energy is deposited in the source resulting in an absorbed fraction near or equal to unity. In 
human tissue, beta particles, electrons and photons with energies below 20 keV are classified as 
‘non-penetrating’ radiation (Loevinger et al. 1988). Radiation that deposits significant energy to 
organs other than the source is labeled as ‘penetrating’ and will have absorbed fractions between 
zero and one (see Figure II.2b). Because the absorbed fraction is dependent on the geometry 
relating the source region to the target region and the absorption properties of the tissues 
comprising the body, values are often obtained from MC calculations that model particle 
transport and energy deposition between source and target regions. 
 
Figure II.2: Non-penetrating and penetrating radiation in human tissue. 
Absorbed Dose 
Expressing the total absorbed energy in terms of cumulated activity (?̃?𝑠), energy emitted per 
disintegration (Δi), and absorbed fraction (ϕi ) results in an equation describing the dose 
contribution to a target region from a source given by: 
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 𝐷𝑇→𝑆 =
𝑘?̃?𝑆 × ∑ Δ𝑖 ∙ 𝜙𝑖𝑖
𝑚𝑇
 II.3 
In equation II.3, mT is the mass of the target region and k denotes a constant of proportionality. It 
can be reduced to a simple product of two values, the cumulated activity in a source region (?̃?𝑠) 
and the absorbed dose to a target region per unit cumulated activity in the source, called the S-
value (S) (see equation II.4). 
 𝐷𝑇←𝑆 = ?̃?𝑆 × 𝑆 II.4 
By comparing equation II.3 to equation II.4, the S-value takes the following form: 
 𝑆𝑇←𝑆 =
𝑘 ∑ Δ𝑖 ∙ 𝜙𝑖𝑖
𝑚𝑇
 II.5 
The total absorbed dose to the target (DT) is simply the sum of the dose contributions to the 
target from all the different source regions (see equation II.6). 
 𝐷𝑇 =∑?̃?𝑆𝑖 × 𝑆𝑇←𝑆𝑖
𝑖
 II.6 
The virtue of a fixed-geometry approach to dosimetry is that it reduces complex 
computations to a simple formula. S-values can be pre-calculated for a specific anatomic model 
and tabulated for each radionuclide, considerably reducing the required numerical work. The 
methodology is easily extended to clinical use in the form of software applications, requiring the 
user to only provide the cumulated activity for each source organ exhibiting uptake. The 
RAdiation Dose Assessment Resource (RADAR) Task Group of the Society of Nuclear 
Medicine has created large databases of S-values, calling them instead Dose Factors (DFs) 
(Stabin & Siegel 2003). 
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Three-Dimensional Image-based Dosimetry  
For many years, dose calculations were limited by available computational resources and 
were generated using fixed geometry with standard phantoms. The approximations of applying a 
fixed geometry approach to patient dosimetry could result in errors up to 100% (Flux et al. 
2006). While these uncertainties are acceptable for estimating stochastic risks from diagnostic 
nuclear medicine studies and radiation protection surveys, they are inadequate for therapeutic 
dosimetry when tumor control and toxicity are imperative. Several other limitations arise when 
fixed-geometry dosimetry is employed in TRT. Fixed-geometry dosimetry has no way to 
incorporate the spatial distribution of activity and only reports mean organ doses from uniform 
activity sources. Moreover, the use of pre-determined specific absorbed fractions (SAFs), the 
absorbed fraction scaled by the mass of the target volume, from standard phantoms lacks a 
suitable method for quantifying dose to and from tumor volumes, which is the primary goal of 
dosimetry for disease-targeting radioactive agents. Finally, radiobiological models, used to 
assess the biologic effects indicative of toxicity and tumor control from non-uniform absorbed 
doses, require knowledge of the spatial dose distribution to tumors and sensitive tissue. In the 
last few decades, significant efforts have been made towards patient-specific image-based 
approaches to dosimetry. Technological advancements in tomographic image, the availability of 
greater computational resources, and enhanced simulation capabilities have overcome many of 
the limitations to performing voxel-based 3D dosimetry. 
Image-based dosimetry requires the following essential components. 3D anatomical images 
enable the definition of volumes of interest (organs and tumor) and provide tissue density 
information. Time-sequential voxel-based activity distributions describe the radiopharmaceutical 
kinetics permit the calculation of total absorbed dose. Lastly, a computational method for dose 
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calculation in the patient-specific model, such as MC simulation, is necessary. A detailed 
discussion of each of these elements is provided below. 
Anatomical Model 
The application of absorbed fractions to patient anatomy that greatly differs from a standard 
phantom causes a large amount of uncertainty in dose estimates using the MIRD schema. 
Incorporating a patient-specific anatomical model helps to reduce the error in the dose 
calculation. Patient anatomy provides accurate information about organ sizes and densities and 
permits tumor localization. Suitable image modalities for obtaining anatomical data include CT 
and magnetic resonance imaging (MRI), as both yield high contrast and high resolution 3D 
images. Image segmentation techniques, both automatic and manual, are used to define source 
and target region of interests (ROIs). 
Radiopharmaceutical Kinetics 
Personalized dose estimates require a quantitative measurement of the biodistribution of the 
radionuclide based on the uptake, retention and clearance rates of different organs. Once the 
source regions are identified from anatomic imaging, the distribution of the radiopharmaceutical 
in the body can be determined by sequential quantitative imaging methods such as SPECT or 
PET. At the present time, most therapeutic radionuclides do not emit positrons, making SPECT 
more applicable for activity quantification. However, there have been several studies 
investigating the use of PET-based imaging analogues in 3D dosimetry (Hobbs et al. 2009, 
Sgouros et al. 2011, Sgouros et al. 2004).  
The selection of optimal time points for sampling is an important factor in activity 
quantification. The temporal sampling is related to the effective half-life of the 
radiopharmaceutical and applying inappropriate sampling points may have a significant effect on 
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the accuracy of the cumulated activity measurements. Insufficient sampling of tissue activity at 
times just after administration results in an overestimation of the area under the time-activity 
curve. If long-term retention is neglected from insufficient sampling at times long after 
administration, the cumulated activity will be underestimated (Siegel et al. 1999). Imaging after 
administering a therapeutic level of activity may be postponed due to the dead time of the 
camera. A short but finite amount of time is required to process a recorded event and proceeding 
events may be lost or incorrectly positioned during this time. At high levels of activity, these 
losses may be substantial, requiring either a delay of imaging, dead-time correction or both. 
When the imaging tracer differs from the therapeutic one, it is necessary to correlate the 
behavior of the imaging and the therapeutic radiopharmaceutical. For chemically different 
imaging tracers, as is the case when using a gamma-emitting image surrogate to predict the 
therapeutic response from beta emitters such as 
90
Y, it is assumed that the similar physical and 
biological half-lives of the two agents yield comparable in vivo pharmacokinetics and 
biodistributions (Brans et al. 2007). Half-life differences must be accounted for when 
determining the cumulated activity for the therapeutic agent by multiplying the measured activity 
at a given time point by the ratio between the decay constants for the therapeutic agent and 
imaging tracer. 
The tomographic quality of SPECT permits modeling radiopharmaceutical kinetics for each 
voxel in the source region. Ideally, several SPECT studies are taken over time and registered to 
each other and the anatomical image (CT). The integration of voxel activities yields a 3D 
representation of cumulated activity. If multiple 3D images are unavailable, a hybrid planar/3D 
method of pharmacokinetic analysis is possible. The 3D cumulated activity is derived from a 
single SPECT scan by assuming a static spatial distribution for the region of interest and 
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applying average kinetics over the whole volume from the planar images. Values obtained based 
on average kinetics using the hybrid method may under- or over-estimate voxel-level doses by 
more than 50% compared to estimates made from time-sequenced 3D data (Sgouros et al. 2004). 
It is important to note that the acquisition and reconstruction methods for diagnostic SPECT 
imaging may not be optimal for activity quantification for patient-specific 3D imaged-based 
dosimetry. A review article by Frey et al. (Frey) summarizes aspects of the imaging process that 
affect the reliability of quantitative measurements. Factors that degrade the image during 
acquisition include attenuation and scatter in the patient, increased septal penetration in the 
collimator due to higher energy gamma emissions associated with therapeutic radionuclide, and 
the intrinsic sensitivity of the detector to the emitted photon energies. Reconstruction of 
projection images using iterative statistical algorithms such as ordered-subsets expectation-
maximization (OSEM) compensates for attenuation, scatter, collimator–detector response and 
partial volume effects, and generally yields more accurate quantitative data (He et al. 2005). In 
addition, quantitative methods require a conversion of image counts to a physical activity value. 
For planar imaging, this may be a simple counts-to-activity conversion factor that includes both 
the imaging system sensitivity as well as an approximate correction for source thickness (He & 
Frey 2006). However, voxel-level activity cannot be obtained from multiplication of a spatially 
invariant conversion factor without compensation for physical image degrading effects such as 
attenuation and scatter during reconstruction. The current guidelines for best practices in 
quantitative SPECT imaging for dosimetry are summarized in MIRD Pamphlet 23 (Dewaraja 
et al. 2012). 
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Absorbed Dose Calculations 
Unlike absorbed dose estimates using the MIRD schema, image-based dosimetry does not 
rely on pre-determined SAFs from reference phantoms to relate the cumulated activity in a 
source to the dose deposition in a target. Therefore a method must be employed to model particle 
transport and energy deposition using patient anatomy and the biodistribution of the 
radionuclide. The spatial distribution of absorbed dose is determined by one of several methods 
including assuming complete, local absorption of short-range electrons, the application of voxel 
S values, dose-point kernel convolution, or direct calculation from MC simulation (Dewaraja 
et al. 2012). 
The simplest approach is to assume local energy absorption of all electron and beta 
emissions within the same voxel as the decay. This method is fast as it only requires a rescaling 
of the activity distribution based on the energy spectrum and abundances for the radionuclide. It 
is best suited for pure-beta emitters (i.e. 
90
Y) and may limit accuracy in the absorbed dose 
estimates for radionuclides with significant gamma emissions (i.e. 
131
I) that deposit energy far 
from their source (Ljungberg & Sjögreen-Gleisner 2011). 
Voxel level S value calculations provide another simple technique for determining spatially 
variant dose rates without having to perform patient-specific MC simulations. This method 
applies the MIRD schema to a target voxel using S values for nearby source voxels (see equation 
II.7) (Bolch et al. 1999). 
 𝐷𝑣𝑜𝑥𝑒𝑙 𝑇 =∑?̃?𝑣𝑜𝑥𝑒𝑙 𝑆𝑖 × 𝑆𝑣𝑜𝑥𝑒𝑙 𝑇←𝑣𝑜𝑥𝑒𝑙 𝑆𝑖
𝑁
𝑖
 II.7 
Computation of voxel S values assumes the source and target voxels are contained within an 
infinite homogeneous medium. Therefore, voxel S value method offers accurate dosimetry for 
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anatomic regions of uniform density tissue but does not support tissue inhomogeneity. In 
addition, S values are specific to voxel dimensions. S values must be generated for each set of 
tissue type, voxel dimension, and photon or electron energy. Efforts have been made to tabulate 
S values for different voxel dimensions and radionuclides (Lanconelli et al. 2012) and create 
methods to rescale S values to arbitrary voxel sizes (Fernández et al. 2013) in order to make 
voxel S values a reliable and fast approach to dosimetric calculations. 
The dose kernel convolution method (see Figure II.3) involves convolving the spatial 
activity distribution with a medium-specific radionuclide dose kernel. The dose kernel is defined 
as the absorbed dose per decay at a radial distance (r) from the source, assuming an infinite, 
homogeneous medium. Monte Carlo simulation is used to sample initial photon energies from 
the radionuclide decay scheme, generate the particle in a random direction, and score its energy 
deposition at a distance from the point source. 
 
Figure II.3: Dose kernel convolution using both anatomical and functional image information to 
produce a dose map. The CT image on the left provides tissue density information. The center 
image represents the distribution of activity which is convolved with the dose kernel. The image 
on the right is the resulting dose distribution (Tsougos et al. 2010). 
Dose kernels are simple to implement and calculation times are not prohibitively long 
especially if carried out in the Fourier domain. However, the dose kernel method has two major 
shortcomings. First, photon dose kernels do not model dose deposition due to electrons. This 
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limitation may be mitigated by assuming the electron dose is deposited within the voxel 
containing the activity. Second, modeling tissue inhomogeneity is difficult because dose kernels 
are generated assuming an infinite, homogeneous medium. Tissue density corrections can be 
applied using an energy loss factor derived from the specific material dose kernel such as water 
(soft tissue), bone or air (Loudos et al. 2009), but contain significant inherent uncertainties. 
Direct patient-specific dose calculations are possible with the use of MC codes that simulate 
the transport of radiated particles and record energy deposits in complex geometries and for 
heterogeneous media. A personalized simulation is performed based on the patient geometry, 
radionuclide type, and activity concentration. Three-dimensional dose information is determined 
by discretizing the patient body into a voxelized phantom with a different material and activity 
assigned to each voxel. Common MC computer codes suited for internal dosimetry calculations 
include Geometry and Tracking (Geant4) (Agostinelli et al. 2003, Allison et al. 2006), Monte 
Carlo N-Particle (MCNP) (Sweezy et al. 2003) and Electron-Gamma Shower (EGS) (Hirayama 
et al. 2005). These codes have been developed over many years by teams of experts. Some have 
unique advantages (e.g. Geant4's visualization tools are superior to those provided with a 
standard MCNP or EGS installation), but all have undergone significant validation to provide 
reliable results for most particle energies and geometries. 
Monte Carlo methods for dose calculations are known to be the most accurate; however 
there are some limitations. MC simulations are computationally rigorous, requiring considerable 
computing resources, and may exceed time constraints for clinical dosimetry. Furthermore, dose 
estimates from MC methods must be validated. The inherent flexibility in generic MC packages 
may cause large variability in results. Inconsistencies in particle transport and interaction models 
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and cross-section data and variances in patient anatomy and overall simulation geometry may 
contribute to these differences. 
Many of the above techniques are applied to activity distributions at a moment in time after 
administration of the radionuclide. Therefore, the result is a 3D map of the dose rate at the time 
of image acquisition. In order to determine the total absorbed dose, 3D dose rate maps must be 
calculated using sequential SPECT or PET scans, co-registered and integrated voxel-by-voxel. 
Analysis of 3D Absorbed Dose 
Fixed-geometry dosimetry is limited to reporting mean doses to tumor and organs. In reality, 
tissues often manifest a heterogeneous distribution of activity, and thus dose during treatment. 
Results of 3D imaging-based calculations can be expressed as the mean or range of absorbed 
doses for a delineated volume or as a Dose-Volume Histogram (DVH) (see Figure II.4). DVHs 
are valuable for comparing organs doses from TRT to standard constraints used by conventional 
methods such as external beam therapy. Tumor isodose curves overlaid on anatomical images 
indicate the conformality of treatment. Performing these analyses from a pre-therapy tracer study 
allows optimization of the dose delivered to malignant tissue while avoiding possible toxicity 
during treatment. 
Evidence indicates that deterministic biological effects including tumor response and normal 
tissue toxicity are not well predicted by the mean absorbed dose and may be significantly 
influenced by the spatial and temporal dependence of the dose rate (Flynn et al. 2003, 
O’Donoghue 1999). Radiobiological modeling of the 3D absorbed dose distribution may help to 
correlate patient outcome with delivered dose by taking into account these dependencies. 
Converting the spatially-variant dose distribution into the equivalent uniform dose (EUD) results 
in a single dose value that would yield a similar biological response similar. The EUD may 
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indicate the likelihood that the magnitude and spatial distribution of the absorbed dose is 
sufficient for tumor kill. Likewise, the biologically effective dose (BED) is an adjustment to the 
physical dose to yield the expected biological effect if it were delivered at a reference dose rate. 
The BED may provide a metric of how the temporal dependence of dose rate influences response 
and its relationship to tumor control and normal tissue toxicity. 
 
Figure II.4: Dose-volume histograms for metastatic thyroid carcinoma tumors treated with 
131
I 
(Sgouros et al. 2004). 
Use of Anthropomorphic Phantoms in Internal Dosimetry 
The goal of internal dosimetry is to assess the biological response of healthy and diseased 
tissue from a spatially and temporally-dependent distribution of radioactivity in the body. 
Because it is impractical to measure dose from energy imparted to organs using in vivo physical 
detectors, dosimetry methods must rely on realistic computational phantoms to model human 
anatomy. Anatomical models contain body surface definition, organ geometry and volume, and 
tissue densities and compositions. Computational phantoms are classified into one of three main 
categories including stylized phantoms, voxel phantoms, and boundary representation phantoms. 
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This section summarizes each type of anthropomorphic phantom and some of their specific 
applications in internal dosimetry. A comprehensive review of anatomical models used in 
radiation dosimetry has been compiled previously (Xu & Eckerman 2010). 
Stylized Computational Phantoms 
The first type of model developed for dosimetry represented the human body using 
geometric shapes. These mathematical, or stylized, phantoms were based on the idea of a 
standard or “reference man”, characterizing the average size and weight of adults in primarily 
Western populations. The use of simple mathematical equations for organ and body definition 
minimized computational time for simulation of particle interactions from internal emissions. 
The original stylized reference phantom, described below, was created for the specific purpose of 
calculating SAFs for internal dose assessment using the MIRD schema (Snyder et al. 1969). 
Other standard models were also developed to include pediatric ages (Cristy 1980), separate 
male and female adults (Kramer et al. 1982), and even pregnant females at different stages of 
gestation (Stabin et al. 1995). 
Snyder-Fisher Phantom 
In the 1960’s, Snyder and Fisher developed the first stylized computational phantom for 
internal dose assessment (Snyder et al. 1969). The hermaphroditic phantom, shown in Figure 
II.5, consisted of a cylindrical base representing the combined torso, abdomen, and arms. An 
elliptical cylinder modeled the head and neck and legs were approximated as a truncated 
elliptical cone. The dimensions of the phantom were chosen to represent an average-sized man, 
modified later in accordance with the International Commission on Radiological Protection 
(ICRP) Reference Man (ICRP 1975). Originally, the entire phantom consisted of homogeneous 
soft tissue but was later updated to include the skeleton and lungs. 
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Figure II.5: Schematic representation of the stylized Snyder-Fisher phantom (Snyder et al. 1978). 
The MIRD schema was first implemented using S values from the Snyder-Fisher phantom, 
with results published in MIRD Pamphlet No. 5 (Snyder et al. 1969) and a subsequent revision 
(Snyder et al. 1978). SAFs for 12 photon energies were estimated by MC simulation with 
uniform distribution in the source organ. Photon transport was tracked with the assumption of 
local energy deposition from photon-electron interactions. 
Cristy-Eckerman “Family” Phantom Series  
The limitations of scaling the reference adult Snyder-Fisher phantom for use in age-
dependent applications motivated the creation of individualized pediatric phantoms. In the 
1970’s, Cristy and Eckerman developed a series of phantoms of adults and children ages 
newborn, 1, 5, 10 and 15 years (Cristy 1980). These phantoms were constructed in the same 
fashion as the existing Snyder-Fisher adult phantom to form a developmentally consistent 
family. The pediatric phantoms have relatively larger heads; their legs are relatively smaller, and 
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the trunk is relatively thicker than the adult models. The positioning of the organs varies from 
birth to adulthood based on age-dependent anatomical data (see Figure II.6). Reference phantom 
and organ masses were based on ICRP Publication 23 (ICRP 1975). 
Additional improvements on the Snyder-Fisher phantom were made to the Cristy-Eckerman 
series. Female breast tissue was added to the 15-year-old phantom to represent an adult female. 
Breasts were also added to the hermaphroditic adult phantom to represent a larger than average 
female. Modifications to individual organs include an updated heart model and changes to the 
lungs to incorporate different sizes of the right and left lungs. Changes were made to the density 
and composition for soft tissue, lung, and skeletal tissues with different skeletal and soft tissue 
compositions for the newborn phantom. 
-  
Figure II.6: Pediatric phantom series developed by Cristy and Eckerman. This series models the 
anatomy of newborn, 1-year, 5-year, 10-year, 15-year, and adult patients (Cristy & Eckerman 
1987). 
Specific absorbed fractions were calculated for these phantoms using MC simulations of 
photons similar to the method used by Snyder et al. (Cristy & Eckerman 1987). Cristy and 
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Eckerman also implemented a new technique to estimate the dose to red bone marrow in the 
vicinity of higher density bone where electronic equilibrium is not established. The MC transport 
code was adapted to determine the photon fluence in the skeletal volume from the target and 
calculate the dose to the active marrow using the linear attenuation coefficients for those photon 
energies. 
Voxel Computational Phantoms 
Stylized computational phantoms, although simple to implement in MC simulations, lack 
sufficient complexity to realistically model the details of the human body. Computer technology 
advancements in the 1980’s, including the development of tomographic imaging (CT, MRI) to 
visualize internal anatomy, no longer restricted models of the human body to idealized geometric 
shapes. Instead, imaging data could be used to create a highly accurate representation of a human 
body comprised of small 3D volume elements (voxels). These phantoms, named voxel 
computational models, consist of an identification number for each voxel corresponding to a 
tissue type or organ and the specification of its density and elemental composition. 
Many research groups have created voxel-based phantoms (e.g. Williams et al. 1986, Xu 
et al. 2000, Zankl et al. 1988, Zubal et al. 1994). These models consist of either the whole body 
or a partial body region such as head-torso or trunk only. Below is a summary of two of the more 
widely used types of voxel models, the VIP-Man and the GSF family of voxel phantoms. 
VIP-Man  
One of the first whole-body, high resolution voxel computational models, the Visible 
Photographic Man or VIP-Man (see Figure II.7), was developed at the Rensselaer Polytechnic 
Institute (Xu et al. 2000). The phantom was created using high resolution images (voxel size of 
0.33 × 0.33 × 1 mm) of a 38-year-old male from the Visible Human Project that includes 3D 
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representations of the normal male and female human bodies from CT, MRI and color 
photography. Organs were identified on the color images and segmented using mainly manual 
techniques. Because the phantom is a representation of an actual person, the mass of the whole 
body and individual organs are not reference values. The VIP-Man is 103 kg, containing more 
than 30 kg of fat compared to the reference male of 70 kg. 
Monte Carlo simulations of the VIP-Man voxel phantom were used to calculate SAF’s for 
internal electron emitters (Chao & Xu 2001). Voxels were assigned tissue compositions and 
densities using recommended values in ICRP Publication 23 (ICRP 1975). These calculations 
were the first for charged particles and were significant for internal dosimetry. They permitted 
the investigation of subtle dose variations in anatomical structures due to incomplete energy 
absorption of the emitted electrons that were traditionally assumed to be non-penetrating. The 
results showed that over 20% of the energy can escape even large organ volumes at electron 
energies above 1 MeV. 
 
Figure II.7: 3D view of the internal organs of the VIP-Man voxel based model (Xu et al. 2000). 
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GSF Voxel Computational Phantom Family 
A long-term research effort by the National Research Center for Environment and Health 
(GSF) in Neuherberg, Germany resulted in a series of voxel-based phantoms (Petoussi-Henss 
et al. 2002, Veit et al. 1989, Zankl et al. 1988, Zankl & Wittmann 2001). These phantoms were 
created using high-resolution CT images of individuals over a wide range of ages. The subjects 
included both adult males (Frank, Golem, Otoko) and females (Donna and Helga) of various 
physical builds and an infant and child (7 years).  
Organ segmentation was accomplished using a variety of methods. For high contrast 
volumes such as the lung and skeleton, structures were defined based on specified ranges of 
Hounsfield Units (HUs) in the images. For most of the other organs, the mask created from 
image thresholds required additional processing to sharpen boundaries and reduce unwanted 
artifacts. In these cases, a number of image processing software packages were used to perform 
morphological operations (i.e. dilation or erosion based on shape parameters) and manual 
segmentation to clearly define the organ volumes. Due to the difficulty to visually delineate bone 
marrow on a CT image, the amount of red marrow was determined for each bone voxel using 
linear interpolation of the HU between values for pure cortical bone and pure red marrow. Tissue 
densities and compositions were compiled from multiple sources (Cristy 1980, Kramer et al. 
1982). 
The GSF voxel phantom series was used to determine the influence of body size and varying 
organ masses on absorbed doses (Petoussi-Henss et al. 2002). SAFs for internal photon emitters 
were calculated from MC simulation and compared to values from stylized MIRD-type 
phantoms. The SAFs to the voxel phantoms were found to be different (greater or lower) by 
factors of up to 1000 for low photon energies and small organs. Organ doses were comparable if 
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the masses were similar between phantoms, but deviated up to a factor of three in some cases. 
Changes in body morphology including organ size, shape and location contributed to these 
differences, confirming the limitations inherent in stylized geometrical phantoms. 
Boundary Representation Phantoms 
Voxel computational phantoms are anatomically realistic but, because they are created from 
patient images, represent an individual and not a reference man, woman or child. Moreover, 
voxel models may not correctly define the thickness of anatomical structures (i.e. skin or 
stomach and intestinal walls) because it is not possible to segment volumes smaller the resolution 
of the image. In the early 2000’s, efforts began to create “deformable” human models from 
boundary representation (BREP) techniques, which can be manipulated to fit particular organ 
shapes and used to simulate time-dependent body motions. BREP modeling, initially created for 
computer-aided design, delineates solid volumes using a bounding surface consisting of a set of a 
connected faces (or patches). Most BREP phantoms consist of organs and body contours 
constructed from NURBS, a precise mathematical representation of a surface defined by a set of 
control points. These surfaces can be scaled and translated via affine transformations, making 
phantoms constructed from NURBS easily manipulated to replicate the size and shape of a 
specific patient. 
Segars created the first BREP anthropomorphic phantom, the NURBS-based Cardiac Torso 
(NCAT) phantom, which incorporated dynamic modeling of the cardiac and respiratory cycles 
(Segars et al. 1999, Segars et al. 2001a, Segars et al. 2001). Since then, many other NURBS 
phantoms have been developed, including a series of adult and pediatric models at ICRP 
Publication 89 reference ages (Stabin et al. 2012), adult and pediatric phantoms of various ages, 
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sizes and statures (Johnson et al. 2009, Marine et al. 2010) and moderately and severely obese 
adults (Clark et al. 2010). 
NCAT/XCAT Phantom 
As mentioned above, the NCAT phantom (Segars et al. 2001) (see Figure II.8a) was the first 
BREP phantom developed. The phantom was constructed using manually-segmented CT images 
from the Visible Human Project. Segmented structures were converted to polygon meshes that 
were then fit with cubic NURBS surfaces. A time-dependent phantom was created to model the 
cardiac cycle using 4-dimensional (4D) tagged MRI data and respiratory motion based on 
respiratory-gated CT. The NCAT phantom consists of approximately 100 structures, limited to 
the torso region of the body. A later update, the extended cardiac-torso (XCAT) phantom (see 
Figure II.8b), contains thousands of anatomical structures including detailed modeling of the 
brain, nervous and vascular systems (Segars et al. 2010). The original XCAT phantoms were 
scaled to match body and organ volumes for a 50
th
 percentile adult male and female defined in 
ICRP Publication 89 (Valentin 2002). The XCAT series has been further expanded to include a 
number of models representing adults and pediatrics at various ages and sizes (Norris et al. 2014, 
Norris et al. 2014a, Segars et al. 2013). 
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Figure II.8: Boundary representation models constructed from NURBS for organ and body 
surface definition, (a) NCAT and (b) XCAT phantom. 
The NCAT/XCAT phantoms have been used in various applications related to internal 
dosimetry. Quantitative SPECT reconstruction methods have been evaluated using simulated 
projection data from the phantoms (He et al. 2009, He et al. 2005). The impact of 3D volume of 
interest definition on activity quantification using simulated planar and SPECT imaging was 
investigated by randomly moving control points to the nearest neighbor voxel to deform the 
original organ volumes (He & Frey 2010). In this same study, the effect of misregistration of 
sequential SPECT images on time-activity in organs was assessed by shifting the simulated 
images of the NCAT phantom by up to ± 1 voxel in each direction. 
RADAR Reference Adult and Pediatric Phantom Series 
In 2012, a new generation of NURBS-based reference phantoms was created at Vanderbilt 
University to update photon- and electron-SAFs originally derived from stylized models (Stabin 
et al. 2012). The phantom series includes male and female adults, pediatric ages for both sexes 
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and the pregnant woman. They were based on the original NCAT adult phantom (Segars et al. 
2001) with modifications of the organ, body, and fetal masses using ICRP Publication 89 
recommended values (ICRP 2002). 
Changes in the SAFs in the NURBS reference phantoms were observed, but in most cases 
were small. Some cross-organ contributions from photons were found to increase due to organ 
proximity in the NURBS phantoms being much more realistic. Moreover, electron SAFs were 
explicitly modeled using MC simulation and non-negligible contributions were found for organs 
in direct contact (e.g. lung/liver and kidneys/adrenals) due to beta energy deposited in the first 
few millimeters of the boundary. 
Motivation for Patient-Specific Dosimetry 
In contrast with radiotherapy using external sources, patient-specific dose calculations for 
internal emitters are not routinely employed in clinical practice. Typical TRT treatments are 
based on administering a fixed activity to all patients. The aim is to deliver sufficient dose to the 
tumor while limiting toxicity to healthy tissue determined by the maximum tolerated dose in 
clinical trial. The fixed-activity approach is well established for treating thyroid disorders with 
radioactive iodine that has a large therapeutic window (the difference in dose levels between 
tumor and normal tissues). However this method is ill-suited for other forms of therapy including 
RIT and PRRT that have lower tumor-to-normal tissue dose ratios. If a fixed-activity is 
employed, patients are almost always given low amounts of the radionuclide in order to avoid 
harmful effects to normal tissue. Because there is significant variability in the biokinetics of 
radiopharmaceuticals in different patients and because the administered activity is based on the 
maximum tolerated dose of a patient population, only a small fraction of patients receive optimal 
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care. Although this method spares the normal tissue, it may result in incomplete tumor response 
and possible relapse (Stabin 2008c). 
Pre-therapy dosimetry calculations using fixed-geometry methods can be performed to 
assess normal tissue toxicity; however, these measurements are not without significant errors. 
The largest uncertainties stem from applying phantom-related parameters such as SAFs and 
target organ mass to individuals that vary from the median represented by the model. Absorbed 
dose estimates based on standard phantoms may have uncertainties of a factor of two or greater. 
Patient-specific dosimetry can reduce the uncertainty in dose estimates to ±10-20% when data 
acquisition, analysis, and measurement of individual organ volumes are optimized (Stabin 
2008c). 
The most significant obstacle to employing patient-specific dose assessment for clinical 
treatment planning is the lack of data indicating a tumor dose-response correlation. Although 
studies attempting to correlate dose to treatment efficacy and patient survival have been 
conducted, the investigation of dose-effect relationships in TRT has never been the focus of a 
large multi-center clinical trial (Strigari et al. 2014). The limited number of statistically 
significant correlations between delivered dose and patient outcomes combined with the lack of a 
standardized method for performing dosimetry has made clinicians hesitant to adopt an 
individualized approach to treatment. 
Despite the skepticism from the clinical community, significant research findings over the 
past decade indicate the necessity of patient-specific dosimetry, as summarized in a review 
article by Strigari et al. (Strigari). Studies indicate that better outcomes are achieved when 
dosimetry is performed for 
131
I treatments (e.g. Flux et al. 2010, Lassmann et al. 2010). In the 
case of thyroid therapy with radioiodine, the use of activity-based criteria results in over-dosing 
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the majority of patients (Jönsson & Mattsson 2004). A similar comparison was performed for 
treatment of B-cell lymphoma using 
131
I-tositumomab (Brans et al. 2007). It was determined that 
administering activity calculated per kilogram body weight resulted in 50% of patients being 
either over- or under-dosed by 10% or more and 16% of patients by 25% or more compared to 
therapeutic activity calculated on the basis of a diagnostic pre-therapy tracer study. Furthermore, 
Dewajara et al. (Dewaraja) investigated the relationship between tumor dose and patient 
outcomes in 
131
I RIT for lymphoma with the inclusion of radiobiological modeling and found 
clear separation of progression-free survival curves at a threshold of 2 Gy. Dosimetric studies for 
PRRT have largely focused on renal toxicity as a limiting factor in treatment. Barone et al. 
(Barone) determined that nephrotoxicity was dose-dependent for neuroendocrine tumors treated 
with 
90
Y-DOTATOC when including patient-specific parameters such as kidney volume and 
dose rate. Likewise, a comprehensive study of 200 patients treated with 
177
Lu-octreotate using 
the standard protocol of 7.4 GBq per cycle concluded that over 50% of patients could tolerate 
more than the typical four cycles without reaching the kidney dose limit of 23 Gy (Sandström 
et al. 2013). These results indicate that determining both the administered activity per cycle and 
the number of cycles given to each patient is essential to tumor control and toxicity as the 
majority of patients receiving fixed activity amounts die from lack of control of their disease. 
Patient-specific dosimetry was performed in a Phase II clinical study of the safety and response 
of high-risk osteosarcoma tumors to high dose of 
153
Sm-EDTMP as a follow up treatment to the 
standard low-dose administered activity (Senthamizhchelvan et al. 2012). It was determined 
from post-therapy dosimetry for both the low- and high-dose treatments that absorbed tumor 
doses over 21 Gy or EUD greater than 6 Gy led to a reduction of tumor size and stable disease. 
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In summary, evidence suggests that individualized dosimetry offers four major advantages 
over current fixed-activity treatments: 
 The minimum effective and maximum tolerated absorbed doses are determined for 
each individual patient, which allow for optimized treatment and improved 
outcomes.  
 Normal organ toxicity is predicted from pre-therapy dosimetry, preventing 
deleterious side-effects from treatment.  
 3D image-based dosimetry permits radiobiological modeling that accounts for 
varying dose rates and non-uniformity, which is suggested as an improved metric for 
determining tumor dose-response relationships.  
 And lastly, dose-response results of different patients can be compared and 
correlated to outcome. 
Advancements in Patient-Specific Internal Dosimetry 
Over the years, great strides towards patient-specific dosimetry have been made. These 
developments aim to provide clinical techniques for optimized personal treatment planning and 
dose assessment in TRT. Efforts have focused on methods for quantitative imaging, simulation 
applications for dose calculations, and patient outcome prediction with radiobiological modeling 
and analysis of tumor dose-response. This section provides a brief summary of the research that 
has advanced the field of patient-specific dosimetry in TRT. The discussion is not an exhaustive 
review of all research found in the literature, but instead highlights major accomplishments. 
Quantitative Imaging 
The ability to accurately quantify 3D voxel activity at each imaging time point directly 
influences the reliability of dosimetry calculations for TRT. Research efforts have focused on the 
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development and validation of custom image reconstruction algorithms due to the lack of 
commercially available systems supporting quantitative SPECT. Other groups have investigated 
the use of PET imaging surrogates to estimate activity distributions for non-positron emitting 
therapeutic radionuclides. This section presents an overview of current capabilities for activity 
quantification and the results of recent studies aimed to evaluate their efficacy.  
Table II.2 summarizes research studies on quantitative SPECT, including details about the 
reconstruction algorithm and validation methods. Most of these quantitative reconstruction 
methods employ OSEM algorithms that optimize using a different subset of the projections in 
each iterative update. Attenuation correction (AC) and compensation for the collimator-detector 
response (CDR) is performed by including attenuation factors and the depth-dependent CDR in 
the system model matrix. Image-degrading photons from Compton scattering are compensated 
using methods for scatter correction (SC) including triple-energy-window (TEW)-based scatter 
estimation and sophisticated models such as effective scatter source estimation (ESSE). In some 
cases, partial-volume correction (PVC) is applied to small volumes to recover count spill-out. 
Each method requires a camera sensitivity calibration factor that converts reconstructed counts to 
absolute activity derived from experimental measurement of known activity quantities.  
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Table II.2: SPECT reconstruction algorithms for quantitative imaging 
Reference Radionuc. Reconstruction Method Validation Quantification Error 
(Ljungberg et al. 
2002) 
131
I OSEM, CDR, EESE SC, CT-
based AC 
Zubal voxel phantom, SIMIND-
simulated projection images 
9% (total phantom) 
2-54% (most organs) 
(Koral et al. 2005) 
131
I OSEM, CDR, CT-derived AC, 
energy window-based SC, PVC 
Physical lung phantom with central 
100 ml uniform sphere & no bkg. 
5.2-7.3% 
(Dewaraja et al. 
2005) 
131
I OSEM, CDR, CT-based AC, 
TEW SC, no post-filtering 
Zubal voxel phantom with added 
spherical tumor volumes, SIMIND-
simulated projection images 
<7% (organs and spheres 
16-56 ml) 
37% (7 ml sphere) 
(He et al. 2005) 
 
 
(He et al. 2009) 
111
In OSEM, CDR, CT-based AC, 
EESE SC, PVC 
Physical torso phantom with 
uniform spheres, lung, heart, liver 
and bkg. Activity 
Voxelixed NCAT phantom 
population (7 total) 
2-12 % (8-23 ml spheres) 
 
 
1-9% (organ averages) 
(Shcherbinin et al. 
2008) 
(Shcherbinin et al. 
2012) 
111
In, 
131
I 
 
177
Lu 
OSEM, CDR, CT-derived AC, 
analytic photon distribution SC 
Physical thorax phantom with 32 ml 
uniform cylinders & no bkg. 
Physical phantom with 70 ml 
uniform cylinder & no bkg. 
3-5% (32 ml cylinders) 
 
<2% (70 ml cylinder) 
(Dewaraja et al. 
2010a) 
131
I OSEM, CDR, CT-derived AC, 
energy window–based SC 
Physical phantom with 4-95 ml 
uniform spheres & bkg. activity 
<17% (8-95 ml spheres) 
31% (4 ml sphere) 
(Ljungberg & 
Sjögreen-Gleisner 
2011) 
111
In, 
131
I, 
177
Lu 
OSEM, CDR, density AC, 
ESSE SC 
Voxelized XCAT phantom with 
added spherical tumor volumes in 
liver, SIMIND-simulated projection 
images 
<9% (spheres, no bkg.) 
<38% (18-61 ml spheres, 
liver bkg.) 
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In vivo evaluation of quantitative reconstruction algorithms is difficult and therefore 
quantitative accuracy is typically established from either experimental measurements using 
physical phantoms or image simulation studies. Physical phantom measurements represent the 
true imaging capabilities of the clinical system, but often have simplified geometries with 
spherical, uniform sources. Therefore, simulation of image acquisition using voxel-based 
anthropomorphic phantoms with known activity uptake provides a method to determine 
quantitative accuracy in patient geometries. The simulation application SIMIND (Simulation of 
IMaging In Nuclear Detectors) (Ljungberg & Strand 1989) was developed to model all aspects of 
a clinical SPECT camera and has been used to create simulated projection images for 
reconstruction algorithm evaluation. 
There have been several studies designed to obtain quantitative activity from SPECT images 
reconstructed by commercial software. Pereira et al. (Pereira) performed phantom studies with 
99m
Tc, 
131
I and 
111
In using different source activity concentrations in spheres or organ regions and 
variable background activities in the surrounding water. Images were reconstructed with CT-
based attenuation and window-based scatter corrections using the OSEM algorithm on the 
clinical workstation. System calibration factors for each radionuclide were applied to yield 
quantitative activities in spherical sources ranging from 1.4 to 11.5 ml. Quantification errors 
were found to vary greatly with source volume and activity concentration as well as background 
activity level. For the largest sphere (11.5 ml) the errors ranged from 2–30% for 131I and from 2–
52% for 
111
In. Another study aimed to quantify activity distributions from 
177
Lu SPECT using a 
commercially available camera system and corresponding reconstruction software (Beauregard 
et al. 2011). Images were reconstructed using a proprietary OSEM algorithm allowing for both 
attenuation and window-based scatter correction with no filtering selected. In addition to 
44 
 
applying a system calibration factor to convert counts to activity, a dead time correction factor 
for a paralyzable system based on the observed wide-spectrum count rate was used to 
compensate for dead-time losses. This method was validated with a physical phantom consisting 
of uniform activity cylinders (175 and 2500 ml) with quantitative SPECT activity deviating from 
the calibrated activity between 4 and 10%. 
Quantitative measurements of beta-emitting 
90
Y have been accomplished with SPECT 
through the detection of bremsstrahlung radiation. SPECT imaging of 
90
Y does not rely on a 
photopeak but instead detects the continuous bremsstrahlung energy spectrum with photons 
mostly below 50 keV. Image quality is typically poor due to the low camera sensitivity and non-
linearity at this energy range combined with scatter and septal penetration of high energy 
photons. Despite the poor image quality, 
90
Y bremsstrahlung SPECT has been shown to be an 
effective method for estimating tumor and liver doses and extrahepatic side effects from SIRT 
treatments with 
90
Y microspheres (Ahmadzadehfar et al. 2012, Machac et al. 2007, Walrand 
et al. 2011). 
Research efforts have also focused on using quantitative PET for patient-specific 3D 
dosimetry. Compared to SPECT, PET imaging is more sensitive by two orders of magnitude and 
is currently the most accurate clinical method for determining activity distributions. 
Quantification of PET is well established (Boellaard 2009, Pentlow et al. 1991) and image-
degrading effects, such as random coincidences, dead time, and attenuation and scatter are 
routinely corrected before reconstruction in the clinical setting. However, because the majority of 
therapeutic radionuclides are not positron emitters, the use of PET imaging analogues of the 
same radioisotope is required for 3D dosimetry. Several groups have been successful employing 
high resolution, high sensitivity PET images for TRT dosimetry including using 
124
I as an 
45 
 
analogue for 
131
I treatment of thyroid cancer (Hobbs et al. 2009, Kolbert et al. 2007, Kolbert 
et al. 1997, Sgouros et al. 2004) and 
86
Y PET for analysis of possible kidney toxicity from 
90
Y-
DOTA
0
-Tyr
3
-Octreotide in PRRT (Barone et al. 2005).  
Recently, direct assessment of the biodistribution of 
90
Y-labelled therapeutic agents using 
time-of-flight (TOF) PET has been performed for patients undergoing radioembolization of the 
liver with 
90
Y microspheres (Lhommel et al. 2009). Although 
90
Y decays via β+ emission, there 
is a minor branch to the 0+ excited state of 
90
Zr that de-excites via electric monopole transition 
with internal electron–positron pair production at an abundance of 32 emissions per one million 
decays (Greenberg & Deutsch 1956). Despite low yield and high intrinsic background noise in 
the detector, successful 
90
Y PET imaging of the liver has been achieved post-therapy with 
superior resolution and sensitivity compared to 
90
Y bremsstrahlung SPECT (Kao et al. 2013, Kao 
et al. 2011). 
Dosimetry Methods 
One major obstacle for patient-specific dosimetry in TRT is the lack of clinical applications 
capable of performing the required complex dose calculations. In response, custom software has 
been developed that implements either fixed-geometry organ-level dose assessment using 
standard phantoms or direct absorbed fraction calculations by dose kernel convolution or MC 
simulation to determine the spatial dose distribution. This section summarizes available 
dosimetry applications and highlights their use in clinical studies on patient-specific dose 
estimation. 
Since the MIRD methodology was developed, several groups have created applications for 
fixed-geometry dosimetry. MIRDOSE3 (Stabin 1996) and its successor Organ Level INternal 
Dose Assessment/EXponential Modeling (OLINDA/EXM) (Stabin et al. 2005) is the most 
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widely distributed fixed-geometry dosimetry software. The current application facilitates the 
implementation of equation II.6 and is capable of determining dose from over 1000 radionuclides 
with patient anatomy based on sex and age using the Cristy-Eckerman phantom series. The dose 
calculations are individualized by adjusting for variations between phantom and patient body and 
organ masses. OLINDA/EXM is also capable of simple tumor modeling in the form of self-dose 
to small unit density spheres of various sizes based on published absorbed fractions assuming 
uniform activity distribution (Stabin & Konijnenberg 2000). Another fixed-geometry dosimetry 
application MABDOSE (Monoclonal AntiBody DOSimEtry) (Johnson et al. 1999) was 
developed in an attempt to overcome the lack of contributing tumor dose from penetrating 
radiation from radionuclides with significant gamma emissions. MABDOSE allowed for user-
defined tumor placement in a standard male or female phantom followed by MC simulation of 
radiation transport for penetrating radiations based on cumulated activities in each source region. 
Combining the energy deposition from the gamma rays with locally deposited energy from 
charged particle radiation produced updated S values for both tumor and normal organs.  
Fixed geometry methods using standard phantoms are not optimal for dose assessment to 
individuals treated with TRT. Organ-level dosimetry applications based on standard phantoms 
including OLINDA/EXM and MABDOSE provide no information about the 3D distribution of 
dose in normal tissue and tumors as spheres with uniform activity. The lack of 3D dose 
information prevents radiobiological analysis, which may be necessary to fully assess toxicity 
and tumor control. In response to these limitations, many groups have developed 3D image-
based dosimetry applications including 3D Internal Dosimetry (3D-ID) (Kolbert et al. 1997) 
upgraded to 3D Radiobiological Dosimetry (3D-RD) (Prideaux et al. 2007), SIMDOS (Tagesson 
et al. 1996), SCMS (Yoriyaz et al. 2001), the Royal Marsden Dosimetry Package (RMDP) (Guy 
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et al. 2003), VoxelDose (Gardin et al. 2003), OEDIPE (Chiavassa et al. 2005), an adapted 
version of Dose Planning Method (DPM) (Wilderman & Dewaraja 2007), and RAYDOSE 
(Marcatili et al. 2013). These custom dosimetry codes typically use MC simulation to determine 
voxel-level dose deposition; although some employ MIRD voxel S values (RMDP, VoxelDose) 
and 3D-ID initially performed dose kernel convolution. 
3D-ID and its successor 3D-RD are the dosimetry codes with the most experience with 
clinical application. 3D-ID was used to perform patient-specific dosimetry for radioiodine 
therapy for thyroid cancer (Kolbert et al. 2007, Sgouros et al. 2004) and 
131
I radiolabeled 
antibody treatment for NHL (Sgouros et al. 2003). Patient-specific dosimetry including 
radiobiological modeling with 3D-RD was implemented for thyroid cancer (Hobbs et al. 2009, 
Prideaux et al. 2007) and 
153
Sm-EDTMP treatment for osteosarcoma (Senthamizhchelvan et al. 
2012). 
Significant progress for 3D imaged-based tumor dosimetry for 
131
I RIT has been 
accomplished using DPM. Studies were performed to measure mean tumor dose that 
incorporated measured changes in tumor volume (Dewaraja et al. 2009, Howard et al. 2011). 
Radiobiological modeling to determine tumor EUD has also been applied using 3D dose 
distributions derived from DPM in conjunction with MATLAB-based routines (Dewaraja et al. 
2014, Dewaraja et al. 2010). 
Clinical investigations of personalized dosimetry in TRT have also been completed using 
custom voxel S value calculations. Doses for ablation of thyroid remnants using 
131
I in 
differentiated thyroid cancer were determined using voxel S values generated from EGSnrc (Flux 
et al. 2010). Voxel based dosimetry in patients undergoing 
90
Y RIT using Zevalin was evaluated 
with MATLAB-based voxel S value convolution from data computed using MCNP (D’Arienzo 
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et al. 2012). Patient-specific dose distributions from microspheres labeled with
188
Re for liver 
embolization (Shcherbinin et al. 2014) and 
177
Lu PRRT for treatment of neuroendocrine tumors 
(Jackson et al. 2013) were produced through convolution of voxel S values from MC simulation 
using custom-based EGSnrc code DOSXYZnrc (Strigari et al. 2006). 
Radiobiological Modeling and Tumor Dose-Response 
The ultimate goal of patient-specific dosimetry is to correlate absorbed dose with tissue 
response. This may be tumor control and regression in the case of tumors or toxicity for 
radiosensitive organs. However, initial attempts to relate mean absorbed tumor doses to patient 
outcome were not successful, especially in the case of RIT (Sgouros et al. 2003). Studies indicate 
that deterministic biological effects including tumor response and normal tissue toxicity are not 
well predicted by the mean absorbed dose and may be significantly influenced by non-uniform 
doses and temporally changing dose rates (e.g. Barone et al. 2005, O’Donoghue 1999, Wessels 
et al. 2008). Radiobiological models that better predict desired treatment end points such as 
normal tissue complication probability and tumor control probability have been developed, but 
require knowledge of the 3D dose distribution to tissue (Sgouros & Hobbs 2014). Recent 
research has focused on identifying dosimetric and radiobiological factors that predict patient 
outcomes. These studies have mainly been retrospective in nature, evaluating tumor dose-
response relationships post treatment.  
The first patient-specific dosimetry application dedicated to radiobiological modeling 3D-
RD incorporates the BED and EUD formalisms (Prideaux et al. 2007). Since its conception, 3D-
RD has been applied to several clinical studies including radiobiological dosimetry for 
131
I 
thyroid cancer (Hobbs et al. 2009, Hobbs et al. 2013, Sgouros et al. 2011), kidney toxicity from 
PRRT (Baechler et al. 2012), and osteosarcoma tumor dosimetry with 
153
Sm-EDTMP 
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(Senthamizhchelvan 2012). The initial thyroid dosimetry studies were limited to a few patients to 
demonstrate clinical application of radiobiological methodology. However, Hobbs et al. (Hobbs) 
used 3D-RD to investigate salivary gland toxicity in 
131
I treatment of thyroid cancer where 
toxicity is observed despite measured absorbed dose values below expected thresholds. 
Retrospective dosimetry for five patients using 3D-RD was performed on serial 
124
I-PET images 
to determine if the BED of salivary glands may correlate better with toxicity and if using 3D 
voxel-based dosimetry may identify localized high absorbed dose values. Similarly, Baechler et 
al. (Baechler) proposed a treatment planning methodology using 3D-RD based on individualized 
dosimetry of kidneys with the goal of reducing renal toxicity in PRRT. The three most common 
radionuclides for PRRT (
177
Lu, 
90
Y, and 
111
In) were evaluated and the approach centered on 
maximizing the administered activity, with optimal fractionation, to limit the absorbed dose or 
the BED to the renal cortex to published constraints. 3D-RD has also been used to assess tumor-
dose response in a clinical trial for 
153
Sm-EDTMP treatment of osteosarcoma 
(Senthamizhchelvan et al. 2012). A sample of 6 patients (19 tumors) who received both low and 
high amounts of administered activity were evaluated three months post-treatment with stable 
disease correlating with absorbed doses above 21 Gy (6 Gy EUD). Likewise statistical tests 
yielded a positive correlation between both mean tumor-absorbed dose and EUD, and percent 
tumor volume reduction. 
Researchers at the University of Michigan developed a methodology to incorporate 
radiobiological modeling in patient-specific 3D dosimetry for NHL 
131
I RIT. (Amro et al. 2010). 
This model was used to evaluate the treatment response of 20 patients that participated in a 3D 
patient-specific dosimetry study (Dewaraja et al. 2010). It was determined with statistical 
significance that a EUD of 200 cGy separated the responders (both partial and complete) from 
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those with stable disease. A regression analysis study of 39 
131
I RIT patients using this model 
assessed the relationship between patient outcomes and various dosimetric values (Dewaraja 
et al. 2014). Mean tumor-absorbed dose and equivalent biologic effect showed statistically 
significant correlation with progression free disease with clear separation of response curves 
when stratified by a mean tumor-absorbed dose of 200 cGy. 
Other groups have also applied radiobiological modeling to RIT. Cicone et al. (Cicone) 
investigated dose non-uniformities in patients receiving 
90
Y RIT for treatment of NHL and their 
correlation with tumor response. BED and EUD were derived from the 3D dose distributions and 
compared with patient outcome three months after treatment. Although the study sample (6 
patients, 11 lesions) was not large enough to yield statistically significant results, complete 
response did correlate with larger tumor BED and EUD whereas patients who received low 
radiobiological doses exhibited stable or progressive disease. Hobbs et al. (Hobbs) developed a 
dosimetric method founded on radiobiologic modeling to optimize a combination therapy of both 
131
I- tositumomab and 
90
Y-ibritumomab tiuxetan for treatment of lymphoma. The treatment 
planning steps center around limiting toxicities to normal organs based BED values and 
optimizing response by maximizing the tumor BED within the established normal-organ 
constraints.  
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CHAPTER III  
 
DEVELOPMENT AND VALIDATION OF VIDA: A VOXEL-BASED DOSIMETRY 
APPLICATION FOR TARGETED RADIONUCLIDE THERAPY 
 
Introduction 
This chapter describes the development of VIDA (Voxel-based Internal Dosimetry 
Application), a 3D image-based dosimetry technique using the Geant4 MC toolkit for voxel-by-
voxel absorbed dose calculation. VIDA performs patient-specific dosimetry by coupling 3D 
anatomical data (CT) with functional images (SPECT or PET). VIDA was designed to perform 
particle transport based on the activity distribution at each time point, thus generating 
instantaneous dose rate maps. The total absorbed dose is determined by fitting the time-
sequenced voxel dose rates to exponential functions and integrating over time. The application 
consists of two main components (see Figure III.1), the Geant4 simulation code to generate 3D 
maps of voxel-level absorbed energy and a custom exponential fitting tool developed in 
MATLAB. This chapter also includes a discussion of the methods used to validate the particle 
transport and energy deposition in the MC simulation. VIDA was validated under several 
conditions including dose to uniform activity spheres and organ dose factors from various 
sources in an anthropomorphic phantom. The content presented in this chapter is an extension of 
a paper by S. D. Kost, Y. K Dewaraja, R. G. Abramson and M. G. Stabin, “VIDA: A voxel-
based dosimetry method for targeted radionuclide therapy using Geant4”, © Mary Ann Liebert, 
Inc., reprinted with permission, from (Cancer Biotherapy and Radiopharmaceuticals, vol. 30, pp. 
16-26, 2015) (Kost et al. 2015). 
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VIDA does not provide a method for quantitative SPECT image reconstruction. 
Quantitative estimation of activity from tomographic images requires attenuation and scatter 
correction as well as knowledge of the collimator-detector response that is highly system 
specific. Therefore, it is assumed that functional images used to model patient pharmacokinetics 
in VIDA are representative of quantitative activity. Moreover, VIDA does not contain a method 
to register time-sequence images. Images may be registered via external algorithms, such as the 
intensity-based registration routine in MATLAB. The incorporation of image registration in 
VIDA is an area for future development. 
 
Figure III.1: VIDA procedure flow with key components and inputs. 
Monte Carlo Simulation 
Geant4 is an open source, integrated radiation transport package that simulates many 
different particles and their interactions based on a user-specified geometry. The toolkit provides 
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a comprehensive framework for all areas of MC simulation including geometry, tracking, 
physics models, and run and event management. In addition, Geant4 features a set of random 
number generators with different sampling algorithms and random distributions (i.e. exponential, 
Gaussian, Poisson). The toolkit was designed for a wide array of applications including particle 
physics, space engineering, and medical physics. Given the broad and flexible nature of the 
toolkit, the user is required to define specific characteristics of their simulation including the 
detector geometry, materials, particles, physics processes, and primary events generation. 
The Geant4 framework is a suitable platform for performing MC simulation for TRT for 
several reasons. The built-in radioactive decay module allows for direct simulation of nearly any 
radionuclide without user specification of the decay spectra. Geant4 is supported by a large 
collaboration of researchers and includes the most accurate and up-to-date models for physical 
processes and particle interactions. Moreover, efforts relating to the validation of Geant4 have 
been extensively published and include relevant topics such as radioactive decay simulation 
(Hauf et al. 2013b) and electromagnetic processes of low energy electrons (Lechner et al. 2009). 
VIDA was developed from an existing simulation that tracked photons and electrons 
uniformly distributed in a source organ using a standard anthropomorphic phantom (Stabin et al. 
2012). The detector definition in this simulation was a parameterized (repeated) volume in each 
dimension to represent a voxelized reference phantom. Voxels were assigned a material type 
based on an integer identification number. The materials modeled included air, soft tissue, lung 
tissue and whole bone with the same density and compositions as the Cristy-Eckerman phantom 
series (Cristy & Eckerman 1987). Primary events consisted of either monoenergetic photons or 
electrons generated uniformly in the source organ that were tracked throughout the body. The 
energy deposited in the whole organ was tallied for each target region based on its identifier. 
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Using this existing simulation as a foundation, several updates and modifications were 
required for VIDA to function as a 3D patient-specific dosimetry code. First, the quantity and 
location of primary events must be based on the activity distribution in the patient. Second, 
primary events must be created with the correct particle types, energies, and abundances in the 
decay scheme of the radionuclide. Third, the energy deposited needed to be tallied at the voxel 
level, creating a 3D map of energy deposition that can be converted to a dose rate map. And 
lastly, the detector geometry and materials definitions required updating to include identification 
of multiple tumor volumes. Detailed descriptions of each part of the simulation are included in 
the following sections. 
Detector Geometry and Materials 
Detector definition in VIDA consists of a nested parameterized 3D volume, as shown in 
Figure III.2. The physical parameterized volume is defined to match the patient image array size 
and voxel dimensions. Each voxel is assigned a tissue type by pairing a specific material with the 
integer identifier for each organ contained within the 3D organ map (see appendix C). 
 
Figure III.2: Schematic drawing of a nested parameterization in Geant4. Repetitions in each 
direction are assigned a copy number. Voxels in the geometry are identified by a unique 
combination of copy numbers representing the row, column and slice position. 
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The material definitions in VIDA (Table III.1) include air for voxels surrounding the 
body contour and soft tissue, lung, cortical bone, red and yellow marrow, whole bone, and whole 
skull derived from data tabulated in International Commission on Radiation Units (ICRU) 
Publication 46 Appendix A (ICRU 1992). Patient geometry is represented by a 3D map of 
integer organ identification numbers instead assigning voxel density and composition directly 
from CT images, as done in the Geant4 DICOM application. This approach allows patient 
anatomy to be modeled by a NURBS-based deformable phantom that is digitized to a 3D organ 
map (see Chapter IV). Organ maps can also be created from conventional segmentation methods 
for delineation of organs of interest and tumor volumes on the patient CT. For multiple time 
points, segmentation of each CT can be time-consuming and tissue maps of relevant materials 
can be quickly created for simulation using density thresholds. VIDA includes several different 
material definitions for skeletal tissue. The NURBS models have cavities inside each bone so 
that cortical bone surfaces and marrow can be assigned specific materials. Similarly, if the 
skeleton is delineated by segmentation, hard bone and marrow voxels may be assigned using 
specific cortical bone thicknesses and marrow cellularity values. In the case of using density 
thresholds to generate an organ map, skeletal tissue should be assigned to whole bone. A flag in 
the data input file (see Appendix D) controls which materials are assigned to the skeleton during 
simulation. 
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Table III.1: Material definitions for VIDA MC simulation 
Material 
Density 
(g/cm
3
) 
Chemical Composition (% by mass) 
H C N O Na P S Cl K Other 
Air 1.21×10
-3
  0.01 75.5 23.2      1.3 (Ar) 
Water 1.00 11.1   88.9       
Soft Tissue
*
 1.03 10.5 25.6 2.7 60.2 0.1 0.2 0.3 0.2 0.2  
Lung Tissue
†
 0.26 10.3 10.5 3.1 74.9 0.2 0.2 0.3 0.3 0.2  
Adipose
&
 0.95 11.4 59.8 0.7 27.8 0.1  0.1 0.1   
Mammary 
Tissue
‡
 
1.06 10.2 15.8 3.7 69.8 0.1 0.1 0.2 0.1   
Whole Bone
§
 1.35 6.5 28.6 3.6 41.7 0.1 5.9 0.2 0.1 0.1 
0.1(Mg) 
13.2 (Ca) 
0.1 (Fe) 
Whole Skull
‖
 1.65 4.8 20.5 4.1 43.5 0.1 8.4 0.3   
0.2 (Mg) 
18.1 (Ca) 
Cortical 
Bone
#
 
1.92 3.4 15.5 4.2 43.5 0.1 10.3 0.3   
0.2 (Mg) 
22.5 (Ca) 
Red Marrow 1.03 10.5 41.4 3.4 43.9  0.1 0.2 0.2 0.2 0.1 (Fe) 
Yellow 
Marrow 
0.98 11.5 64.4 0.7 23.1 0.1  0.1 0.1   
*‘average soft tissue, male’ 
†‘lung, adult healthy, inflated’ 
&’adipose tissue, adult #3’ 
‡’breast-mammary gland adult #3’ 
§composite material defined using average density and elemental compositions of adult whole bones 
(excluding cranium and mandible) 
‖composite material defined using average density and elemental compositions of adult whole cranium 
and mandible 
#’skeleton-cortical bone, adult’ 
 
Particles and Physics Processes 
Geant4 has the capability to model a wide range of particles and the physics processes 
governing their interactions with matter. Each particle type is associated with a unique set of 
processes. The user can choose to apply only those processes that are relevant to their simulation 
and register them via the process manager. In the case of TRT, electromagnetic interactions for 
all decay products must be considered. The particle types registered to the simulation were 
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defined by the particle constructor of the decay physics class and include leptons, bosons, 
mesons, baryons and ions created in radioactive decay. Physics processes in VIDA include decay 
of unstable particles, radioactive decay of unstable isotopes, and standard electromagnetic 
processes such as photoelectric absorption, Compton scattering, gamma conversion, coulomb 
scattering, and bremsstrahlung. 
Geant4 also contains several options for modeling electromagnetic physics processes. 
The standard electromagnetic physics package is optimized for electron and photon interactions 
at high energies between 1 keV and 100 TeV. At low energies, atomic shell structure plays a 
significant role in particle interactions and additional electromagnetic physics processes for 
photons, electrons, hadrons, and ions have been implemented in Geant4 in order to extend the 
validity for these energies. Low energy models available in Geant4 include the Livermore and 
PENELOPE packages that make direct use of shell cross section data, providing reliable results 
for energies as low as 250 eV. This is in contrast with the standard electromagnetic processes 
that rely on parameterizations of these data. 
The physics models implemented in VIDA (Table III.2) are a modified version of the 
standard electromagnetic package. The low energy Livermore and PENELOPE models available 
for the version of Geant4 used in this work (Geant4 9.4) contain older interaction cross-section 
data and the Geant4 Low Energy Electromagnetic Physics Working Group advised against their 
use. Moreover, the standard package available for Geant4 9.4 was updated to be a coherent 
approach to the modelling of all electromagnetic interactions over both low and high energies 
(Ivanchenko et al. 2011). Options were selected to increase accuracy when tracking electrons, 
hadrons, and ions at low energies. Detailed explanations for these options follow below. 
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Table III.2: Electromagnetic processes in VIDA MC simulation. 
Particle Type EM Process Model 
Gamma 
Photoelectric Effect (G4PEEffectFluoModel) 
Compton Scattering Klein-Nishina (G4KleinNishinaModel) 
Gamma Conversion Bethe-Heitler (G4BetheHeitlerModel) 
e
‒
 and e
+
 
Multiple Scattering L. Urban (G4UrbanMscModel95) 
Ionization 
 
Möller (e
‒
e
‒
) Bhabha (e
+
e
‒
) 
(G4MollerBhabhaModel) 
Bremsstrahlung (G4eBremsstrahlungModel) 
e
+ 
e
‒ 
Annihilation (e
+ 
only) (G4eplusAnnihilation) 
 
VIDA includes a Compton scattering model that allows atomic de-excitation of the resulting 
ionized atom. The standard model for Compton scattering in Geant4 assumes the energy of the 
recoil electron is large compared to the binding energy and ignores the binding energy when 
determining the kinetic energy of the electron. This assumption becomes invalid in the low 
energy realm. The Compton scattering model used in VIDA contains Doppler broadening due to 
the non-negligible influence of atomic shell effects at low interaction energies that may result in 
interactions with non-valance electrons producing atomic shell vacancies.  
Atomic relaxation processes induced by ionization events that leave the atom in an 
excited state are activated in VIDA. These processes include fluorescence and Auger electron 
emission and make use of radiative and non-radiative transition probabilities for each sub-shell 
of each element. Characteristic x-rays and Auger electrons are produced above the same 
threshold energy as secondary electrons and bremsstrahlung gammas, defined in the simulation 
as a production cut range (set to 1 mm for electrons, positrons, and gamma rays). 
Many interaction parameters including the mean rate of energy loss below the secondary 
particle production cut, the total cross section per atom for the ejection of a secondary of energy 
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greater than the production cut and, given multiple processes providing energy loss for a given 
particle, the total continuous part of the energy loss are pre-calculated during run initialization 
and stored by Geant4 in tables for use in the simulation. By default, the standard electromagnetic 
package generates these data across the energy interval from 100 eV to 10 TeV divided into 84 
bins. In order to increase the sampling across the range of energies encountered in TRT 
dosimetry, the energy interval in VIDA was set from 10 eV to 50 MeV divided into 220 bins. 
One of the most critical parameters in MC simulation is the step size limit. The 
simulation must balance computational efficiency while also ensuring the step size is small 
enough that all relevant interaction cross sections remain approximately constant during the step 
(an assumption required to randomly sample the distance to interaction for each physics process). 
Continuous energy loss imposes an additional limit on the step size due to the energy 
dependence of interaction cross sections. Typically, tracking precision can be preserved while 
not compromising execution performance by limiting the step-size to no more than 20% of the 
stopping range. At low kinetic energies (i.e. less than 1 MeV), this limit results in step sizes that 
are too short. Geant4 imposes a lower limit on the step size, controlling the step function with 
two parameters (see Figure III.3). At high energy, the step is limited by the ratio of step size to 
stopping range (dRoverRange = 0.20) As the particle interacts and loses kinetic energy, the step 
size decreases gradually until it becomes lower than a specified cut off (finalRange). Below this 
range, the remaining distanced traveled is completed in a final step. A large portion of the energy 
imparted to tissue in TRT comes from continuous energy loss from charged particles and the 
parameter finalRange in VIDA was reduced from the default of 1.0 mm to 0.1 mm for electrons 
and positrons to ensure accurate dose deposition. 
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Figure III.3: Step size control in Geant4 with dRoverRange and finalRange. 
The multiple scattering (MSC) algorithm for charged particles accounts for changes in 
the geometrical step length due to scatterings along the step. The MSC models in Genat4 limit 
the step size based on three parameters, two of which may be modified by the user (Ivanchenko 
et al. 2010). The step size limit (L) for MSC is determined by computing the minimum of the 
following values: 
 𝐿 = min {𝐹𝑅 ∙ max(𝑅, 𝜆) , 𝐹𝑆 ∙ 𝑠, 𝐷 𝐹𝐺⁄ } III.1 
The range factor (FR) scales the maximum range computed based on the particle energy and 
inverse interaction cross sections (λ) for all possible interactions. If FR is decreased, the limit on 
step size decreases and the simulation will perform more steps. The distance to a geometrical 
boundary (D) is weighted by the geometry factor (FG) to insure a minimal number of simulation 
steps within each volume. An additional safety factor (Fs), fixed at 0.3, weights the straight 
distance between the start and end point of the step (s). The default values for MSC range factors 
(“fUseSafety”) are 0.04 for FR, and FG is ignored. The low energy electromagnetic processes 
constructor used in the VIDA employs the strictest variant for MSC step sizes 
("fUseDistanceToBoundary") setting FR to 0.04 and FG to 2.5. 
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Primary Event Generation and Scoring 
Instead of randomly placing events in the source region to create a uniform activity 
distribution, events in VIDA are generated voxel-by-voxel based on an activity map derived 
from quantitative SPECT or PET imaging. The simulation can be run to include events in the 
whole body or by selecting an organ or tumor volume as source, as specified in the input file (see 
Appendix D). Within each voxel, events are assumed to be uniformly distributed, with randomly 
selected position and direction vectors. 
VIDA employs the built-in radioactive decay module (Hauf et al. 2013a) to produce 
primary particles based on the branching ratios and decay energy of the radionuclide of interest. 
The radionuclide is defined as an ion with an atomic number and mass from the simulation input 
file. The decay library includes information on the nuclear half-life, nuclear structure of the 
parent and progeny, branching ratios, and energy of the decay structure taken from the Evaluated 
Nuclear Structure Data File (Tuli 1996) for each nuclide. For the case of nuclides that decay to 
excited isomers, the prompt de-excitation of the daughter nucleus via isomeric transition occurs 
based on photon evaporation files that include internal conversion coefficients. 
Particle interactions in Geant4 are performed “silently,” requiring the user to define a 
scorer for the detector volume(s) to extract desired information. Each scorer collects one physics 
quantity for each physical volume. VIDA employs a primitive scorer for deposited energy. 
Energy deposition due to each primary event, including secondary particles and any subsequent 
gamma emission due to de-excitation of the nucleus, is tallied for each voxel. Once all events are 
tracked, the simulation produces a map of the total energy deposited that is used to create a 3D 
dose rate map for input to VIDA’s voxel-level kinetics processing. 
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The ability to produce primary events based on the decay scheme of a radionuclide and 
perform whole field of view simulation by sampling the activity distribution in a patient from 3D 
functional image is a distinctive feature of VIDA. Other 3D dosimetry applications such as 3D-
RD (Prideaux et al. 2007) require separate simulations of decay products (i.e. electrons for β‒ and 
Auger emission or photons for gamma emission and characteristic x-rays). The energy 
deposition distributions from all decay components must then be added together, weighted by the 
transition probabilities. The Geant4 3D dosimetry code RAYDOSE (Marcatili et al. 2013) uses 
the general particle source (GPS) to access the radioactive decay module. The GPS is limited to 
generating primary particles with 2D spatial sampling and thus, each slice of the functional 
image must be run independently. RAYDOSE must then perform a post-processing summation 
of the 3D dose rate maps corresponding to each slice as the source of activity. Another Geant4 
dosimetry application for internal dosimetry GRNT (McKay 2011)
 
uses the command line 
interface to define all necessary simulation components including phantom geometry, physics 
options, simulation materials, and the radionuclide emission spectrum. Although this approach 
may offer increased flexibility, it also demands significant effort from the user to create a 
working simulation. 
3D Kinetics Processing 
Patient kinetics modeling is performed by the exponential fitting module in VIDA. This 
module (see Figure III.4) consists of a MATLAB-based GUI for curve fitting by iterative least 
squares estimation (Statistics Toolbox, Release 2012a). Non-linear regression is performed using 
the Levenberg-Marquardt nonlinear least squares algorithm. The user has a choice of fit 
functions depending on uptake kinetics and number of sequential scans. Instantaneous activity 
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uptake, resulting in exponentially decaying dose rates, can be fit to a mono-exponential or bi-
exponential function of the general form: 
?̇?(𝑡) = 𝐷1̇𝑒
−𝜆1𝑡 + 𝐷2̇𝑒
−𝜆2𝑡. 
Initial guesses for the rate components (𝐷1̇ and 𝐷2̇) are derived from the time-sequence data and 
elimination constants (λ1 and λ2) from the physical half-life of the radionuclide of interest. The 
fitting algorithm automatically detects voxels with non-instantaneous uptake (i.e. tumor) and fits 
these data to a bi-exponential including the (0, 0) point of the form: 
?̇?(𝑡) = 𝐷0̇(𝑒
−𝜆1𝑡 − 𝑒−𝜆2𝑡). 
The voxel dose is computed by integration of the fitted function based on a time interval supplied 
by the user, with a default range of zero to infinity. Non-physical clearance (e.g. increased 
activity at later time points) may arise at body and organ boundaries due to errors in image 
registration across sequential scans. The application checks for these occurrences during the fit 
routine and attempts to fit an exponential curve with this time point omitted. 
The exponential fitting tool in VIDA provides the user with several options. The user may 
choose to fit the entire body in the image field of view or select specific organs and tumors based 
on the organ map. Also, the user may specify the resolution of the resulting dose map. A scaled 
map with voxel dimensions twice as large in the transverse plane is created by fitting a voxel 
dose curve to the data in the corresponding 2×2×1 cell in the original array. This option 
decreases the overall processing time and may facilitate regression convergence when data are 
only available for a limited number of time points. 
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Figure III.4: Graphical user interface of the MATLAB-based exponential fitting tool in VIDA. 
Evaluation tools are provided by the exponential fitting module to assess the results. The 
user can plot a histogram of the coefficients of determination (R
2
) for fitted voxels. If necessary, 
voxels with R
2
 values below a user-defined threshold may be refined by re-running the 
regression using an array of different initial coefficient values to improve the fit. In addition, the 
VIDA exponential fitting module provides a three-plane viewer to evaluate the results and plot 
the raw data and fitted curve for a selected voxel (see Figure III.5).  
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Figure III.5: 3D viewer in VIDA exponential fitting tool to evaluate integrated dose map and 
voxel fits. 
VIDA was designed to generate dose rate maps at each time point and perform curve fitting 
and integration of dose at the voxel. Although this technique requires additional simulations, the 
rational for this approach is twofold. The determination of instantaneous dose rates permits 
inclusion of tumor regression over scan times in the absorbed dose estimates. Also, incorporation 
of radiobiological models requires 3D absorbed dose rate images at each time point rather than 
the simulation of absorbed dose from a single map of cumulated activity. A similar approach of 
generating multiple dose rate maps has been implemented in other dosimetry studies (Dewaraja 
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et al. 2009, Howard et al. 2011, Senthamizhchelvan et al. 2012, Sgouros et al. 2011). However, if 
desired, the user can use the exponential fitting tool in VIDA to create a map of cumulated 
activity for input in the MC simulation to determine the integrated dose in each voxel with only 
one run. 
Validation 
Due to the inherent flexibility of MC simulation tools such as Geant4, verification of the 
results is of the utmost importance. Monte Carlo results in VIDA were validated using two 
independent techniques. The first method applies a simple geometry of a spherical source in a 
semi-infinite scattering medium. The self-dose to spheres of various volumes was determined 
assuming a uniformly distributed activity. The second approach compared dose factors for 
selected target organs in a standard male reference phantom assuming uniform activity in the 
source organs. 
Methods 
Simulations were performed to determine absorbed fractions for self-absorption in unit-
density spheres ranging in size from 10 to 1000 grams. For consistency with the way a patient is 
modeled, each sphere was “voxelized” into an array of cells large enough to include the 
surrounding scattering medium. The spatial resolution of the voxelized map was chosen to limit 
the error in sphere mass due to the digitized approximation of the surface to less than 0.5%. The 
spheres were modeled as a tissue-equivalent material surrounded by a semi-infinite scattering 
medium of water. The tissue composition of the sphere was taken from MIRD Pamphlets 3 and 8 
(Brownell et al. 1968, Ellett & Humes 1972), chosen to facilitate comparison to previously 
published results.  
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Uniform activity was simulated for common radionuclides used in TRT including 
90
Y, 
131
I, 
111
In and 
177
Lu. For each radionuclide of interest, one million events were tracked resulting 
in absorbed energies within the sphere with relative errors of less than 0.5%. Relative error is 
defined as the 1σ standard deviation of the average tally (energy deposited) divided by the 
average tally (Sweezy et al. 2003). Self-dose factors were calculated and compared the unit 
density sphere model in OLINDA/EXM (Stabin et al. 2005). The OLINDA/EXM program 
calculates dose factors from self-irradiation of unit density spheres of discrete masses ranging 
from 0.01 to 6000 grams. These doses factors are based on the most currently published 
absorbed fractions of photon and electron emitters in spheres of various sizes (Stabin & 
Konijnenberg 2000) 
In order to validate VIDA in a more complex geometry with different tissue types, dose 
factors for several organs of interest were determined using the RADAR reference adult male 
phantom (see Figure III.6) (Stabin et al. 2012). Cross-organ dose factors were included to 
confirm dose contributions from far-reaching photons. Phantom anatomy is represented by 
NURBS surfaces adapted from the 4D NCAT/XCAT phantom (Segars et al. 2001, Segars et al. 
2010) to have reference organ masses for the adult male defined by ICRP publication 89 (ICRP 
2002). The phantom was rendered in voxel format with a resolution of 1.5 x 1.5 x 5.0 mm to 
create an organ map for simulation. Any voxels in the array outside of the phantom were defined 
as air. Instead of using the default materials defined in Table III.1, simulation materials were 
changed to the densities and compositions of soft tissue, lungs and bone (see Table III.3) used to 
generate new specific absorbed fractions (SAFs) for the RADAR reference data.  
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Figure III.6: Anterior views of the RADAR adult male NURBS phantom. 
Simulations were performed for the same radionuclides as the uniform spheres (
90
Y, 
131
I, 
111
In, and 
177
Lu) with three different organs designated as the source of radioactivity (liver, 
spleen, and pancreas). These organs were chosen as representative sources centrally located in 
the body with varying shape. Each run generated 5 million decay events uniformly throughout 
the source organ, resulting in relative errors of less than 2% in the total energy deposited in each 
target volume. Dose factors were determined using the average dose deposited in each target 
organ and compared to reference data. Target volumes included the three source organs and also 
the lungs and kidneys to evaluate self-dose and cross-organ doses to distant structures that may 
be of interest in TRT dosimetry.
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Table III.3: Materials used in the simulation of dose factors for the reference adult male phantom. Tissue definitions taken from Oak 
Ridge National Lab Report ORNL/TM-8381/V1, Table A-1 (Cristy & Eckerman 1987). 
Material 
Density 
(g/cm
3
) 
Chemical Composition (% by mass) 
H C N O Na Mg Si P S Cl K Other 
Air 1.21×10
-3
  0.01 75.5 23.2        1.3 (Ar) 
Soft Tissue
*
 1.03 10.45 25.66 2.49 63.53 0.11 0.01 0.03 0.13 0.20 0.13 0.21 0.02 (Ca) 
Lung Tissue
†
 0.296 10.13 10.24 2.87 75.75 0.18 0.01 0.01 0.08 0.23 0.27 0.19 0.01 (Ca), 0.04 (Fe) 
Whole Bone
‡
 1.40 7.34 25.48 3.06 47.89 0.33 0.11  5.10 0.17 0.14 0.15 
0.03 (F), 0.01 (Fe), 
10.19 (Ca)  
*
Also contains 0.005% or less of Fe, Zn, Rb and Zr 
†
Also contains 0.005% or less of Zn and Rb 
‡
Also contains 0.005% or less of Si, Zn, Rb, Sr, and Pb 
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Results 
Dose factors for self-dose to uniform activity spheres are shown in Figure III.7. The 
differences between VIDA and OLINDA/EXM (Stabin et al. 2005) ranged from 0.4% to 5%, 
with the largest deviations occurring in the smallest sphere (see Table III.4). Dose factors for 
90
Y 
show the largest difference between the two models with a range of 2–5%. 
 
Figure III.7: DF comparison between VIDA and OLINDA/EXM for unit density soft tissue 
spheres of different masses.  
 Table III.4: Relative percent differences in VIDA and OLINDA/EXM sphere dose factors
 
Mass (g) Diameter (cm) 
131
I 
90
Y 
111
In 
177
Lu 
10 2.7 -1.4 -5.0 3.8 -1.3 
20 3.4 -0.9 -4.1 3.8 -0.9 
100 5.8 -0.9 -2.5 2.8 -0.7 
400 9.1 -0.9 -2.3 0.9 -0.7 
1000 12.4 -0.5 -2.1 0.4 -0.4 
Relative % difference defined as 100 × (DFVIDA – DFOLINDA) / DFOLINDA. 
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Figure III.8: Self and cross organ dose factors for liver, spleen, and pancreas in the RADAR adult male phantom. Solid bars are 
reference values (Stabin et al. 2012) and outlined bars are from VIDA. Percent differences are listed above each pair, defined as 100 × 
(DFVIDA – DFRADAR) / DFRADAR. 
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Results for the reference phantom study are presented in Figure III.8. Cross-organ dose 
factors are omitted for 
90
Y because beta-emission energy is mostly absorbed locally. Any dose 
deposited in target regions far from the source organ is mainly due to contributions of 
bremsstrahlung radiation, with low scoring statistics. Deviations in the dose factors for organ 
self-dose ranged between 0.6% and 5%. The difference in cross-organ dose factors spanned from 
0% to 9% with VIDA results being lower than OLINDA/EXM values for almost all source-target 
organ pairs. 
Discussion 
The agreement in dose factors for the spheres was within 5% and improved with 
increasing mass, due to the decreased likelihood of an electron escaping the source volume 
before complete energy absorption. For all sphere sizes, the largest differences occurred for 
90
Y, 
a nearly pure beta emitter. The discrepancy is most likely due to different methods used to 
sample the beta energy spectrum. OLINDA/EXM applies a single SAF for the average energy of 
the beta emission spectrum, whereas beta particles created from a decay event in Geant4 are 
assigned energies by sampling the β-Fermi-function (Hauf et al. 2013a). Beta emissions with 
energy higher than the spectrum mean have a longer range in tissue and higher interaction 
likelihood; however there is also an increased possibility of these electrons exiting the sphere 
without being scored, which results in less total energy absorbed reflected by the lower dose 
factors from VIDA. 
For radionuclides that undergo beta decay (
131
I, 
90
Y and 
177
Lu), dose factors calculated by 
VIDA for spheres and the majority of source/target pairs in the reference phantom are slightly 
lower compared to OLINDA/EXM. However, all self-dose factors from VIDA are higher for 
111
In. 
111
In decays by electron capture and dose is locally deposited by low energy Auger 
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electrons and small yield internal conversion electrons. The difference in 
111
In self-dose factors 
may be due to error in the interpolation of SAFs for the very low energy Auger electrons by 
OLINDA/EXM and improved low energy electron transport models in Geant4 compared to 
MNCP4B; nonetheless, the differences are small. 
Several other groups have performed simulations of internal radioactive sources using 
Geant4. Amato et al. (Amato, Amato) reported absorbed fractions for monoenergetic photons 
and electrons in ellipsoids. Using these data, they specified the average energy deposited per 
disintegration of 
131
I as a function of the generalized radius. The energy deposited per 
disintegration of 
131
I by VIDA for the two smallest spheres (10 and 20 g) was 201 keV and 205 
keV respectively. These energies are in excellent agreement with Amato et al. (Amato) for 
ellipsoidal sources with generalized radii of 1.34 cm (201 keV) and 1.68 cm (206 keV). The 
dosimetry application RAYDOSE (Marcatili et al. 2013) was validated using dose factors for 
water spheres based on imaging a phantom containing activity-filled spheres of various sizes. For 
131
I and 
177
Lu, RAYDOSE dose factors were within 1–3% of OLINDA/EXM and agree with the 
evaluation of VIDA and OLINDA/EXM for spheres of comparable sizes. The radionuclide 
therapy code GRNT (McKay 2011) was validated by comparing organ dose factors from the 
MIRD-5 phantom to RADAR reference data. The relative differences found using GRNT for 
liver as the source organ were approximately 5% for self-dose factors and 1-10% for cross-organ 
dose factors to the kidneys, lungs, pancreas, and spleen for 
131
I and 
90
Y, which are similar to 
those from VIDA. 
Summary 
We have developed VIDA, an application for patient-specific dosimetry in targeted 
therapy using the Geant4 Monte Carlo toolkit to model radiation absorption in tissue from 
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internal emitters. The simulation generates voxel-level dose rate maps based on anatomical and 
quantitative functional imaging. It has been benchmarked with results using the RADAR 
formalism including self-dose factors for uniform activity spheres and organ self-dose and cross-
organ doses in a standard phantom. Validation results were compared to published results from 
other Geant4-based dosimetry methods with excellent concordance. VIDA also includes a useful 
curve fitting tool to automate voxel-level dose rate fitting and integration over time to create a 
3D absorbed dose map. It is our aim to employ this dosimetry technique in conjunction with 
patient-specific organ maps created from a deformable NURBS anatomical model. The method 
for creating an individualized patient model from a standard NURBS model is the topic of 
Chapter IV. VIDA, combined with the ability to define patient anatomy from a deformable 
phantom, offers a novel method for patient-specific dosimetry in TRT that can be completed in a 
short time-frame more favorable with the clinical treatment schedule. 
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CHAPTER IV  
 
PATIENT-SPECIFIC ANATOMICAL MODELING USING DEFORMABLE NURBS 
PHANTOMS  
 
Introduction 
Patient-specific dose assessment requires three distinct components. Anatomical images 
enable the definition of volumes of interest (VOIs) and provide tissue density information. Time-
sequential voxel-based quantitative activity distributions reveal the radiopharmaceutical kinetics 
in the patient. A computational method, such as MC simulation, calculates the absorbed dose in 
the patient-specific model. Much of the progress in patient-specific dosimetry in TRT focuses on 
the latter two elements. Definition of VOIs is still primarily limited to manual or semi-automatic 
segmentation, which is a time consuming and labor-intensive endeavor. Often, this step is a 
major bottleneck in the overall dosimetry process and full-scale patient segmentation is avoided. 
Dosimetry studies have restricted their focus solely on tumor dose (Dewaraja et al. 2014, 
Senthamizhchelvan et al. 2012), alleviating the need to define healthy organs. In some cases, 
such as RIT for lymphoma, this approach is permissible because the doses are low and do not 
pose a risk for organ toxicity. Other studies have employed simple segmentation methods to 
define dose limiting volumes for treatment planning, such as using an activity threshold to 
separate lung tissue from thyroid cancer metastases (Sgouros et al. 2011). Newly-developed 
molecular-based therapies (i.e. PRRT) have a much lower therapeutic window and the risk to 
normal tissues, especially kidneys, is high. This necessitates calculation of dose to not only 
tumor volumes but also to radiosensitive organs, and performing satisfactory dosimetry for these 
treatments requires delineating multiple volumes from anatomical patient data. To date, PRRT 
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dosimetry studies have used manually drawn VOIs (Baechler et al. 2012) or mean activity 
concentrations of spherical volumes inside organs of interest (Sandström et al. 2013) to obtain 
dose estimates to organs such as liver, kidney and spleen. Compared to manual segmentation, the 
approach by Sandström et al. is simple and efficient, but limits organ doses to mean values 
assuming a uniform activity distribution in the organ. 
There has been growing interest in constructing NURBS-based patient-specific phantoms 
for use in dosimetry. Numerous patient-specific NURBS-based XCAT models have been 
developed by Duke University to assess CT dose in pediatric patients (Norris et al. 2014, Norris 
et al. 2014a) and adults (Segars et al. 2013). These models were constructed based on manually-
segmented patient CT data. The bones and major organs were segmented from the CT data to 
define a framework for each phantom. The multichannel large deformation diffeomorphic metric 
mapping (MC-LDDMM) algorithm (Segars et al. 2009, Tward et al. 2011) was used to calculate 
a high-level transform from a given XCAT template (male or female) to the segmented 
framework for each patient. The transform was then applied to the XCAT phantom template 
(Segars et al. 2010) to define the additional organs and structures, not segmented from the CT 
data, into the patient-specific model, creating a new patient-specific XCAT phantom. 
The MC-LDDMM algorithm relies on the manually-segmented patient organs as landmarks 
to deform the entire phantom. This approach provides accurate results, with structures in 
agreement within a few voxels and organ dose estimates within 10%. However, the 
computational time to produce a patient-specific model is considerable, and significantly varies 
depending on the number of processors and patient size (less than an hour for a small patient 
using 24 processors up to 28 hours for a large patient using a single processor). This method of 
patient-specific NURBS modeling does not completely eliminate manual segmentation and may 
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require excessive computational processing power and time for it to be viable for clinical 
treatment planning for TRT. Moreover, the conversion of the segmented structures to 3D 
NURBS surfaces requires the use of commercial NURBS modeling software such as Rhinoceros 
3D (McNeel North America, Seattle, WA). 
Here, we describe a more efficient method for creating patient-specific models by deforming 
a NURBS reference phantom. In order to complete this task, we have developed custom software 
with a collection of tools and algorithms that can be used to manipulate the NURBS surfaces that 
define the reference organs to match the patient anatomy. The software loads patient CT images 
and overlays the outline of phantom in each viewing plane. Following a specified work-flow, the 
user modifies the body contour, skeleton, and individual organs to reflect the anatomical data in 
the CT. This chapter is organized into three main sections. The first section introduces the reader 
to NURBS and provides a formal definition of their mathematical form. The second section 
outlines the development of the software, including descriptions of the implemented algorithms 
and the procedure to construct a patient-specific NURBS model. The chapter concludes with the 
validation of the method using manually-segmented PET/CT images. 
Overview of NURBS 
Non-Uniform Rational B-Splines (NURBS) are mathematical representations of arbitrary 
3D geometries using polynomial basis functions. A NURBS model is defined by its degree and 
contains control points, corresponding weights, knot vectors, and a set of evaluation rules for the 
polynomial basis functions that determine how the control points influence the geometry. 
Surfaces are defined by a bi-directional NURBS model with parametric variables u in longitude 
and v in latitude. Points on the surface S(u, v) are defined by the following equation (Piegl & 
Tiller 1997): 
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 𝐒(𝑢, 𝑣) =
∑ ∑ 𝑁𝑖,𝑝(𝑢)𝑁𝑗,𝑞(𝑣)𝑤𝑖,𝑗𝑷𝑖,𝑗
𝑚
𝑗=0
𝑛
𝑖=0
∑ ∑ 𝑁𝑖,𝑝(𝑢)𝑁𝑗,𝑞(𝑣)
𝑚
𝑗=0
𝑛
𝑖=0 𝑤𝑖,𝑗
 IV.1 
where Pi,j is a control point weighted by the scalar value wi,j, and Ni,p(u) and Nj.q(v) are 
polynomial (B-spline) basis functions of degree p and q respectively. The surface points of S(u,v) 
and the (n + 1) by (m + 1) matrix of control points P in equation IV.1 are expressed in 
homogeneous coordinates (x, y, z, 1). 
The basic shape of the surface geometry is governed by the control points that may, but 
typically do not, lie on the surface. Instead, control points fall on a grid defined by the knot 
vectors U and V:  
 
𝐔 = (0,… ,0⏟  
𝑝+1
, 𝑢𝑝+1, … 𝑢𝑟−𝑝−1, 1,… ,1⏟  
𝑝+1
) 
𝐕 = (0,… ,0⏟  
𝑞+1
, 𝑣𝑞+1, … 𝑣𝑠−𝑞−1, 1,… ,1⏟  
𝑞+1
) 
IV.2 
where r = n + p + 1 and s = m + q + 1. The knot vectors partition the surface into piecewise 
components in the parametric directions u and v (see Figure IV.1). Knot intervals are not 
restricted to uniform spacing, hence “non-uniform” in the name NURBS. Control over the 
spacing and multiplicity of the knots provides the ability to define complex geometries, including 
sharp edges, without discontinuities.  
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Figure IV.1: Schematic representation of knot vectors that divide the NURBS surface into 
piecewise segments. Surface degree of p = 3 and q = 3 with knot vectors given by U = (0, 0, 0, 0, 
u1, u2, 1, 1, 1, 1) and V = (0, 0, 0, 0, v1, v2, 1, 1, 1, 1). Note that the spacing is not uniform in each 
parametric direction. 
Each piecewise component of the surface has a set of unique basis functions that weight the 
control points. Basis functions Ni,p(u) and Nj,q(v) are defined by equation IV.3. For each point on 
the surface S(u,v), basis functions are only non-zero over the knot interval [ui,ui+p+1) and 
[vj,vj+q+1) of U and V respectively, where ui ≤ u < ui+1 and vj ≤ v < vj+1. The weighting coefficient 
of control point Pi,j is the product of Ni,p(u), Nj,q(v) and wi,j, and is therefore only non-zero if at 
least one basis function is non-zero over the knot interval. This property creates local control of 
the surface shape, and altering the position of a control point only influences the p + 1 (or q + 1) 
neighboring surface patches (see Figure IV.2). 
 
𝑁𝑖,0(𝑢) = {
 1, 𝑖𝑓 𝑢𝑖 ≤ 𝑢 ≤ 𝑢𝑖+1
0, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
  
𝑁𝑖,𝑝(𝑢) =
𝑢 − 𝑢𝑖
𝑢𝑖+𝑝 − 𝑢𝑖
𝑁𝑖,𝑝−1(𝑢) +
𝑢𝑖+𝑝+1 − 𝑢
𝑢𝑖+𝑝+1 − 𝑢𝑖−1
𝑁𝑖+1,𝑝−1(𝑢) 
IV.3 
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Figure IV.2: Modification of NURBS surface by moving control points. (a) NURBS 
representation of a plane with controls points (*) aligned on the surface. (b) Surface with shaped 
altered by translating two of the center control points in the z-axis. 
As shown in equation IV.3, the area of the surface impacted by the control points depends 
on the degree of the NURBS model. Thus increasing the degree of the model, in turn increasing 
the degree of the basis polynomials, will result in control points influencing a larger area of the 
surface. Although higher degree polynomials provide increased flexibility, they may also affect 
the smoothness of the surface and create unwanted bumps. Typically, cubic polynomial basis 
functions (degree = 3) provide an adequate compromise between elasticity and constraint. The 
degree of all NURBS models used in this work is three in both parametric directions. 
Although NURBS are complex mathematical models, they have many properties that make 
them a desirable primitive for modeling patient anatomy. NURBS surfaces have affine 
invariance, meaning that applying a transformation to the surface is equivalent to applying the 
same transformation to the control net that defines the surface. A surface is easily translated, 
rotated or scaled by multiplying the matrix of control points (Pi,j) by the appropriate 
transformation matrix (T): 
  𝐏𝒊,𝒋
𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 = 𝑻𝐏𝒊,𝒋 IV.4 
The local morphology of a surface can also be altered by manipulating individual control points. 
If the location a control point changes, only the piecewise surface patches influenced by that 
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specific point (through non-zero basis functions) are modified. The local modification property 
of NURBS allows specific areas on the surface to be deformed by the altering the positions of 
the control points. Thus, organs in the phantom template can be modified to match patient 
anatomy as if they were made of clay. Additionally, NURBS surfaces are continuous and surface 
points can be expressed at any resolution. This permits the creation of a 3D image map of the 
anatomical NURBS phantom to be generated with arbitrary spatial resolution. Thus, patient-
specific NURBS phantom can be transformed or “voxelized” to create an organ map that 
matches the spatial resolution of the quantitative activity images. 
Development of the Phantom Morphus Software 
Introduction 
The Phantom Morphus software is based on an existing interactive application to model 
patient populations using the NCAT Phantom (Segars et al. 2000, Segars et al. 2001). The 
focused use of this software was to study patient anatomy in myocardial SPECT and was limited 
to anatomical modifications to the original NCAT phantom using SPECT images as a reference. 
The transformations included translation and scaling of the diaphragm, heart, lungs, rib cage, and 
body outline as well as rotations of the rib cage and heart. The remaining organs (liver, spleen, 
stomach and kidneys) were not deformed. 
We have expanded this software to perform interactive modification of anatomical structures 
guided by high-resolution CT as a method to create full body patient-specific models for 
dosimetry in TRT. The NCAT phantom, initially limited to torso anatomy including the heart, 
lungs, liver, stomach, spleen, kidneys and surrounding skeleton (sternum, ribs, and thoracic 
vertebrae), has been extended to the entire body resulting in the XCAT phantom (Segars et al. 
2010). The Phantom Morphus software employs the extended full-body XCAT phantom to 
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create individualized anatomical models that include all organs at risk for TRT and a complete 
skeleton for bone marrow dosimetry. Ten small spherical surfaces were added to the reference 
phantom used in Phantom Morphus for definition of tumor volumes. In addition to applying 
simple affine transformations to the control points, the software includes new algorithms that 
enable non-rigid transformations of the organ models. This section contains descriptions of these 
algorithms as well as a detailed summary of the overall software design. Guidance is given on 
how to use Phantom Morphus to construct a patient-specific model. 
Software Design 
Phantom Morphus is written in Visual C++ using the OpenGL application programming 
interface for rendering 3D graphics. The main GUI (see Figure IV.3) consists of two display 
windows, one for the 3D NURBS phantom and the other containing a 2D display of the CT 
image, with transverse, sagittal and coronal view options. The user loads a patient CT by 
selecting “Load Patient Data” from the “Patient Data” drop down menu. The phantom is 
rendered as an overlay to the CT image using triangulated surfaces that match the voxel 
dimensions of the CT image. 
The CT data must be in raw image format to load into Phantom Morphus. Because raw data 
lacks header information, the user must specify the image dimensions (number of rows, columns, 
and slices) and the data type and storage order (e.g. unsigned short, big-endian) before the 
software can load the data into memory. The user must also set the voxel dimensions of the 
image in the “Image View Tools” GUI (see Figure IV.4) so that the NURBS surfaces are 
triangulated and displayed over the 2D CT image at the matching resolution. The Image View 
Tools panel also contains other image display options including zoom, brightness and contrast 
adjustment and toggles between the three image planes (transverse, coronal, and sagittal). 
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Figure IV.3: 3D and 2D views of the Phantom Morphus software main graphical user interface. 
Selection of phantom structures for transformation is handled by the “Phantom Structures” 
window (see Figure IV.5). The user is permitted to select a single organ or a set of organs for 
manipulation. Options to display or hide selected and unselected objects in the CT image 
window are available. The organ models in the 3D phantom view window can be rendered as 
wireframe (default for body contour) or solid objects (default for organs and skeleton). The 
control points of the selected structures can also be shown in the 2D image view. 
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Figure IV.4: GUI of image view tools for CT image display. 
 
Figure IV.5: GUI for NURBS phantom viewing options and selection of structures. 
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A screen capture of the “Tools” window is show in Figure IV.6. This GUI contains all the 
tools provided to the user to deform the template organ. The window is divided into three main 
sub-panels. One sub-panel includes the available options for modifying the surface(s) using 
affine transformations. Another sub-panel contains a set of standard segmentation tools to 
manually define volumes of interest from the CT image. The third sub-panel includes special 
transformation tools for surface modification. Details of these custom deformation algorithms are 
given in the following section. 
 
Figure IV.6: GUI of surface transformation tools. 
Transformation Algorithms 
Affine Transformations 
Modification of organ models by affine transformation is performed by applying a 
transformation matrix to the control points (see equation IV.4). The affine transformations 
available in Phantom Morphus include translation, rotation and scaling. These transformations 
can be applied to multiple structures at the same time by selecting them in the “Phantom 
Structures” window. Translation of surfaces in a specific direction, denoted as x, y, and z in the 
“Tools” window, is performed by simply translating the coordinates of the control points by a 
user-specified amount. Selected surfaces can also be translated in the 2D slice view using the 
mouse by clicking and dragging the selected surface overlays to the desired position. Rotation of 
selected structures is performed about the center each object. The coordinates of the control 
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points are rotated in the selected plane about this center point. The anterior-posterior plane is 
designated as the x direction, the lateral plane as the y direction, and the longitudinal plane as the 
z direction. Models can be scaled in several different ways. Scaling can be performed in only one 
dimension about the center of the selected object based on a user-specified scale factor. Scale 
factors larger than one will dilate the surface in the selected dimension and factors less than one 
will shrink the surface. The surface may also be scaled in 3D by the scale factor about the center 
point of the model or a selected center point defined by click the mouse in the 2D image view. 
A first order approximation of patient-specific organ anatomy can be achieved by applying 
affine transformations to the reference organs. Figure IV.7 shows an example of the original left 
kidney and the modified organ shape using only affine transformations. The kidney was scaled 
by a factor of 1.1 in the longitudinal direction, rotated -15° about the lateral plane and centered 
on the patient CT by translation using the mouse in the 2D view. 
 
Figure IV.7: Result of organ modification using affine transformation of the left kidney. The top 
panel shows the original position of left kidney. The bottom panel shows the organ after scaling, 
rotation and translation. The phantom kidney is shown as a yellow contour in the images. 
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Surface Fitting to Threshold Mask 
Phantom Morphus has the capability of fitting an existing surface to a defined mask. 
Although this is not different from conventional methods of manual segmentation, it does offer 
an efficient way to deform surfaces of high contrast with surrounding tissue such as the lungs 
and body contour. The user first defines ROI contours using the mouse in the 2D image view. 
The software has the ability to interpolate the contours in the longitudinal plane so the user is not 
required to manually define the ROI on each image slice. Once the contours are complete, the 
ROI surface is created using a minimum and maximum threshold of CT intensities set in the 
“Image View Tools” window. If necessary, the defined ROI can be dilated or eroded to refine its 
shape. The user then has the option of fitting the entire NURBS surface to the threshold mask or 
the partial surface that spans the mask. The latter option is especially useful for fitting 
incomplete body contours or lung volumes to CT images spanning a partial field of view of the 
patient anatomy commonly encountered in imaging data available in TRT (see Chapter 5 for 
examples). 
Surface Fitting to a Point Cloud 
Many methods to fit NURBS curves and surfaces to a set of measured data points have been 
developed (Brujic et al. 2011, Brujic et al. 2002, Cheng et al. 2004, Flöry & Hofer 2010, 
Pottmann & Leopoldseder 2003, Ristic et al. 2004, Wang et al. 2006). This process, known as 
reverse engineering, is especially important in computer-aided design. Most approaches employ 
least-squares optimization of a defined function relating the distance between each measured 
point and the closest point on the NURBS surface, denoted as the “foot point”. The algorithm 
developed to fit a surface to a point cloud for the Phantom Morphus software utilizes point 
distance minimization (PDM) that essentially solves a set of generalized normal equations to 
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minimize the sum of the squares of the distance between the base surface and the measured data 
(Brujic et al. 2011, Brujic et al. 2002). The surface fitting algorithm consists of three main steps: 
point inversion to determine the corresponding surface parameter values (u, v) of the foot point 
for each point in the point cloud, setting up the system of linear equations including the 
introduction of additional criteria to regularize the system and ensure the overall minimization 
problem is well posed, and solving the linear system using an iterative least squares algorithm. 
These steps are iterated using the updated surface until a tolerance or iteration limit is reached. 
Point inversion is performed using a second order geometrical algorithm (Hu & Wallner 
2005). The iterative algorithm projects the point onto a curvature circle using an initial guess for 
the foot point (see Figure IV.8). This projection is used to update the surface parameter values 
(u, v) of the foot point until convergence is reached. The point projection requires a good initial 
guess of surface parameter values. We have implemented the method of surface patch 
elimination in Ma and Hewitt (Ma & Hewitt 2003) to obtain the initial guess. This approach 
exploits the convex hull property of NURBS surfaces to excluded surface regions. The surface is 
first subdivided into Bézier patches (defined below). Using the geometrical relationship between 
the cloud point and the control point net of each Bézier patch, candidate patches are identified 
and used to obtain the initial surface parameters (u, v) of the foot point.  
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Figure IV.8: Example iteration of point inversion algorithm. The cloud point (black dot) is 
projected onto the curvature circle (black curve) to update the surface parameters corresponding 
to the foot point. The red arrows indicate the tangent and normal vectors at the current surface 
point. 
A Bézier patch is similar to a NURBS surface, defined by a set of control points weighted 
by Bezier basis functions: 
 𝑸(𝑢, 𝑣) = ∑∑𝑷𝒊𝒋𝐵𝑖,𝑛(𝑢)𝐵𝑗,𝑚(𝑣)
𝑚
𝑗=0
𝑛
𝑖=0
 IV.5 
The basis functions, or Bernstein polynomials, are defined by: 
 
𝐵𝑖,𝑛(𝑢) =
𝑛!
𝑖! (𝑛 − 𝑖)!
𝑢𝑖(1 − 𝑢)𝑛−𝑖  
𝐵𝑗,𝑚(𝑣) =
𝑚!
𝑗! (𝑚 − 𝑗)!
𝑣𝑗(1 − 𝑣)𝑚−𝑗 
IV.6 
with n and m the degrees of the polynomials in the u and v directions, respectively. The main 
difference between a Bézier patch and a NURBS surface is that the control point net of Bézier 
patch has only (n + 1)(m + 1) control points. For a cubic Bézier patch, there are a total of 16 
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control points. The surface of the Bézier patch Q passes through the control points at the four 
corners, with Q(0,0) = P00, Q(0,1) = P01, Q(1,0) = P10, and Q(0,0) = P11.  
NURBS surfaces can be subdivided into multiple Bézier patches using knot insertion (Piegl 
& Tiller 1997). Given a NURBS surface of degree p and q (see equation IV.1), the Bézier 
patches are obtained by inserting interior knots in until each knot in U has multiplicity p and then 
until each knot in V has multiplicity q. Once the surface is subdivided, each Bézier patch can be 
tested to determine if the foot point is located within the patch, by discarding any patches which 
the closest surface point to the cloud point is on one of the four boundary curves (see Figure 
IV.9). Once the closest Bézier patch is located, the midpoint of the (u, v) span for this patch is 
used as the initial guess in the point inversion algorithm. 
 
Figure IV.9: Eliminated Bézier patch. Closest surface points lay on the boundary curves. 
Fitting a NURBS surface to a series of points becomes a linear optimization problem under 
the assumption that the weights and knot vectors are fixed and only the control points are 
unknown. The function for minimization is defined by equation IV.7 with Qk representing each 
cloud point with the corresponding closest surface point given by S(uk,vk) and fs is a 
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regularization term to prohibit rank-deficiency or an ill-conditioned system and ensure a smooth 
surface. 
 𝑓 =
1
2
∑‖𝑸𝒌 − 𝑺(𝒖𝒌, 𝒗𝒌)‖
2
𝑀
𝑘=1
+ 𝜆𝑓𝑠  IV.7 
The point cloud minimization algorithm in Phantom Morphus includes two regularization terms 
modulated by separate weights (α and β). The first regularization term is generated by the 
assumption that control points approximate the shape of the surface by the convex hull property 
and should stay close to the surface (Brujic et al 2011). Mathematically this term is expressed as: 
 𝑓1 =∑∑‖𝑷𝒊,𝒋 − 𝑺(𝒖𝒊,𝒋, 𝒗𝒊,𝒋)‖
2
𝑚
𝑗=0
𝑛
𝑖=0
 IV.8 
where Pi,j are the control points and S(ui,j,vi,j) are the corresponding surface points. The 
parametrization points ui,j and vi,j are determined using Greville abscissae (Milroy et al. 1995). 
The second term regularizes the surface curvature by applying a discretized version of the 
Laplacian to the control points in both parametric directions (u and v) (see equation IV.9).  
 𝑃𝑖,𝑗 =
1
4
(𝑃𝑖−1,𝑗 + 𝑃𝑖+1,𝑗 + 𝑃𝑖,𝑗−1 + 𝑃𝑖,𝑗+1) IV.9 
The linear system of equations determined by evaluating the basis functions of S(uk,vk) and 
S(ui,j,vi,j), and the discretized Laplacian is sparse. The software solves for a new set of control 
point positions using the LSMR algorithm for sparse least squares problems (Fong & Saunders 
2011) using modulation weights α and β of 0.5 and 0.1 respectively. The surface model is then 
updated and these steps are repeated until the system converges or a maximum number of 
iterations are completed. 
One of the key factors in the success of the PDM algorithm is the ability to choose an initial 
surface that is a good approximation to the point cloud of measured data. The anatomy of the 
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reference phantom provides a template for organ geometry that makes surface fitting using PDM 
an efficient method for patient-specific anatomical modeling. Although this approach still relies 
on user interaction, defining organ and tumor volumes via point cloud fitting only requires the 
user to only select a set of surface points that are representative of the overall shape compared to 
time-intensive slice-by-slice contouring. 
Fit Intestines with Vector Field Transform 
Digestive organs are complex in morphology, with many twists and turns, and change 
temporally during the course of a patient’s treatment. The complexity of their shape makes them 
difficult to deform to match the patient anatomy. We have implemented a method to fit reference 
organs to the general shape of the small intestines, colon, and rectum of the patient using a vector 
field transform. The NURBS template model includes two boundary surfaces that completely 
enclose the bowel. Using the methods described above, the user deforms one of these surfaces to 
match the complete boundary of the intestines and rectum using the CT image as a reference. 
The differences between the two boundary surfaces are used to calculate field motion vectors 
that represent the necessary transformation from a point on the original boundary to the 
correspond point on the patient-specific boundary. These motion vectors are then applied to each 
of organ models to shift the control point locations to fit the intestines inside the patient 
abdomen. Although this approach does not account for exact differences between the surfaces of 
reference phantom and patient bowel, it does provide an estimate of where the small intestines, 
colon and rectum are positioned relative to the other organs in the abdominal cavity of the 
patient. 
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Construction of Patient-Specific Models 
The workflow to construct patient-specific models using the Phantom Morphus software is a 
top down approach. The process begins with coarse alignment of the entire phantom to the body, 
first in the transverse plane and then in the coronal and sagittal views, using the base of the lungs 
as a reference landmark. Once general alignment is achieved, the next step is to scale the body 
trunk in each dimension. It is important to not scale the body based on the external body contour, 
especially if the patient is overweight or obese, but with respect to the internal organs. This can 
be achieved by using the rib cage as a reference in the anterior-posterior and lateral directions 
and the length of the spinal column in the longitudinal plane. 
 
Figure IV.10: Example of data point selection and results for surface fitting to a point cloud. 
Each pair of images represents one set of results. The left image in each pair shows the original 
phantom kidney contour along with the point cloud to fit. The right image in each pair shows the 
resulting contour of the fitted phantom kidney. 
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The next step is to modify each organ to match the patient anatomy. The NURBS surface 
can be centered by over the organ using the “click and drag” function. Once centered, the user 
can scale and rotate the surface in each dimension to improve the alignment. Often, using these 
affine transformations may result in a suitable organ volume. If refinement is required, the point 
cloud surface fit algorithm can be applied. The user selects points along the organ boundary on 
the CT. This should be done at each end of the organ and on a subset of slices between the ends 
(see Figure IV.10). Areas of high curvature require more densely defined points. The user 
specifies the number of times the least squares fitting is performed (default = 5). Larger and 
complex surfaces require more iterations to achieve acceptable results. 
The right and left lungs can be matched to the patient anatomy by fitting the NURBS 
surfaces to a masked defined by a threshold or by using the point cloud surface fitting algorithm. 
Because all NURBS surfaces in the reference phantom are closed at both end points, both lung 
surfaces actually extend down past the base in order include the area in the base of the lungs at 
the position of the diaphragm (see Figure IV.11a). In the transverse view, the right lung will have 
significant overlap with the liver and the left lung will continue down into the spleen and 
stomach. These overlaps will be handled during the voxelization process as the organs are 
converted in a specific order. Thus, the liver surface will replace the areas of right lung that 
coincide. Because there is significant mediastinum between the base of the left lung and the top 
of the spleen and stomach, the excess lung surface is corrected by placement of a NURBS 
surface representing the left diaphragm. Once the left lung is deformed to match the patient, the 
left diaphragm should be adjusted at the lung base. During voxelization, the left diaphragm is 
voxelized as body and then areas that overlap with the spleen and stomach replace those voxels 
(see Figure IV.11b). 
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Figure IV.11: Overlap of the lungs at the base before deforming structures to match the patient 
(a) and after modification (b). The white area is the left diaphragm that is voxelized as body and 
replaced by other organs including the spleen (red), stomach and heart (pink). 
The small and large intestines cannot be deformed with the point cloud surface fit algorithm. 
In order to accurately represent the bowel loops and avoid self-intersection of the surface, the 
small intestine is comprised of a series of NURBS surfaces. Likewise, parts of the large 
intestines, namely the transcending and sigmoid colon, consist of more than one NURBS surface. 
The abdominal anatomy of the patient can be approximated in one of two ways. The user can 
apply a vector field transform to these organs by first delineating a boundary surface around the 
entire bowel. This algorithm requires the entire bowel to be visible in the patient CT. The 
alternate method for creating patient-specific abdominal organs is to use affine transformations 
to estimate the size and position of the small and large intestines. 
Definition of the patient’s skeleton is achieved by applying affine transformations to 
individual or groups of bones in the phantom. Additionally, the user can create patient-specific 
ribs by using an algorithm that fits a NURBS surface to a center line through each rib defined by 
the user on the image. Depending on the image size, the task of modifying each bone to match 
the patient may be tedious and lengthy. If this process is time-prohibited, the skeleton can be 
added to the 3D organ map after voxelization by identifying voxels containing bone using a 
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threshold mask. The bone voxels can then be modeled as whole bone during MC simulation. The 
definition of each bone surface using the NURBS model has one advantage. The voxelization 
process can be modified to insert marrow cavities inside each bone. Using a few anatomical 
measurements on the patient CT, patient-specific active marrow mass in each bone can be 
estimated (Pichardo et al. 2007) and used to populate voxels in the cavity as red marrow. Then 
dosimetry can be performed using VIDA with a skeleton that contains separate cortical bone, 
yellow and marrow voxels. This approach provides a method to estimate red marrow dose that is 
not easily performed when the skeleton is modeled as whole bone. Often, red marrow toxicity is 
a concern in TRT and the ability to measure energy deposition in voxels specified as red marrow 
during MC simulation may offer improved dose estimates to this radiosensitive organ compared 
to currently available approaches such as fixed geometry dosimetry based on measuring 
radioactivity levels in blood after treatment (Forrer et al. 2009). 
The final step in creating a patient-specific NURBS model is to fit the body contour. The 
reference NURBS phantom has separate surfaces representing the trunk, right and left arms, and 
right and left legs. The fastest way to deform these surfaces to match the patient is to fit either 
the whole surface or partial NURBS to a mask. The body contour mask can be quickly created 
by applying a threshold to user-defined ROI contours. These contours are drawn on a subset of 
the CT slices, with interpolation performed between each one to achieve a continuous mask (see 
Figure IV.12). 
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Figure IV.12: Example of fitting the body contour to the patient. The ROI contours are defined 
approximately every 20 slices in the axial view (top). The surface mask is created using a 
threshold range of CT intensities and interpolated in the longitudinal direction (lower left). The 
partial NURBS surface is fit to the mask (lower right). 
Validation 
Introduction 
Techniques for image segmentation require appropriate validation, especially if the 
results will be used in patient treatment. There is a long history of the use of standard test images 
for image validation, dating as far back as 1974 with the development of the Shepp-Logan head 
phantom for testing of CT image reconstruction algorithms (Shepp & Logan 1974). 
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Segmentation standards have been created for various regions of the body including the brain 
(Aubert-Broche et al. 2006, Collins et al. 1998) and lung (Armato III et al. 2004) to validate 
interactive, semi-automatic and automatic segmentation methods. Typically these standards are 
generated using high-resolution images of individual patients or realistic simulated anatomical 
volumes. 
The primary difficulty in quantifying the performance of medical image segmentation 
techniques is the lack of ground truth for in vivo data. Interactive drawing of volumes of interest 
by experts is often the gold standard for segmentation in clinical practice, as in the case for TRT. 
Therefore, we chose to validate the construction of patient-specific deformable models using a 
set of manually-segmented high-resolution CT images. PET/CT data was selected because the 
large field of view included all organs of interest to TRT. Additionally, the inclusion of the PET 
data facilitated the investigation of how patient-anatomy defined by deformable NURBS impacts 
the dosimetry. 
In this section, we present the validation of patient-specific NURBS models constructed 
using the methods described previously in this chapter. Patient-specific models were built and 
compared to manually-segmented organs verified by a radiologist with experience in body CT. 
Several evaluation metrics were applied, including volume differences, set similarity coefficients 
of spatial overlap, and Euclidean distance between surfaces. 3D imaged-based dosimetry was 
also performed using VIDA to assess the relevance of volume misfits between deformable 
models and patient anatomy to organ dose. 
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Methods 
Patient Data 
Four adult patients, two male and two female, who had undergone an 
18
F-FPEB 
dosimetry study for a new radioligand that binds to the metabotropic glutamate receptor subtype 
5 (Kessler et al. 2014) were chosen from our archives. The 
18
F-FPEB study received approval 
from our institutional review boards and all subjects the provided written informed consent 
before enrollment. All images were anonymized prior to use in accordance with the Health 
Insurance Portability and Accountability Act (HIPPA). Patient demographics and anthropometry 
are presented in Table IV.1. 
Table IV.1: Description of patients used in deformable model validation 
Patient Sex Age (yr) Height (m) Weight (kg) 
1 F 19 1.65 72 
2 F 52 1.68 84 
3 M 23 1.65 77 
4 M 22 1.80 72 
 
The PET/CT studies include high resolution CT images (1.37×1.37×3.27 mm
3
) with a 
field of view spanning from the top of the skull down to the mid-femur. Patient anatomy was 
defined using a combination of manual and semi-automatic segmentation techniques included in 
the ITK-SNAP toolkit (Yushkevich et al. 2006). Organ volumes were verified by a subspecialty 
radiologist with experience in both body CT and nuclear medicine. Likewise, patient-specific 
NURBS models were created using the CT image as a template for deformation using the 
process described in the previous section. The manually-segmented standards and deformable 
models included all trunk organs, ranging from the heart and lungs in the upper chest to the 
reproductive organs in the lower pelvis.  
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Evaluation Metrics 
Three evaluation metrics often used to assess image segmentation results of the same 
structure were chosen to evaluate the organ volumes in the patient-specific NURBS models 
(Van Ginneken et al. 2007). The organs volumes from manual segmentation using were set at the 
reference or “ground truth” for this analysis. First, the volumetric error of each organ was 
calculated as the relative percent difference between the total target and reference volumes. 
Over-definition of the NURBS organ is indicated by a positive difference and under-definition is 
given by a negative value. The Jaccard similarity metric (Jaccard 1912) was used to determine 
the percent volumetric overlap. The Jaccard similarity coefficient (J) is defined as the size of the 
intersection divided by the size of the union of the sample sets (A and B) (see equation IV.10). 
 𝐽(𝐴, 𝐵) =
|𝐴 ∩ 𝐵|
|𝐴 ∪ 𝐵|
 IV.10 
The average surface distance between the two organs was calculated using Euclidean distance 
mapping (Danielsson 1980, Mishchenko 2015). Surface boundaries of the reference and target 
volumes were delineated and for each voxel in the target the distance to closest voxel to the 
reference boundary was determined. The average of all these distances was tallied to produce a 
metric of the average symmetric absolute surface distance between the segmented and NURBS 
organ. These evaluation metrics were applied to the entire body contour and skeleton to assess 
the global accuracy of the patient-specific NURBS models. Individual organs of importance to 
dosimetry in TRT were evaluated including lungs, heart, liver, spleen, kidneys, and gall bladder. 
Dosimetry 
To assess the impact of discrepancies in the patient-specific model anatomy on dosimetry, 
organ maps were generated from the individualized phantoms and used as input into VIDA to 
obtain dose rate maps. NURBS models were voxelized at resolution of the PET images 
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(5.47×5.47×3.27 mm
3
). The voxelization program assigns organ ID numbers to each voxel as 
specified in an input parameter file. The integer IDs were assigned to organs to match those used 
in VIDA (see Appendix D). Overlapping surfaces (e.g. liver and right lung) are handled based on 
a priority value assigned to each organ. For voxels corresponding to surface overlap, the voxel is 
assigned the ID number of the organ with the highest priority. These results were compared to 
dose rate maps generated by VIDA for the reference anatomy using manually-segmented organ 
maps. In order to match the resolution of the PET images, the organ maps created using manual 
segmentation methods were down-sampled from 512×512 pixels to 128×128 pixels in the 
transverse plane with nearest neighbor interpolation of the organ identification numbers. 
VIDA was run using 
131
I as the radionuclide to assess the locally-deposited dose from 
charged beta particles and dose due to penetrating radiation from gamma emission. 
Approximately 10 million primary decay events were simulated, distributed non-uniformly 
specific to voxel-level PET activity for the patient. The simulated field of view covered the 
complete torso from above the apex of the lung to the bottom of the ischium in order to estimate 
dose to most radiosensitive organs. The skeleton was modeled as whole bone (see Table III.1). 
Results 
Patient-specific NURBS models and the corresponding manually-segmented reference 
models are shown in shown in Figure IV.13. The results from applying the evaluation metrics to 
individual volumes of interest are summarized in Table IV.2. Mean and standard deviations of 
the evaluation metrics for each organ across all patients are presented in Table IV.3. With the 
exception of the gall bladder and the distributed skeleton, most NURBS organ volumes differ 
less than 10% on average compared to the manually-segmented structures. The average 
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Euclidean distance between surface boundaries ranged from 1.3 to 3.8 mm, corresponding to a 
separation of approximately 1 to 3 voxels. 
 
Figure IV.13: Example patient-specific NURBS model and reference manual segmentation for 
(b) male and (b) female patients. The opaque body contours and breasts are not shown. 
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Table IV.2: Evaluation metrics for patient-specific deformable models 
Organ 
Volume 
Diff. (%) 
Volume 
Overlap (%) 
Avg. Distance 
Error (mm) 
Volume 
Diff. (%) 
Volume 
Overlap (%) 
Avg. Distance 
Error (mm) 
 Patient 1 Patient 2 
Body 2.7 94.6 2.0 2.4 94.4 2.6 
Skeleton 28.0 53.1 2.4 12.0 47.6 3.6 
Gall 
Bladder 
56.0 58.8 2.7 71.5 54.4 2.6 
Heart -10.7 74.3 1.9 9.2 78.3 2.7 
Kidneys 5.2 82.7 1.3 0.0 82.6 1.5 
Liver 1.7 88.6 1.5 1.5 86.9 1.9 
Lungs 13.1 80.3 1.9 5.9 84.6 1.9 
Spleen 7.0 79.4 1.8 7.0 81.5 1.7 
 Patient 3 Patient 4 
Body 5.5 90.4 3.8 0.0 93.7 2.2 
Skeleton 12.0 53.4 2.1 21.5 49.9 2.5 
Gall 
Bladder 
3.4 45.8 2.9 39.5 62.4 1.8 
Heart 10.0 78.9 2.3 -1.6 78.9 2.1 
Kidneys 0.8 83.2 1.3 8.8 79.4 1.5 
Liver -15.5 71.2 3.7 4.7 82.5 2.2 
Lungs 6.6 83.6 2.1 9.7 85.4 1.8 
Spleen -4.9 68.6 2.2 -9.9 82.6 1.6 
 
Table IV.3: Mean evaluation metrics for each organ 
 Volume Diff. (%) Vol. Overlap (%) Avg. Distance Error (mm) 
Body 2.7 ± 2.2 93.3 ± 2.0 2.6 ± 0.8 
Skeleton 18.4 ± 7.8 51.0 ± 2.8 2.7 ± 0.6 
Gall Bladder 42.6 ± 29.2 55.3 ± 7.2 2.4 ± 0.4 
Heart 7.9 ± 4.2 77.6 ± 2.2 2.2 ± 0.3 
Kidneys 3.7 ± 4.1 81.7 ± 1.7 1.4 ± 0.1 
Liver 5.8 ± 6.6 82.3 ± 7.8 2.3 ± 1.0 
Lungs 8.8 ± 3.3 83.5 ± 2.2 1.9 ± 0.1 
Spleen 7.2 ± 2.0 78.0 ± 6.4 1.8 ± 0.3 
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Relative percent differences in organ doses using the patient-specific NURBS model 
compared to manually-segmented organ volumes are given in Table IV.4. With the exception of 
lung, the mean absorbed doses calculated from the NURBS models agree with results from 
manually segmented volumes to within 10%. 
Table IV.4: Comparison of organ absorbed doses calculated from patient-specific NURBS 
models and manually segmented CT data expressed in relative percent differences 
Patient Heart Lung Liver Kidney Spleen Skeleton 
1 5.7 20.3 -1.1 3.2 -0.6 -2.0 
2 1.1 3.4 -1.0 1.4 -2.4 -4.1 
3 0.2 18.2 6.8 -0.4 0.1 0.7 
4 -5.7 8.0 -3.8 1.2 1.0 -2.7 
Relative difference defined as 100 × (DNURBS – DManual) / DManual. 
 
Discussion 
The creation of patient-specific NURBS models was evaluated using a set of manually 
segmented patient CTs. Whole body patient models were created in a few hours, resulting in a 
marked reduction of time compared to user-guided manual and semi-automatic segmentation of 
the CT. The ability to convert the NURBS surfaces to a 3D array of voxels at any resolution 
allows these models to be used in image-based dosimetry applications. 
Overall, the organ volumes from the patient-specific NURBS models agree with manually 
segmented structures on average to within 10%. Two exceptions are the gall bladder and lungs. 
The gall bladder is a small organ that is susceptible to large percent volume differences; 
however, the gall bladder is rarely a concern as an organ at risk in TRT. In all the patients, the 
lung volumes in the NURBS models are larger. The over-definition of the lungs is most likely 
due to the inclusion of the bronchi within the NURBS surface. These were excluded from the 
manual segmentation but the NURBS surfaces for the lungs are smooth and do not have the level 
105 
 
of complexity required to shape the surface around the bronchi. Previous studies (e.g. Hermoye 
et al. 2005) have reported that variation in organ volumes manually segmented by experts can 
differ by upwards of 20%, and that these volumes differ with truth by an average of 12%. The 
difference in organ volumes using a deformable NURBS phantom compared to manually 
segmented organs are consistent with differences that may occur between slice-by-slice 
segmentations performed by two different experts. 
Comparison of organ volumes does not provide any information about the position of the 
NURBS surfaces in relation to the manually-segmented structures. The Jaccard coefficient is a 
statistic used to assess similarity between samples and was used to determine the percentage of 
volume overlap between NURBS surfaces and manually-segmented organs. With the exception 
of the gall bladder and skeleton, the NURBS organs overlap with manually defined organs by 
78% or more. The dissimilarity in gall bladder overlap is related to the large volumes in the 
NURBS models, which is on average almost 50% larger than manually-segmented volumes. The 
NURBS skeleton also showed poor alignment compared to bones that were defined semi-
automatically using the snake evolution in ITK-SNAP. There are two factors that may contribute 
to the variation in skeletons. One, only affine transformations were applied to the NURBS bones 
to create a patient-specific skeleton. Bone shape and curvature may vary between the reference 
phantom and the patient. One notable example is the pelvis, which is larger and broader in 
women. Using a hermaphroditic reference phantom generated from male anatomy may 
contribute to the inaccuracy of modeling the female pelvis. Also, some of the bones in the 
NURBS phantoms fail to adequately represent the complex skeletal anatomy, including the 
scapulae and sacrum. The NURBS model of the sacrum does not include space for the sacral 
canal and foramina. Similarly, the surface representing the scapula does not model the curvature 
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of the coracoid process and acromion and overestimates the thickness of the infraspinous fossa. 
These differences may explain the volume of the NURBS skeleton is 10-25% larger compared to 
manually-segmented bones and percent volume overlap is less than 50%. 
The average Euclidean distance from each NURBS organ boundary to the manually-
segmented volume was determined. Overall average distance errors for the organs analyzed in 
this study ranged from 1 to 3 mm. These distances are similar to those calculated for a NURBS-
based pediatric phantom created using the automated MC-LDDMM mapping method (Segars 
et al. 2009). For the high resolution CT images (1.37×1.37×3.27 mm
3
), these distances 
correspond to differences of 1 to 3 voxels; however they are well contained within a voxel in the 
activity image (5.47×5.47×3.27 mm
3
). Thus, errors in the position of organs created using 
deformable NURBS phantoms may not impact the dosimetry results significantly depending on 
the resolution of the available SPECT or PET images. 
Other studies have evaluated CT-based automatic and semi-automatic organ segmentation 
methods using metrics of percent volume overlap and surface distance error. A survey of image 
processing techniques for liver segmentation (Campadelli et al. 2009) summarizes results from 
the literature. Average percent volume overlap compared to manually-segmented livers ranged 
from 78% to 95% for various methods including model fitting, gray-level based thresholds, and 
probabilistic atlases. Average surface distances reported ranged from 2 to 2.3 mm. The average 
percent volume overlap for NURBS-based livers was 84% with average surface distances to 
manual-volumes of 2.0 mm. Both metrics fall within the ranges reported for other liver 
segmentation studies. Automatic kidney segmentation using m-rep models was compared to 
manual segmentation by experts (Rao et al. 2005). For 12 target images, the average volume 
overlap was 82% with a mean surface separation of 1.8 mm. Our results are similar with an 
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average percent volume overlap of 82% and distance error of 1.4 mm. One reason for the 
difference between the NURBS kidneys and manually-segmented volumes is the inclusion of 
parts of the renal vein, artery, and pelvis in the NURBS structure that were not identified in the 
kidney volumes during manual segmentation. Nonetheless, the results of evaluating organ 
volumes of patient-specific NURBS compared to slice-by-slice manual definition are similar to 
outcomes from other automatic and semi-automatic CT-based segmentation methods. 
The impact of using patient-specific NURBS models on organ doses from internal emitters 
was also assessed. The patient-specific NURBS models created in this study were voxelized at 
the resolution of the PET activity data and used to define anatomy during MC simulation using 
VIDA. Although this activity represents the uptake of 
18
F, organ doses were estimated by MC 
simulation assuming 
131
I, a radionuclide commonly used in TRT. The rational of using 
131
I 
instead of 
18
F was to assess dose to organs from a radionuclide that emits both short-ranged beta 
particles and gamma rays that deposit dose at larger distances. 
18
F decays mainly through 
positron emission and the high energy annihilation photons do not deposit as much dose 
compared to the beta-emitting radionuclides used in TRT. In general, the organ doses from the 
NURBS models are within 10% of those generated using manually-segmented organ maps with 
the exception of lung dose in patients 1 and 3. The lungs have low uptake of 
18
F-FPEB and the 
increased lung doses in the patient-specific NURBS models could be due to the erroneous 
inclusion of high-activity pulmonary veins and arteries and liver in the NURBS surfaces defining 
the lungs. We conclude that using deformable NURBS to define patient anatomy does not 
contribute to the uncertainty in dose estimates to a greater extent than other factors such as 
accuracy in activity quantification and statistical error from MC simulation. 
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Summary 
We have developed a new method for creating patient-specific models by deforming a 
NURBS-based anthropomorphic reference phantom. The software creates an interactive 
environment for the user to easily transform organ models using patient CT data as a guide. 
Models of patient anatomy ranging from the shoulders down to the bottom of the pelvis can be 
created in a few hours. Using deformable models significantly reduces the time required to 
outline patient anatomy compared to conventional manual and semi-automatic segmentation. 
This chapter has demonstrated a preliminary method for creating NURBS-based patient-specific 
models for use in dose optimization for TRT.  
Currently, the software employs a single reference phantom representing a 50
th
 percentile 
person. Substantial modifications to the reference anatomy may be required depending on the 
height and weight of the patient. NURBS-based reference phantoms of larger and smaller normal 
stature (Marine et al. 2010) and different levels of obesity (Clark et al. 2010) have been 
developed. The process of creating patient-specific NURBS models described in this chapter 
may be expedited by matching the patient to a reference phantom using patient information 
including height, weight and body-mass index. 
Phantom Morphus includes a novel algorithm to fit a reference surface to a point cloud 
outlining the boundary of the patient organ. This non-rigid transformation exploits the local 
surface modification property of the model’s control points to create an accurate representation 
of the patient organ. The current algorithm performs a least squares minimization of the distance 
between cloud points and the surface point. It has been shown that using different minimization 
schemes such as tangent distance minimization (TDM) and surface distance minimization 
(SDM) yield faster convergence and prevent the system from becoming trapped in a local 
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minimum that may create surfaces with self-intersections (Cheng et al. 2004, Wang et al. 2006). 
Employing SDM in the Phantom Morphus surface fitting algorithm may increase efficiency and 
produce more accurate surfaces. 
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CHAPTER V  
 
APPLICATION TO PATIENT STUDIES 
 
Introduction 
Understanding tumor response and normal tissue toxicity are vital for successful treatment 
using TRT. Each patient has different pharmacokinetics and fixed activity protocols result in 
vastly different doses to both healthy and malignant tissue. Treatment optimization in TRT using 
image-based3D patient-specific dosimetry requires measuring the spatial distribution of 
radioactivity over time to obtain an absorbed dose calculation based on administration of a small 
tracer amount of radioactivity. Measurement of temporally-dependent spatial distributions of 
radioactivity involves acquisition a set of SPECT/CT or PET/CT images at several time points 
after administration of the tracer dose. 3D dose rate maps are generated from the time-sequence 
activity information, which are then integrated to determine the absorbed dose. Predicted organ 
and tumor doses, along with dose limits to organs at risk and knowledge of tumor-dose response, 
are used to optimize the therapeutic administered activity. 
In this chapter we present results of patient-specific dose calculations two follicular NHL 
patients treated with 
131
I-labeled tositumomab (Bexxar®). VIDA was used to predict dose from a 
tracer study and also determine the actual administered absorbed dose from treatment based on 
post-therapy imaging. 3D dose maps were obtained using both manually-segmented patient 
anatomy and from a patient-specific NURBS phantom generated using the techniques described 
in chapter 4. Results were compared to standard reference doses from RADAR adult phantom 
and tumor doses from the Dose Planning Method (DPM) MC software (Dewaraja et al. 2009, 
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Howard et al. 2011, Wilderman & Dewaraja 2007) using the same tumor VOIs in order to 
minimize error due to differences in segmentation between institutions. The content presented in 
this chapter is an extension of a paper by S. D. Kost, Y. K Dewaraja, R. G. Abramson and M. G. 
Stabin, “VIDA: A voxel-based dosimetry method for targeted radionuclide therapy using 
Geant4”, © Mary Ann Liebert, Inc., reprinted with permission, from Cancer Biotherapy and 
Radiopharmaceuticals, vol. 30, pp. 16-26, 2015 (Kost et al. 2015). 
Methods 
Patient Data 
Individualized dosimetry was performed for two NHL patients treated with 
131
I-labeled 
tositumomab (Bexxar®) using multiple SPECT/CT scans. The treatment protocol is summarized 
here; additional details are described in Dewaraja et al. (Dewaraja). All patients participating in 
the study provided written informed consent for the additional SPECT/CT scans not included in 
the clinical protocol.  
SPECT/CT images were acquired using a Symbia TruePoint system (Hoffman Esta, IL). 
Each patient was imaged at three time points after administration of a diagnostic tracer of 
approximately 185 MBq. Therapeutic doses were administered to deliver a nominal whole-body 
absorbed dose of 75 cGy based on post-tracer imaging (see Table V.1). Patients were imaged 
again at three time points post-therapy, with a delay for the first scan of approximately 48 hours 
due to dead time and exposure considerations (Patient 1, 47.5 hours; Patient 2, 48.58 hours). 
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Table V.1: Administered tracer and therapy activity and whole body pharmacokinetics. 
 Patient 1 Patient 2 
Administered tracer activity (MBq) 189 196 
Tracer effective half-life (hours) 60 48 
Tracer residence time (hours) 40 38 
Administered therapy activity (GBq) 3.74 3.43 
Therapy effective half-life (hours) 61 46 
Therapy residence time (hours) 41 38 
 
SPECT/CT images were acquired with a 128×128 matrix and a pixel size of 4.8 mm 
using a high-energy parallel-hole collimator. Scatter correction was performed using the triple-
energy-window technique. The CT data were reconstructed to an image size of 512×512×196 
using commercial software. Quantitative SPECT with an array size 512×512×78 was obtained 
with a custom 3D OSEM reconstruction algorithm using 35 iterations and 6 subsets. The 
reconstruction algorithm includes 3D depth-dependent detector-response compensation, 
attenuation and scatter correction, and dead-time correction for the post-therapy projection data.  
Image counts were converted to activity using a calibration factor specific to the 
SPECT/CT scanner and radionuclide. The calibration factor was obtained from measurement of 
a 100 ml plastic sphere filled with a known amount of 
131
I activity placed in an elliptical water 
phantom. Recovery coefficients for partial volume correction were not applied as tumor and 
organ volumes were large and there is no widely accepted, well-validated method for voxel-by-
voxel compensation. Additional details of image acquisition, reconstruction and activity 
quantification for this dosimetry study are included elsewhere (Dewaraja et al. 2009, Dewaraja 
et al. 2005, Dewaraja et al. 2010). 
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Patient-Specific Anatomical Models 
Patient anatomy was defined using two methods. Tumors and normal tissue organs were 
segmented on the high resolution first post-tracer CT image (512×512×196 matrix, 
0.98×0.98×2.0 mm voxel size) using a combination of manual and semi-automatic segmentation 
techniques included in the ITK/SNAP toolkit (Yushkevich et al. 2006). Organ volumes were 
verified and tumors were identified by a subspecialty radiologist with experience in both body 
CT and nuclear medicine. Additionally, patient-specific NURBS models were created using the 
CT scan from first post-tracer SPECT/CT study following the methods described in Chapter 4. 
The NURBS phantoms were only used to model patient organs and not to define tumor volumes. 
Voxel-based Dosimetry 
Dose rate maps at each time point were obtained using VIDA (see Chapter 3). An organ 
ID map defining different materials for simulation (see Table C.1) was automatically generated 
from the CT images in a pre-processing step using MATLAB. First, CT images were converted 
to density maps using a bi-linear fit calibration curve relating HU to material density based on 
data from Schneider et al. (Schneider). Air was defined for voxel densities less than 0.15 g/cm
3
, 
lung by a range of 0.15 g/cm
3 
to 0.61 g/cm
3
, soft tissue between 0.61 g/cm
3
 and 1.17 g/cm
3
and 
whole bone greater than 1.17 g/cm
3
. Activity maps were sampled to simulate 20 million events, 
resulting in relative errors in the deposited energy of less than 1% in whole organs and a 
maximum of 10% for individual voxels in the tumor and organs of interest. The voxel-tallied 
energy deposited was converted to absorbed dose using voxel masses derived from the 
simulation tissue densities (see Table III.1). Instantaneous dose-rate maps per administered 
activity were generated by scaling the dose deposited in each voxel by the ratio of actual field-of-
view activity to simulated activity. 
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Conversion to 3D Absorbed Dose 
Each 3D deposited energy map from the MC simulation was converted to an 
instantaneous dose-rate map using voxel masses calculated from the materials in Table III.1. CT-
based registration of serial dose-rate images was performed with an affine rigid registration 
algorithm based on maximizing mutual information (Viola & Wells III 1997) developed by the 
Vanderbilt University Institute of Imaging Science. The CT images were down-sampled to a 
resolution of 256×256×78 (1.95×1.95×5.0 mm) to match the slice thickness of the SPECT data 
and to expedite registration. The CT image set of the first post-tracer scan was assigned to be the 
reference image in the registration algorithm. All other time points were registered to the 
reference image by first performing CT–CT registration and applying the transformation 
matrices to the corresponding dose-rate maps. 
Voxel-level dose-rate curves were fit to a mono-exponential decay function for both the 
pre-therapy tracer data and the post-therapy scans using the exponential fitting tool in VIDA. An 
absorbed dose map with voxel dimensions of 3.9×3.9×5.0 mm
3
 (128×128×78 array) was 
generated using the option to fit a voxel dose curve to all data in the corresponding 2×2×1 cell 
array of the higher resolution dose-rate maps. This resolution was chosen to improve fit results, 
decrease processing time, and estimate voxel doses at the resolution of the SPECT camera (full 
width at half maximum ≤ 3.9 mm). 
Tumor and Organ Dosimetry 
Malignant lymphomas can be highly sensitive to radiation, leading to measurable changes 
in volume within the first few days of treatment (DeNardo et al. 1998). The effect of tumor 
regression on absorbed tumor dose was investigated by defining tumor VOIs on the CT at each 
time point. The average absorbed tumor dose was calculated by fitting the volume-adjusted dose 
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rate curve. A comparison was made to mean absorbed tumor doses from the DPM MC software
 
(Dewaraja et al. 2009, Howard et al. 2011, Wilderman & Dewaraja 2007) using the same tumor 
VOIs in order to minimize error due to differences in segmentation between institutions. 
Organ dosimetry was performed based on both the manually-segmented images and 
patient-specific NURBS phantoms. Manually-segmented organ maps were down-sampled to 
same size of the dose map (128×128×78). Organ maps were also created by voxelizing the 
NURBS phantoms this resolution. Because tumors were not explicitly modeled in the patient-
specific NURBS models, the manually-segmented tumor volumes were added to the voxelized 
data in a post-processing step. Mean absorbed organ doses were compared to reference doses 
calculated for the RADAR phantom, with correction for differences in organ mass between 
patient and reference phantom. Tumor dose-volume histograms were also generated for both the 
predicted dose using the tracer study results and the actual delivered dose assuming a static 
initial tumor volume. 
Results 
SPECT/CT images with tumor outlines and resulting dose maps for each patient are shown 
in Figure V.1. Between the initial tracer study and the last imaging point post-therapy, significant 
decreases in both tumor volumes occurred (see Table V.2). When accounting for shrinkage, the 
tumor dose differed as much as 16% compared to the mean absorbed dose to a static volume. 
Table V.2 also lists the mean tumor doses with decreasing mass calculated using the DPM MC 
software. Mean tumor doses from VIDA and DPM agree within 12% or less. 
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Figure V.1: Fused SPECT/CT images for (a) Patient 1 and (b) Patient 2 with matching 3D dose 
maps overlaid on CT for (c) Patient 1 and (d) Patient 2. Dose maps are displayed in Gy. 
Table V.2: Comparison of mean absorbed tumor doses between VIDA and DPM. 
 
Patient 1:  
Abdominal Tumor 
Patient 2:  
Lt. Axillary Tumor 
Initial tumor volume ( ml) 269 226 
Total tumor shrinkage 53% 23% 
 VIDA DPM VIDA DPM 
Predicted dose, static vol. (cGy) 291 — 153 — 
Predicted dose, changing vol. (cGy) 292 261 (12%) 154 164 (-6.1%) 
Delivered dose, static vol. (cGy) 196 — 150 — 
Delivered dose, changing vol. (cGy) 252 266 (-5.3%) 151 162 (-6.8%) 
Relative difference defined as 100 × (DVIDA – DDPM) / DDPM. 
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Figure V.2: Patient anatomy defined by (a) manual segmentation and (b) deformable NURBS. 
Patient-specific anatomy was defined using two different methods, by manually-
segmented organ volumes and a deformable NURBS model (see Figure V.2). Mean absorbed 
doses to tumor and organs were calculated for both types of patient models and compared to 
results from dose factors derived from the RADAR adult male reference phantom (Stabin et al. 
2012) and the unity density sphere model (Stabin & Konijnenberg 2000). Organ doses are 
reported only if the entire volume was included in the field of view. With the exception of heart 
dose in patient 1, the organ doses from the patient-specific NURBS models agrees with manually 
segmented organs within 10%. In all cases, the mean absorbed doses to organs in NURBS model 
were larger. Compared to the reference phantom, patient organ doses differed by 3 to 19%. 
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Table V.3: Mean absorbed doses to organs and tumors from post-therapy dosimetry. 
 Patient 1 Patient 2 
 
VIDA Dose (cGy) 
RADAR Dose 
(cGy) 
VIDA Dose (cGy) 
RADAR Dose 
(cGy) 
Organ 
Segmented 
Model 
NURBS 
Model 
Segmented 
Model 
NURBS 
Model 
Lungs — — — 221 224 [1%] 254 (-13%) 
Heart 411 504 [23%] 438 (-6%) 311 322 [7%] 380 (-18%) 
Spleen 186 207 [11%] 191 (-3%) 183 189 [3%] 160 (14%) 
Liver 223 246 [10%]  210 (6%) — — — 
Kidneys 190 194 [2%] 160 (19%) — — — 
Tumor 196 — 187 (5%) 150 — 135 (11%) 
Relative percent differences (in brackets) defined as 100 × (DNURBS – DManual) / DManual  
Relative percent differences (in parentheses) defined as 100 × (DVIDA – DRADAR) / DRADAR 
 
Additionally, tumor DVHs (see Figure V.3) were generated using volumes from the first 
post-tracer scan for both the predicted dose from the tracer study and the delivered dose from 
treatment. The first post-tracer time point, scaled by the ratio of activity administered for the 
therapy and tracer studies, was included in the therapy data set due to the lack of an early 
imaging time point. 
 
Figure V.3: Tumor DVHs from tracer and therapy scans for (a) Patient 1 and (b) Patient 2. The 
tumor volumes were taken from the first post-tracer scan. 
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Discussion 
We have performed SPECT-based tumor and organ dosimetry for patients receiving 
131
I 
RIT using VIDA and patient-specific anatomical models created from a deformable NURBS 
phantom using the Phantom Morphus software. This study investigated VIDA’s treatment of 
non-uniform activity distributions and clinical utility of using deformable phantoms in TRT dose 
assessment. Tumor doses, accounting for volume changes over the scan times, were compared to 
DPM MC, offering an additional validation of VIDA for application to patient dosimetry. 
Tumor volumes were manually segmented from the CT for each time point by a 
radiologist with expertise in body CT. When we account for changes in tumor volumes, the 
tracer-predicted tumor doses concur with the delivered therapeutic dose within 16%. For both 
patients, the tracer scans over-predict the delivered dose, although the difference for patient 2 is 
very small. This trend is consistent with a previously reported study (Dewaraja et al. 2009). The 
therapy-delivered mean absorbed doses were compared to results from DPM MC using the same 
tumor volumes. With the exception of the tracer study for Patient 1, the tumor doses from VIDA 
are lower by 5–7% compared to DPM. Our dose rates for the changing tumor volumes were 
derived from mean values from the 3D energy deposited maps for the tumor VOI defined at each 
time point. These volume-averaged dose rates were fit to a bi-exponential curve and directly 
integrated to determine the mean tumor dose. In comparison, the calculation of the mean tumor-
absorbed dose using DPM involves a piecewise integration of the absorbed dose rates over three 
time periods using a mixed model fit (Schipper et al. 2012). These varying approaches may 
account for the discrepancies in tumor dose, even though the differences in instantaneous tumor 
absorbed-dose rates between the two simulations were less than 2%.  
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Figure V.4 Overlay of high heart activity uptake in patient 1 on CT image 
Mean absorbed organ doses from the patient-specific NURBS models were compared to 
manually-segmented data with relative differences of 1% to 23%. That largest difference occurs 
in the heart dose for patient 1. This could be due to the high activity in blood (see Figure V.4) in 
conjunction with the smaller heart volume in the NURBS model (-8.3%) compared to the 
manually-defined heart VOI. The smaller NURBS surface may fail to encompass regions of the 
outer heart wall that received lower doses, skewing the mean absorbed dose higher. All other 
NURBS organs showed good agreement with doses from the manually-segmented patient model 
with organ doses higher in the NURBS models in all patients. The bias towards higher doses in 
the NURBS organs may be due to their larger organ volumes, with differences ranging from 1% 
to 15%. However, this trend was not observed in the validation study of patient-specific NURBS 
models and no correlation between volume differences and the over- or underestimation of organ 
dose is indicated (see Chapter 4). One possible explanation for the higher doses may be the way 
the NURBS surfaces are voxelized, leading to a systematic difference in absorbed dose. Another 
contributing factor to the differences in organ doses may be slight errors in the registration 
between the NURBS model and 3D absorbed dose map. As this study consisted of only two 
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patients, further investigation must be performed in order to fully quantify any effect organ doses 
calculated using patient-specific NURBS models in 3D image-based time-sequenced TRT 
dosimetry. 
Patient mean absorbed organ doses from the manually-defined volumes and patient-
specific NURBS model were compared to doses from a reference phantom with relative 
differences less than 20% (see Table V.3). The differences could be caused by several different 
factors. The reference dose calculations were performed based on activity in user-specified 
source organs. Activity in the rest of the field of view was assigned to the body remainder. The 
dose to target organs from the body remainder activity is calculated based on a uniform 
distribution of this activity spread across the entire volume in the phantom (including arms and 
legs). Thus, we would expect the reference organ doses to be lower compared to VIDA where 
dose is deposited in target organs from activity solely from the available field of view. Also, 
there are slight differences in the material densities and compositions in VIDA compared to 
those used to generate the SAFs for the RADAR reference phantom. The lung density is lower in 
VIDA by more than 10%, which may account for the underestimation of lung dose for Patient 2. 
Additionally, tumor doses were also compared to self-irradiation doses using the uniform sphere 
model in OLINDA/EXM. As expected, the tumor doses from VIDA are larger by 5-11% due to 
the contribution from the remaining body. 
Tumor DVHs were generated based on the predicted and delivered dose maps (see Figure 
V.3). Tumor volumes were defined based on segmentation of CT from the first post tracer scan. 
It is difficult to assess the impact of tumor regression on 3D dose heterogeneities, and mass 
changes across the imaging time period were not incorporated in the DVHs. Both patients exhibit 
more conformal dose distributions for the delivered tumor dose compared to the tracer-predicted 
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distribution. The maximum delivered dose is also lower compared to the predicted DVH. One 
possible explanation for these differences is an increased antibody clearance in tumor cells after 
treatment due to radiobiological damage caused by the tracer dose, as previously suggested by 
Eary et al. (Eary). 
Many contributing factors make estimating the uncertainty in organ and tumor doses for 
patient studies difficult. When performing voxel-based patient dosimetry using MC, there are 
multiple sources of error, including the quantification of the activity distribution, the fidelity of 
the registration process between the serial SPECT/CT scans, and the ability to properly define 
organ and tumor volumes. Also, fitting voxel dose rates with a limited number of time points 
may introduce additional uncertainty. Acquisition of more than 3 sequential SPECT scans post-
tracer or post-therapy administration would reduce uncertainty in the 3D dose from the fitting 
process but may be prohibitive in the clinical environment.  
The 3D OSEM reconstruction methods used for the patient studies in this work have 
produced quantitative results within 10% for volumes 16 ml and larger without partial volume 
correction (Dewaraja et al. 2005). Furthermore, the organ and tumor volumes in the patient 
studies presented here are sufficiently large, preventing partial volume effects from being a 
significant source of error in the average absorbed doses. MIRD Pamphlet 23 recommends PVC 
for objects less than dimensions of 3 × Full Width at Half Maximum (FWHM) of the spatial 
resolution of reconstructed images, but a well-validated method for voxel based corrections for 
SPECT has yet to be developed (Dewaraja et al. 2012). Therefore, voxel-level PVC was not 
applied prior to using the activity distributions in VIDA. In order to mitigate the uncertainty in 
reported doses due to partial volume effects, we limited the voxel resolution of the 3D dose map 
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to 3.908×3.908×5 mm
3
, a factor of four larger than the original reconstructed image resolution 
and on the order of the intrinsic FWHM of the SPECT system used to acquire the data. 
Image registration accuracy for 3D internal dosimetry has been discussed previously (He 
& Frey 2010, Papavasileiou et al. 2007, Sjögreen-Gleisner et al. 2009). Availability of high 
resolution co-registered SPECT/CT images in our patient studies permitted CT based 
registration. Thus, possible errors in SPECT-SPECT registration from poor spatial resolution and 
temporal variability in the activity distributions were avoided. A mutual information rigid 
registration algorithm was used in this study. Non-rigid techniques have been shown to provide 
the most robust results; however only small differences in doses for volumes of interest were 
found between rigid and non-rigid registration (Sjögreen-Gleisner et al. 2009). Nonetheless, rigid 
registration may affect the accuracy of the 3D dose to the axillary tumor in Patient 2, as non-rigid 
movements are more likely to occur in the neck and shoulder region of the body. An effort to 
quantify the effects of mis-registration on 3D patient dose was beyond the scope of the present 
study. 
Organ segmentation may also contribute to the uncertainty in reported doses. Errors in 
structure are typically small compared to those from image registration; however erosion or 
dilation of the volume by only one voxel can contribute as much of 7% difference in activity (He 
& Frey 2010). Because volume of interest definition is typically a subjective task reliant on 
human observation, it is difficult to predict the true magnitude of the error. The tumor volumes 
were identical in VIDA and DPM to avoid segmentation uncertainties in our relative dose 
comparisons, but no assessment was done to determine the error in the defined volumes outlined 
by the radiologist compared to the true physical volumes. Additionally, tumor volumes were not 
created in the NURBS models, although there are tumor surfaces included in the reference 
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NURBS phantom. It is possible to outline the tumor and fit these structures to NURBS surface. 
The accuracy of this method and its impact on tumor dosimetry is an area of future investigation.  
Summary 
Evidence of correlation between patient outcomes and dosimetric quantities including tumor 
absorbed dose and equivalent biological effect (Dewaraja et al. 2014), and between organ dose 
and toxicity (Bodei et al. 2008, Stillebroer et al. 2012) exemplifies the benefit of performing 
patient-specific treatment planning in TRT. In this chapter, we have shown how VIDA can be 
used to predict 3D tumor and organ doses from time-sequenced SPECT/CT scans acquired after 
tracer administration of radioactivity. Despite requiring time-intensive Monte Carlo simulations, 
dosimetry results from VIDA can be obtained within 24-48 hours of obtaining the final image set 
of the study. Thus, VIDA is capable of performing treatment planning with a similar timeline as 
accepted clinical procedures for dose optimization and quality assurance in external bean 
radiation therapy.  
In this clinical study, we also reported organ doses using patient-specific anatomy derived 
from a deformable NURBS model. Our results show that dosimetry using organ volumes from 
NURBS-based phantoms agree within 1–23% of doses obtained from manually-segmented 
volumes of interest. The reduction in time required to create a patient-specific NURBS model 
compared to conventional segmentation techniques (i.e. 2–3 hours versus 8–12 hours depending 
on field of view, organs at risk and inclusion of individual bone surfaces) resolves one of the 
major impediments to performing dosimetry in TRT clinically. 
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CHAPTER VI  
 
DISCUSSION AND CONCLUSIONS 
 
Summary of Results 
Recent advancements in health care have ushered in the era of personalized medicine with 
the goal of tailoring medical treatment to the individual. Targeted radionuclide therapies offer the 
prospect of highly individualized cancer treatments. However, the necessary dose assessment 
required to optimize patient treatment is not routinely employed as a clinical tool. The objective 
of this work was to develop a clinical application to perform patient-specific dosimetry in 
targeted radionuclide therapy with the use of deformable anthropomorphic phantoms. The 
developed dosimetry method includes two separate applications, VIDA to perform 3D dose 
estimation using the Geant4 toolkit and the Phantom Morphus software to create patient-specific 
models from a NURBS-based reference phantom using CT images as a template for the 
transformation. The utility of these applications was evaluated with two studies. Manually 
segmented PET/CT images were compared to the patient-specific NURBS model to investigate 
the ability to construct an accurate representation of a patient using the Phantom Morphus 
software. Application of the dosimetry code to 
131
I RIT patient studies demonstrated the clinical 
feasibility of this method (time, work-flow etc.) and comparison to another dosimetry code 
validated the accuracy of the dose results. 
The first goal of this work was to develop VIDA, a 3D dosimetry application based on 
Monte Carlo simulations performed by the Geant4 toolkit. The application consists of three 
major components, the Geant4 simulation code performs particle transport and tallies energy 
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deposition in each voxel based on user-supplied organ and activity maps, the fitting tool fits 
exponential functions to the time-sequenced dose rate maps and integrates the fit to calculate 
voxel-based absorbed doses, and evaluation of the dosimetry results is performed by computing 
tumor and organ mean absorbed doses and dose-volume histograms. 
Studies have indicated that dosimetric factors, including tumor absorbed dose and equivalent 
biologic effect, are predictive of patient outcomes (Dewaraja et al. 2014). Additionally, our 
application of VIDA to RIT patient studies indicates that tracer dosimetry is a good predictor of 
therapeutic tumor doses (see Chapter 5). Given the importance of accurate dose estimates to 
predictive outcomes, VIDA can be used for patient-specific treatment planning in a clinical 
setting. VIDA’s workflow is designed to calculate voxel-level dose rate maps from a set nuclear 
medicine studies acquired at several time points after the administration of a tracer amount of 
radioactivity and integrate these over time. Although this approach requires multiple MC 
simulations, it does not impose additional time to perform the dosimetry as each simulation 
commences soon after the completion of each scan, exploiting the time interval between image 
acquisitions. The time-limiting step is the dose-rate simulation of the last scan and the voxel-by-
voxel integration of dose rates. Simulation of dose-rate maps with relative uncertainties of less 
than 10% in each voxel by VIDA require approximately 20 hours to complete without parallel 
computing; these times are on the order with other 3D dosimetry codes (Furhang et al. 1997, 
Marcatili et al. 2013). Therefore, patient-specific dose estimates can be completed within 48 
hours of the last tracer scan. This time frame is comparable to the treatment planning timetable 
for external beam therapy, as the completion of intensity-modulated radiation therapy planning 
and quality assurance requires at least two days after acquisition of the patient CT. We conclude 
that VIDA is a viable method for prospective image-based treatment planning for patients 
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receiving TRT. The ability to predict tumor and organ doses and optimize delivered dose lends to 
improved treatment outcomes and minimizes toxicity and harmful side-effects. 
The second and third objectives of this work were the development of a software application 
to create NURBS-based patient-specific anatomical models using patient CT as a template and 
the evaluation of these models compared to manually-segmented volumes, the current gold 
standard in TRT. The Phantom Morphus software developed as a part of this dissertation 
provides an interactive platform for a user to deform a reference NURBS model based on patient 
anatomy from CT imaging. This approach significantly reduces the time required to define 
volumes of interest for dose assessment. Additionally, the use of the NURBS XCAT phantom 
offers a new method of modeling bone marrow in the skeleton as each bone surface contains a 
marrow cavity that can be populated with red marrow voxels. Bone marrow is often the dose-
limiting organ when radiolabeled antibodies are employed (i.e. RIT) and the ability to measure 
dose to red marrow regions of the skeleton when MC simulation is employed may provide an 
alternative method for estimating dose compared to analysis of activity in blood. The ability to 
accurately model patient anatomy using deformable models was assessed using PET/CT studies 
of four patients. Evaluation metrics including total volume difference, percent volume overlap 
and average surface distance error were used to compare the NURBS models to careful slice-by-
slice manual segmentations. Overall, the NURBS organs were in good agreement with manually-
segmented volumes and the differences observed were similar to results by controlled observer 
studies of other automatic and semi-automatic segmentation methods (Campadelli et al. 2009, 
Rao et al. 2005, Segars et al. 2009). 
NURBS-based patient-specific anatomical models may have applications other than tissue 
and organ definition in dose assessment. One notable example is tracking tumor motion during 
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treatment with external beam therapy. The XCAT phantom includes 4D models of respiratory 
and cardiac cycles (Segars et al. 2010) that can be used to track the position of the lung lesions 
during treatment. The XCAT phantom contains thousands of anatomical structures. Given this 
complexity, the use of patient-specific NURBS models may expand into other medical 
applications beside cancer radiation therapy as personalized medicine grows.  
The final goal of this work was to apply VIDA and Phantom Morphus to perform 3D 
dosimetry in patients receiving 
131
I RIT for NHL. This study demonstrated the clinical viability 
of these applications and also provided additional validation of the dose results by comparing 
tumor doses obtained using VIDA to another established MC dosimetry method (DPM). The 
tumor doses from VIDA were in agreement with those from DPM within 12%. Likewise, 
differences in organ doses between manually-segmented volumes and NURBS-based models 
were small, with differences being typically 10% or lower. We conclude that the dosimetry 
methods described in this work provide a novel and accurate approach to dose assessment in 
TRT and form a practicable solution to performing clinic patient-specific dosimetry prior to 
therapeutic treatment, which is currently not widely available. This will permit optimized 
treatment for each patient, hopefully leading to better outcomes and longer survival. 
Future Work 
Currently, the methods for performing patient-specific dosimetry described in this work are 
contained in individual applications. The Phantom Morphus software is a stand-alone application 
used to create patient-specific NURBS models. The resulting model is then converted to a voxel 
format by a command line voxelization program and must be registered to the activity data. Prior 
to running VIDA Monte Carlo, additional processing steps are necessary to create an activity 
map with the desired number of decay events and to ensure the model is registered to the activity 
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data. These steps are completed in MATLAB. Once 3D energy deposited maps are generated 
from the MC simulations, these time-sequenced maps are converted o dose-rate maps and co-
registered using custom MATLAB scripts. The voxel-by-voxel exponential fitting is performed 
using VIDA’s fitting tool, and the resulting 3D integrated dose map is used to generate tumor 
and organ DVHs and mean absorbed dose values. The future direction of this project will focus 
on integrating these processes, with the exception of the MC simulation typically performed on a 
computing cluster, into a single comprehensive software package. 
Future work will also emphasize optimization of MC simulations to increase computational 
efficiency. Beginning with the release of Geant4 version 10.0 (December 2013), multi-threaded 
processing is possible to allow for efficient execution of simulations using parallel computing 
architectures (Cosmo, G. (). Multi-threading occurs at the event level, and the generation of 
events in parallel leads to a linear speed up of processing time with the number of threads used. 
Running VIDA on a computing cluster using the multi-threading capabilities of Geant4 10.0 
would result in decreased simulation time, greatly reducing the overall time required to perform 
patient-specific treatment planning in TRT in a clinical setting. Furthermore, it is possible to 
decrease simulation run times by altering the way Geant4 navigates voxel boundaries. We plan 
on investigating modification of the voxel search algorithm for parametrized volumes to increase 
simulation efficiency (Jiang & Paganetti 2004). Others groups, who have performed voxelized 
dose calculations with this customized geometry navigation library, have seen run time 
improvement of two orders of magnitude (Sutherland et al. 2007). If the impact on VIDA’s 
simulation time is similar, the particle transport can be performed in a matter of minutes 
compared to around 20–30 hours. 
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The method for creating patient-specific NURBS models can be advanced and improved. 
We aim to optimize the point cloud surface fitting algorithm using surface distance minimization 
instead of the current point distance method. The addition of different reference phantoms sizes 
as a starting point for creating patient-specific models may shorten the overall time required to 
deform the reference organs to match the patient. As mentioned earlier, more and more XCAT 
phantoms are being produced which may form a library of reference phantoms. Other NURBS 
phantom libraries may also be used. The inclusion of an atlas of NURBS organs representing a 
variety of morphologies and anatomical orientations that can be interchanged with reference 
anatomies may also facilitate the process and further reduce the fitting time. 
The scope of this work was limited to the assessment of absorbed dose, namely the amount 
of energy deposited per unit of mass. Because TRT involves the use of open source radioactivity, 
the temporal change in dose rate as the radionuclide decay may play a significant role in the 
biological response to treatment. Studies have shown that incorporation of radiobiological 
modeling in dosimetric analysis may better elucidate tumor-dose response and correlate with 
therapy endpoints (Dewaraja et al. 2014, Dewaraja et al. 2010). Thus, including radiobiological 
modeling in VIDA is a logical extension of this work.  
The study of molecular-based targets is growing and many new radiopharmaceuticals for 
use in TRT have been developed. As the ability to treat disease with targeted radiolabel agents 
grows, so does the necessity for fast and accurate dose assessment. With the ability to quickly 
create anatomical models and perform MC simulation of decay of any radionuclide, the methods 
described in this work provide a foundation for a clinical dosimetry application that can be 
widely distributed with a broad use in many types of targeted radionuclide treatments. 
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APPENDIX A 
 
PHYSICAL PRINCIPLES OF INTERNAL DOSIMETRY 
 
Several fundamental physical principles shape the field of nuclear medicine and the 
methodology behind internal dosimetry. Outlined in this appendix, these principles include the 
modes of radioactive decay and how particles emitted through these mechanisms interact with 
matter. Absorbed dose, the primary measure of the biological effects caused by ionizing 
radiation is formally defined and radiobiological considerations in internal dosimetry are briefly 
described. More in-depth discussions of the physics of nuclear medicine and radiobiology are 
found in textbooks on these subjects (Bushberg et al. 2011, Cherry et al. 2012, Hall & Giaccia 
2006, Stabin 2007, Stabin 2008a). 
Radioactive Decay Mechanisms 
Nuclear medicine involves the use of substances in the form of a drug, chemical, or 
compound labeled with a radioactive isotope to diagnosis or treat disease. Radioactive decay is 
the transition of an unstable atomic nucleus to a lower energy level, producing ionizing radiation 
in the process. Three types of radioactive decay, alpha, beta, and gamma emission, provide the 
physical mechanism for detecting malignant tissue and depositing dose in radionuclide therapy. 
Alpha (α) decay occurs in heavy nuclei with the ejection of an alpha particle consisting of 
two protons and two neutrons (a helium nucleus, 𝐻𝑒2
4 ). Radium decay into the inert gas radon is 
an example of α-decay (see equation A.1). Although not traditionally used in targeted therapy, 
alpha-particle emitters provide high potency and specificity and have been a focus of 
investigation for cancer therapies. The first and only alpha-emitting radiopharmaceutical for use 
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in humans, 
223
Ra dichloride (Xofigo, Bayer Healthcare) for treatment of metastatic castration-
resistant prostate cancer, received FDA approval in 2013 (Parker et al. 2013). 
 𝑅𝑎88
226 → 𝑅𝑛86
222 + 𝐻𝑒2
4  A.1 
Atomic nuclei with a ratio of neutrons to protons that is either too high or too low for 
stability undergo radioactive decay with the emission of a beta (β) particle. Two types of beta 
decay occur. In the case when the nucleus has an excess neutron, the neutron transforms into a 
proton and an electron (β‒ particle) is ejected from the nucleus. The generalized formula for β‒ 
decay is given by equation A.2. 
 𝑛0
1 → 𝑝1
1 + 𝑒− + ?̅? A.2 
Positron (β+) decay results in a nuclear transition for a nucleus with an excess proton. The proton 
transforms into a neutron and a positron and neutrino are ejected from the nucleus (see equation 
A.3). The emission of the neutrino or antineutrino conserves lepton number in the transition. 
 𝑝1
1 → 𝑛0
1 + 𝑒+ + 𝜈 A.3 
Beta decay is characterized by the maximum energy of the emitted particle. However, many 
particles are ejected with energies less than the maximum with the remaining energy carried 
away by the neutrino or antineutrino. This results in a spectrum of beta energies with a mean 
value of approximately one-third of the maximum. 
Beta decay plays a vital role in internal dosimetry. Targeted therapy relies on β‒ emission to 
deliver dose to diseased tissue through electron interactions with matter. PET provides 3D 
functional imaging by coincidence detection of annihilation photons created as secondary 
products of β+ decay. The positron emitted through β+ decay will quickly interact with an 
electron creating an annihilation event and the detection of these photons pinpoints the uptake of 
the radiopharmaceutical.  
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A competing process to β+ decay is electron capture (see equation A.4), in which the number 
of neutrons in the nuclide increases by capturing an orbital electron. Electron capture does not 
directly produce ionizing particles but characteristic x-rays or one or more Auger electrons are 
released to fill the vacancy of the inner shell electron. 
Radioactive decay events often leave the progeny nucleus in an excited energy state. The 
nucleus returns to the ground state via isometric decay producing one or more gamma rays with 
characteristic energies based on transition probabilities. SPECT detects these gamma emissions 
and provides a method to quantify the activity distribution within the patient. 
In some cases, an isomeric transition occurs by internal conversion where an electron 
interacts with the nucleus and the energy contained in the excited nuclear state transfers to the 
electron. The electron is ejected from the atom with kinetic energy equal to the energy released 
by the nucleus reduced by the binding energy of the electron. In addition to the ejected electron, 
characteristic x-rays or one or more Auger electrons are created when the vacancy of the inner 
shell electron is filled. 
Radioactive decay is a stochastic event and the momentary prediction of which radioactive 
atoms will decay is not achievable. However, given a large sample of radioactive atoms, the 
average rate of decay is an exponential process where the amount of nuclear transformations is 
proportional to the number of unstable atoms present. The mathematical expression for the 
number of radioactive atoms as a function of time is derived from the relationship in equation 
A.5. 
 −
𝑑𝑁
𝑑𝑡
= 𝜆𝑁 A.5 
 𝑝 + 𝑒− → 𝑛0
1 + 𝜈1
1  A.4 
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The minus sign represents that the rate of decaying atoms decreases with time and λ is a 
proportionality constant is known as the decay constant. The left-hand side of equation A.5, the 
number of radioactive atoms undergoing nuclear transformations per unit time, is called the 
activity (A). 
The solution to the differential equation A.5 defines the number of atoms remaining after 
time t given an initial quantity of N0 atoms, given by: 
 𝑁(𝑡) = 𝑁0𝑒
−𝜆𝑡 A.6 
Equation A.6 can be expressed in terms of activity by multiplying both sides by the decay 
constant. Activity behaves exponentially and decreases by a constant fraction in a given time 
interval. 
 𝐴(𝑡) = 𝐴0𝑒
−𝜆𝑡 A.7 
The half-life (T1/2) of a radionuclide is defined as the time required for half of the unstable 
atoms to undergo nuclear transformation, resulting in a residual of 50% of the initial activity. 
Half-life is inversely proportional to the decay constant with the following relation: 
 𝑇1/2 =
ln2
𝜆
 A.8 
Half-life and the decay constant are characteristic of each radionuclide and can vary from less 
than a picosecond to more than billions of years. 
Particle Interactions in Matter 
Particles created during radioactive decay interact with the environment in different manners 
depending on their mass and electric charge. Electrons and positrons interact with other charge 
particles, such as electrons and nuclei in the medium, primarily through the electromagnetic 
force and may produce secondary charged particles capable of their own interactions. Neutral 
particles, such as photons, randomly interact with matter depending on the probability cross-
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sections that are specific to a material. The energy loss from particle absorption, attenuation, and 
scattering is the source of the biological effect of ionizing radiation. Figures in this section were 
adapted from Bushberg et al. (Bushberg).  
Charged Particle Interactions 
Charged particles, including electrons and alpha particles of decay events, continuously 
interact through the Coulomb force with atoms present in matter and lose kinetic energy through 
excitation, ionization, and radiative losses. Electromagnetic interactions occur between a free 
electron and atomic nuclei as well as other electrons in the medium. Heavy charged particles, 
such as an alpha particle, primarily lose energy though coulombic interactions between their 
positive charge and the negative electrons of the absorber atoms. 
Inelastic collision with atomic electrons is the principal process of charged particle energy 
transfer, resulting in the excitation or ionization of orbital electrons in the interaction medium. 
Excitation occurs when some of the energy of the incident particle is transferred to an electron in 
the absorbing material causing promotion to a higher orbital level (see Figure A.1a). The excited 
orbital electron will return to a lower energy level and emit characteristic x-rays or Auger 
electrons (see Figure A.1b). If the energy transferred exceeds the binding energy of the orbital 
electron, the electron is ionized and ejected from the atom. When the impulse of the charge 
particle is large enough, the ionized electron may have sufficient kinetic energy to undergo its 
own interactions as shown in Figure A.2. These electrons are called delta rays and represent an 
indirect method for transferring the charged particle energy to the absorbing medium.  
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Figure A.1: (a) Excitation of orbital electron due to inelastic collision with a charged particle. (b) 
Characteristic x-ray emission from relaxation of excited electron. 
 
Figure A.2: Ionization of orbital electron and subsequent excitation by the δ-ray electron. 
Charged particles are scattered through interactions with atomic electrons in the form of 
elastic collisions. In an elastic scattering event, the total kinetic energy of the colliding particles 
is unchanged. This process is only significant for low-energy electrons and results in small 
energy transfers.  
Electrons also interact with the nucleus in the form of elastic or inelastic collisions. The 
elastic collision of an electron with a nucleus, known as Rutherford scattering, does not produce 
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radiation nor excite the nucleus. The charged particle only loses energy through the recoil of the 
nucleus. The inelastic collision of an electron with a nucleus results in a loss of kinetic energy 
through the deflection of the electron path by the positively charged nucleus. The energy lost is 
carried away by electromagnetic radiation called bremsstrahlung (see Figure A.3). If the electron 
has sufficient kinetic energy, the inelastic collision may excite the nucleus to a higher energy 
level and result in gamma emission through isomeric transition. 
 
Figure A.3: Bremsstrahlung emission due to coulombic interaction between a free electron and 
the nucleus of an atom. 
Positrons, positively charged anti-electrons produced in β+ decay, lose kinetic energy in the 
same way as electrons by excitation, ionization, and radiative interactions. Once at rest, a 
positron interacts with a negatively charged electron and the pair is annihilated. The rest masses 
of the positron and electron are converted to electromagnetic radiation in the form of two 
annihilation photons, each with energy of 0.511 MeV. 
The distance a charged particle travels in matter is dependent on the rate of energy loss, 
which is a function of the type of charged particle and the density of the medium. The amount of 
energy deposited locally along the path length of a charged particle is defined as the linear 
energy transfer and is proportional to the square of the charge and inversely proportional to the 
138 
 
kinetic energy. The total energy loss rate is called the linear stopping power and includes 
radiative losses through bremsstrahlung photons, which may deposit energy at some distance 
from the particle track. 
The range of a charged particle is defined as the distance the particle penetrates the 
interaction medium. Heavy charged particles (α particles) lose energy in a continuous process 
with only slight deflections caused by collisions with atoms and orbital electrons. Thus, the range 
of an α particle is essentially equal to its path length. Electrons may undergo sharp deflections as 
they travel through the interaction medium and follow a tortuous path that is longer than the 
range. Electron ranges are variable even for particles with the same kinetic energy due to 
interaction probabilities. Maximum and mean ranges are calculated by measuring the relative 
number of particles transmitted as a function of the absorbed thickness. 
Photon Interactions 
Photons are electromagnetic radiation with no mass and no charge and because they are 
electrically neutral, they do not interact via the Coulomb force progressively along their path 
length. Instead, the interaction between photons and matter is a stochastic process governed by 
interaction probabilities, resulting in scattering or absorption of the photon. The four major types 
of interactions between photons and matter are coherent (Rayleigh) scattering, the photoelectric 
effect, Compton scattering, and pair production. The most important photon interactions in 
internal dosimetry include photoelectric absorption and Compton scattering due to the creation of 
free electrons that in turn cause ionization effects. Photon interactions via pair production are 
limited to photon energies greater than twice the rest mass of an electron, which exceeds the 
energies typical for gamma emissions of common radionuclides. 
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Coherent scattering is an elastic collision between a photon and a bound electron in an atom, 
resulting in the deflection of the photon without the loss of energy (see Figure A.4). Coherent 
scattering occurs with low energy radiation that is less than the binding energy of the interacting 
orbital electron. Because the photon loses no energy, coherent scattering does not contribute to 
patient dose. 
 
Figure A.4: Coherent scattering of photon from interaction with orbital electron. 
The photoelectric effect is an interaction in which the photon is completely absorbed by an 
atom. The energy absorbed transfers to an orbital electron and causes the electron to be ejected 
from the atom with a kinetic energy equal to the difference between the incident photon and the 
binding energy (see Figure A.5). Photoelectric absorption occurs only when the energy of the 
photon exceeds the binding energy of the shell of the interacting electron. If sufficient energy 
exists, the innermost shell is the most probable electron orbital to participate in the photoelectric 
effect. In low-Z materials such as soft tissue, the binding energies are less than a few keV and 
rarely limit photoelectric interactions.  
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Figure A.5: The photoelectric effect. 
The probability of a photoelectric event is approximately proportional to Z
3
/E
3
, where Z is 
the atomic number of the interaction medium and E is the incident photon energy. For low 
photon energies and high-Z materials, photoelectric absorption is the predominant mechanism 
for photon interaction. 
Compton scattering results when an incident photon interacts with an outer shell electron 
imparting some of its energy to the electron and causing a re-emission of a photon at an angle 
with respect to the original path (see Figure A.6). The electron, initially assumed to be at rest, 
gains kinetic energy and is ejected from the atom. The energy of the scattered photon (E′) 
depends on both the initial photon energy (E0) and the scattering angles (θ) (see equation A.9). 
The amount of energy transferred to the electron ranges from zero to a maximum for a scattering 
angle of 180°.  
 
𝐸′ =
𝐸0
1 +
𝐸0
𝑚𝑒𝑐2
(1 − cos𝜃)
 
A.9 
Unlike the photoelectric effect, Compton scattering is most likely to occur between photons 
and valence shell electrons. The probability is almost independent of the atomic number of the 
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scattering medium and instead is directly proportional to the electron density of the material and 
decreases with increasing photon energy. The maximum amount of energy transferred to the 
Compton electron is very small for low energy photons and is independent of the interaction 
probability. As the photon energy increases, the ratio between photon energy and electron rest 
mass increases and the maximum fractional energy transferred approaches unity for energies 
above 10 MeV. 
 
Figure A.6: Compton scattering of an incident photon. 
Compton scattering is the predominant interaction for gamma ray energies typically 
produced by radionuclides used in nuclear medicine. The ejected electron will interact with the 
absorbing medium and lose energy via excitation and ionization of other atoms. The scattered 
photon may or may not interact again as it traverses the medium. 
Absorbed Dose 
The fundamental metric relating to biological response in radionuclide therapy is absorbed 
dose, the energy absorbed per unit mass of tissue. Absorbed dose is applicable to all types of 
ionizing radiation, both directly and indirectly ionizing sources and can be measured for sources 
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external to the absorbing medium or for radiation distributed within. The absorbed dose (D) is 
expressed in terms of the stochastic quantity energy imparted (ε) and is defined in equation A.10 
as the expectation value of the energy imparted to matter per unit mass (m) at a point (Attix 
1986). The unit of absorbed dose is called a gray (1 Gy = 1 J/kg). 
 𝐷 =
𝑑𝜀
𝑑𝑚
 A.10 
The energy imparted is the difference between the radiant energy of charged and uncharged 
particles entering the volume and the radiant energy leaving the volume, accounting for net 
energy derived from rest mass within the volume (i.e. electron-positron annihilation). For 
indirectly ionizing radiation, as in the case of photons, the energy is imparted to the absorbing 
medium in two steps. First, kinetic energy is transferred from the ionizing radiation to secondary 
charged particles (i.e. electrons and positrons). These charged particles then lose kinetic energy 
to the medium resulting in absorbed dose. The secondary charged particles may also experience 
bremsstrahlung losses that do not contribute to locally imparted energy. 
Radiobiological Considerations 
Although simple and straightforward, absorbed dose calculations do not always predict the 
response of living tissue to ionizing radiation. Factors such as the type of radiation, the radiation 
energy and the rate of energy deposition can influence the biological effects. In nuclear 
medicine, the dose rate varies temporally with the physical and biological decay of the 
radioisotope. The dose rate rises from zero after administration of the activity to a peak value and 
then drops back to zero after many effective half-lives of the source. One method used to 
quantify the effect on response due to dose rate is the Biologically Effective Dose (BED). BED 
is an adjustment of the measured absorbed dose to reflect the expected biological effect as 
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delivered at a reference dose rate. The reference value is chosen to approach zero when the total 
dose is delivered in an infinite number of infinitesimally small fractions (Sgouros et al. 2008).  
BED is based on the linear-quadratic (LQ) model of radiobiological effect that emphasizes 
two distinct types of DNA damage leading to cell death (see Figure A.7). The first type of 
damage occurs when adjacent DNA strands break from a single ionizing event and is 
proportional to the dose. The second type of damage results from two proximal single-strand 
breaks due to separate ionizing events and is proportional to the square of the dose. If only one 
single-strand break occurs, damage may be potentially repairable and is categorized as sub-
lethal. 
 
Figure A.7: The linear-quadratic model of the radiation effect on biological tissue with α the 
number of logs of cell kill per Gy and β the number of logs of cell kill per Gy2. 
BED is expressed as the product of the total physical dose and a relative effectiveness (RE) 
factor that accounts for radiobiological parameters and the dose delivery method (Dale & 
Carabe-Fernandez 2005). The RE factor depends on two principal radiobiological parameters: 
the tissue α/β ratio and the sub-lethal damage recovery constant (µ). The α/β ratio measures the 
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relative importance of the two processes that result in DNA double strand breaks in the LQ 
model (Dale 1985). For therapy with an exponentially decreasing dose rate, the BED is 
expressed in equation A.11 where ?̇?0 is the initial dose rate and λ is the rate constant describing 
exponential loss of activity. 
 𝐵𝐸𝐷 =  
?̇?0
𝜆
(1 +
?̇?0
(𝜇 + 𝜆)(𝛼 𝛽⁄ )
) A.11 
 An alternative method has been proposed for tissue volumes with dose rates that are not well 
fitted with a single decreasing exponential but is rarely implemented clinically as dosimetry 
studies often lack sufficient time points to resolve uptake and clearance-related dose-rate 
differences (Sgouros et al. 2008). 
The relevance of BED to target radionuclide therapy is twofold. One, BED is a useful way 
to compare the effectiveness of targeted therapy to other radiation therapy delivery methods 
including external beam and brachytherapy. Two, absorbed dose values may not be indicative of 
tumor and normal tissue response to certain lower molecular weight targeting agents. The 
biokinetics of these agents differ greatly and pre-clinical and clinical evidence (Wessels et al. 
2008) suggest that the dose rate may be a significant factor in tumor response and normal organ 
toxicity. 
Another radiobiological quantity, equivalent uniform dose (EUD), has potential use in 
assessing tumor response and comparing different tumor absorbed dose distributions across a 
patient population. Accounting for cell kill parameters α and β, EUD is defined as the uniform 
dose that would produce the same biological response as the original spatially-varying absorbed 
dose. EUD is derived by equating the surviving fraction from a uniform absorbed dose to the 
surviving fraction from the probability distribution of normalized BED values (Amro et al. 2010, 
Niemierko 1997, Sgouros et al. 2008).   
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APPENDIX B  
 
FUNDAMENTALS OF NUCLEAR MEDICINE IMAGING 
 
Dosimetry requires knowledge of the spatial distribution of radioactivity within the body. 
Due to the inability to directly measure activity in vivo, tomographic imaging techniques that 
detect emitted particles from radioactive decay have been developed to estimate the 3D 
distribution. Nuclear medicine imaging modalities are characterized by the types of particles 
detected. SPECT imaging relies on the detection of single photons, either x-rays or gamma rays, 
emitted during radioactive decay. PET is an indirect method of imaging radionuclides that decay 
via β+ emission by the detection of pairs of photons produced during an annihilation event 
between the emitted positron and an electron in the body. The basic procedures for SPECT and 
PET imaging are described below; additional details may be found in textbooks on medical 
imaging (Bushberg et al. 2011, Cherry et al. 2012) 
Single Photon Emission Computed Tomography (SPECT) 
SPECT imaging of a radiolabeled pharmaceutical is performed by detecting single photons 
emitted through the radioactive decay process that travel through the body by a scintillation 
camera. The camera rotates around the patient and projection images are taken at different angles 
(see Figure B.1). The camera consists of a collimator, scintillation crystal, photomultiplier tubes, 
and positioning electronics. The collimator serves to focus the camera towards direct emissions 
and minimizes the detection of scattered photons. Photons that pass through the collimator 
interact with the scintillation crystal, typically sodium iodide (NaI). This interaction converts the 
photon energy to visible light that is then collected by an array of photomultiplier tubes (PMTs). 
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The photocathode in the PMT converts the visible light to electrons. The electronic signal is 
amplified as it travels through the PMT array and is processed by the computer electronics to 
determine the position and energy of the event. The number of events collected is proportional to 
the activity at each point. 
  
Figure B.1: SPECT camera and image acquisition. 
One factor that limits the detection sensitivity of SPECT is photon attenuation. As photons 
travel through the body, they interact with tissue and may be scattered or absorbed. This non-
uniform attenuation is dependent on both the distance the photon travels through the body and 
tissue densities along its path (see Figure B.2). The camera cannot distinguish between increased 
counts originating from a point of increased activity or reduced attenuation from photons 
traversing low density tissue (i.e. lungs). Without correction, artifacts of increased counts in 
areas of low attenuation (body periphery and low tissue density) and reduced counts in areas of 
high attenuation (body center and high tissue density) may occur. Correction for attenuation 
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effects requires knowledge of the attenuation coefficient distribution in the patient. Thus, the 
SPECT camera system is coupled to CT to provide co-registered attenuation maps for correction 
during image reconstruction.  
 
Figure B.2: Non-uniform attenuation in SPECT. 
Gamma rays also interact with tissue through Compton scattering causing deflection from 
their original path and a loss in energy. These scattered photons may be detected within the 
photopeak window (see Figure B.3), resulting in reduced image contrast. One approach to 
reducing scatter is to improve the energy resolution of the scintillator as NaI has relatively poor 
energy resolution (e.g. 10% FWHM at 140 keV) and requires a large acquisition window to 
achieve good signal. Semiconductor detectors such as cadmium telluride and cadmium zinc 
telluride offer improved energy resolution between 2–5% for 140 keV gamma rays (Madsen 
2007). Compensation for the reduction in image contrast from scatter may also be achieved using 
energy-distribution-based methods. One example of energy-distribution-based scatter correction 
is the TEW method. Scatter in the photopeak window is estimated by acquiring counts in narrow 
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energy windows on each side of the photopeak and determining the area under the trapezoid 
formed by the signal in each of these windows. 
 
Figure B.3: Compton scattering in SPECT. Scattered photons may be detected in the energy 
window of the photopeak causing decreased image contrast. Correction is made using the triple-
energy-window method, shown by the shaded trapezoid 
Several other degrading factors besides attenuation affect the sensitivity, contrast and 
resolution of SPECT images. SPECT is photon limited with more than 99% of all photons 
emitted in the patient absorbed by the collimator. Noise from low counting statistics in the image 
contributes to loss of contrast. The detection efficiency can be increased by having wider spaces 
between the septa in the collimator, but this reduces the spatial resolution of the image. Thus, a 
tradeoff exists between spatial resolution and efficiency when considering the design of the 
collimator. One way of obtaining a higher counting efficiency without changing the collimation 
is for the SPECT system to have two rotating camera heads. The CDR also contributes to the 
sensitivity and spatial resolution of SPECT. CDR consists of three main components: the 
geometric response, septal penetration, and collimator scatter. Geometric response refers to the 
finite solid angle subtended by the collimator holes. This angle increases with increased distance 
from the detector and resolution is non-uniform with depth (see Figure B.4). While the geometric 
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response can be represented in analytical form, the septal penetration and collimator scatter 
response must be modeled using more advanced techniques such as MC simulation or function 
fitting of point-source measurements (Chun et al. 2013). 
 
Figure B.4: Geometric contribution to CDR. The spatial resolution of the camera decreases with 
increasing depth of the imaging plane. 
The images collected by the SPECT camera are 2D projections taken at different angles. 
These projection images are input into algorithms to reconstruct the 3D distribution of activity. 
Reconstruction algorithms are either analytical or iterative. Analytical reconstruction, such as 
filtered back projection (FBP), uses mathematical solutions to solve the inverse problem of 
determining the 3D activity distribution that forms the projection data. In essence, each 
projection is smeared back along the path of collection and areas of high activity will add 
constructively in the superposition of all projection angles. Analytical reconstruction is simple to 
implement but does not account for image degrading effects including depth-dependent spatial 
resolution, attenuation and scatter. In order to compensate for attenuation and noise, iterative 
approaches to SPECT reconstruction were developed. Iterative reconstruction algorithms start 
with an initial guess of the activity distribution and forward project this distribution through a 
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model of the SPECT camera. The resulting 2D projections are compared to the actual data and 
the difference between them is used to update the original source distribution. This process is 
repeated until convergence is reached. Common iterative algorithms include maximum-
likelihood expectation maximization (MLEM) and OSEM. The MLEM algorithm compares all 
projection data when updating the distribution. The OSEM algorithm is a modification to MLEM 
with data grouped into subsets for comparison between calculated and real projections. Thus, the 
OSEM is computationally more efficient and results in more rapid and accurate data 
convergence. The benefit to iterative algorithms is the ability to incorporate models of 
attenuation, scatter, and CDR specific to the SPECT system. The main limitation to interactive 
techniques is an increased processing time, especially when a large number of iterations is 
required. However, improved computer speeds enabled iterative methods to become the standard 
for clinical SPECT reconstruction.  
Positron Emission Tomography (PET) 
PET imaging is based on the detection of annihilation photons created from the interaction 
of a positron and electron. Thus, PET tracers contain radioisotopes that undergo β+ decay. 
Conservation of momentum requires that the photons are emitted in opposite directions and are 
subsequently detected by a ring of detector elements, shown in Figure B.5. The elements are 
linked electronically and isolate events that occur nearly simultaneously. These coincidence 
events create a line of response (LOR) and form projections that are then reconstructed into 
tomographic images. Because the beta particles only travel a short distance before annihilating 
with an electron, the reconstructed images represent the spatial distribution of radioactivity in the 
body, just as with SPECT images formed by single photon events. 
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Figure B.5: PET imaging acquisition and electronic collimation by coincidence event detection. 
Similar to SPECT systems, the PET detector ring consists of scintillation crystals linked to 
PMTs. However, due to the poor detection efficiency of NaI at the energy of annihilation 
photons (511 keV), scintillation crystals used in PET typically have a higher density and 
effective atomic number, such as bismuth germanium oxide (BGO), gadolinium oxyorthosilicate 
(GSO), or lutetium oxyorthosilicate (LSO). One difference in the PET detector is the lack of a 
physical collimator. Instead, the positional information of an event is defined by the LOR joining 
the two crystal elements that detected the coincidence events, known as electronic collimation. 
Unlike physical collimation, electronic collimation is able to make use of signals from photons 
detected from a range of incident angles and not only those with angles normal to the collimator 
face. This leads to better sensitivity and increased spatial resolution in PET compared to SPECT. 
PET systems typically employ multiple detector rings aligned in the axial direction. These 
camera systems can operate in two different modes. In 2D PET, thin layers of septa are placed 
between the detector rings to reduce interplane scatter. Coincidence events are limited to 
detectors within the same ring or close neighbors. In 3D PET, the septa are removed and LORs 
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are formed between all detector pairs, increasing the overall sensitivity of the camera. Increased 
detector sensitivity reduces patient dose and produces higher quality images with less noise. 
The three types of coincidence events that can be detected, true, scattered, and random are 
illustrated in Figure B.6. In a true event, the photon pair leaves the annihilation site and travel 
through the body without interaction where they are both detected within the timing interval for a 
coincidence event. If one or both of the photons undergoes Compton scattering in the body 
before being detected, a scattered coincidence event forms an incorrect LOR. A random event 
occurs by an incorrect pairing of photons from different annihilations that are detected within the 
coincidence time window. The photon pairs of these detected photons are either absorbed in the 
body or pass through the scintillator without interacting. Both scattered and random events 
contribute to noise in the image with scattered events accounting for up to 40% of the total. 
 
Figure B.6: Types of detection events in PET: (a) true, (b) scattered, and (c) random. The dotted 
lines indicate the assigned and incorrect LOR for scattered and random events 
The resolution of PET is limited by several physical factors. The spatial resolution is 
defined, in part, by the positron range in tissue. Once emitted, the positron will travel a short 
distance, experiencing multiple interactions that reduce its kinetic energy until it slows down and 
annihilates with an electron. The energy and subsequent range of the emitted positron depends 
on the PET radioisotope; for 
18
F, the range in tissue before annihilation is approximately 1 mm 
153 
 
(Levin & Hoffman 1999). Additionally there is a loss in spatial resolution due to non-collinearity 
of the photons that occurs if the positron is not exactly at rest at the time of annihilation. For 
18
F, 
the distribution of angular deviation from 180° was measured experimentally in a patient with 
FHWM of 0.54 degrees (Shibuya et al. 2007). The loss in spatial resolution due to non-
collinearity depends on the diameter of the detector ring and is approximately 1.5 mm (FHWM) 
for an 80-cm system (Levin & Hoffman 1999). 
In order to achieve quantitative results, several corrections must be applied to PET images 
including normalization and compensation for random coincidence, scatter, and attenuation. PET 
image reconstruction is performed with the assumption that all LORs have the same sensitivity. 
However, due to differences in scintillation crystals and PMT response, each detector element 
has a different efficiency. Correction is performed by individual normalization for each. Random 
coincidences must be subtracted from the total number of events. Correction for random events 
is based on the rate of single events in each detector channel (r) and the camera resolving time 
(t). The rate of random coincidences for a given LOR between the i
th
 and j
th
 detector elements is: 
 𝑅𝑖𝑗 = 2𝑡𝑟𝑖𝑟𝑗 B.1 
Another technique for random event correction is delayed event subtraction. Here, a channel is 
created to measure signal from one detector that is delayed by an interval greater than the 
resolving time for true coincidence. The events detected by the delayed channel are not true 
coincidences and represent an estimate of the number of random coincidences in the prompt 
signal. Scatter correction is particularly important in 3D PET where gains in sensitivity are 
coupled to an increase in scattered events. Correction of scattered events is typically performed 
using modeled-based algorithms. These algorithms require knowledge of the attenuation in the 
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patient obtained from CT and a model of the scanner geometry and detector to calculate the 
percentage of Compton scattered photons incident on each detector.  
The necessity of attenuation correction is greater for PET compared to SPECT because 
image data is dependent of the detection of not one but two photons. Attenuation increases image 
noise, artifacts, and distortion and correction is required for both qualitative and quantitative use 
of PET images. This is exacerbated in overweight or obese patients with larger body widths. 
However, unlike with SPECT, attenuation in PET can be determined by an attenuation map 
generated through CT. The probability of detecting each photon is given by: 
 𝑃(𝑥′) = 𝑒𝑥𝑝 (−∫ 𝜇(𝑥)𝑑𝑥
𝑥′
0
) B.2 
where μ(x) is the position-dependent linear attenuation coefficient and x′ is the total path length 
traveled through the photon. Therefore the total probability of detecting both photons is 
 𝑃𝑡𝑜𝑡 = 𝑃1𝑃2 = 𝑒𝑥𝑝 (−∫ 𝜇(𝑥)𝑑𝑥
𝑎
0
) B.3 
where a is the total length of the LOR. The attenuation correction factor is then 1 - Ptot. 
Image reconstruction for PET is similar to SPECT imaging. Analytical reconstruction, 
including FBP, can be applied to both 2D and 3D acquisition modes. In 2D PET, the in-plane 
LORs are arranged to form a set of 1D parallel projections (see Figure B.7); in 3D mode, the 
LORs may be arranged into 2D sets of parallel projections. Although corrections for scatter, 
random coincidences, and the effects of attenuation can be applied to the projection data prior to 
reconstruction, FBP often results in images with amplified noise and streak artifacts. Iterative 
methods alleviate many of the problems of FBP and permit the use of advanced image projection 
models that incorporate detector sensitivity, scatter and random correction models, and artifact 
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and noise reduction techniques directly into the PET reconstruction algorithm. Thus, iterative 
reconstruction improves image quality and yields quantitative results required for dosimetry. 
 
Figure B.7: PET projection data formed from events collected in a single detector ring. 
Advancements in PET imaging include the capability of measuring photon time-of-flight 
(TOF). These systems exploit high light-output scintillators, high-performance PMTs and fast-
timing electronics, to achieve an intrinsic system timing resolution of approximately 600 
picoseconds (Karp et al. 2008). TOF PET systems use the time difference between detection of 
each coincident photon to localize the annihilation event along the LOR. The reduction in 
positional uncertainty results in detector sensitivity gain of up to a factor of four. Therefore, the 
use of TOF information can either decrease the scan time or enhance image contrast in PET. 
TOF PET is particularly useful for imaging large patients, in which increased attenuation and 
scatter results in poor image quality. In order to obtain the same noise-equivalent image for an 
obese patient compared to an average-sized patient, the acquisition time increases dramatically 
and is often unreasonable for clinical imaging. The increased sensitivity of TOF PET leads to 
improved image quality for heavy patients without increasing the scan time.  
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APPENDIX C  
 
OVERVIEW OF MONTE CARLO METHODS 
 
Monte Carlo methods describe statistical sampling techniques that approximate solutions to 
quantitative problems when closed form solutions are not attainable. The method was first 
developed at Los Alamos National Laboratory in 1946 by Stanislaw Ulam and John Von 
Neumann to estimate distances neutrons travel through various materials for radiation shielding 
calculations (Eckhardt 1987). Monte Carlo relies on repeated random sampling to obtain numeric 
results of an unknown probability distribution. Advancements in computer processing and 
architecture in the past 50 years have allowed Monte Carlo modeling and simulation of complex 
systems in many different disciplines. 
Monte Carlo assumes that the system of interest is stochastic in nature, with events and input 
data described in probabilistic terms. The methodology follows three general steps (Harrison 
2010, Raychaudhuri 2008). First, models of the probability density functions (PDFs) defining the 
range of simulation possibilities and their relative probability for each step in the system must be 
created. The PDF is not restricted to an analytical form and may be formulated from 
experimental data, theory or by a combination of data fitting to theory. Once the statistical 
distribution of each input parameter is defined, a set of random numbers is generated to sample 
these distributions to obtain a set of output parameters. This process is repeated, resulting in a 
collection of possible outcomes. The final step tallies the outcomes and statistical analysis is 
performed to provide a statistical confidence of the results as a function of the number of trials. 
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Monte Carlo methods depend on generating a large quantity of random numbers. Truly 
random numbers, such as the time of a radioactive decay event, cannot be created 
algorithmically. Instead, computers generate pseudo-random numbers uniformly over a given 
range of values using a deterministic pattern with an initial “random” seed. These numbers are 
typically sufficient for Monte Carlo, as the goal is to randomly sample large sets of data so that 
the samples are approximately evenly distributed. One benefit of pseudo-random numbers is that 
the sequence can be reproduced for testing or debugging if the same initial seed is used. 
There are various ways to sample continuous or discrete distributions. The inverse transform 
method is the most direct method and can be applied to distributions with invertible PDFs. First 
the integral of the PDF is calculated, denoted as the cumulative distribution function (CDF) that 
is continuous and strictly increasing in [0,1): 
 𝐹(𝑥) = ∫ 𝑝(𝑥)
1
0
 C.1 
Two steps are required to sample a random value x from the PDF. First, generate a random 
number u on the interval [0,1) and locate this position on the y-axis of the CDF. The random 
sample x is given by the inverse of the CDF: 
 𝑥 = 𝐹−1(𝑢) C.2 
The inverse transformation method can also be used when the distribution is discrete. A 
discrete distribution is expressed in terms of the probability mass function (PMF), p(xi), and the 
cumulative PMF is given by: 
 𝐹(𝑥) = 𝑃(𝑋 ≤ 𝑥) = ∑ 𝑝(𝑥𝑖)
𝑥𝑖≤𝑥
 C.3 
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Again, the initial step involves sampling a random number u. The randomly sampled xi from p is 
determined by the smallest positive integer i such that u ≤ F(x). 
The inverse method is used in Geant4 to sample the distance a particle travels before 
interacting with the medium via a specific physical process (e.g Compton Scattering) 
(Agostinelli et al. 2003). The distance to interaction for a given process is determined by the 
mean free path (λ) of the particle. The probability of traveling a distance x without interaction is: 
 𝑃(𝑥) = 𝑒−𝑛𝜆  C.4 
where nλ represents the total number of mean free paths traversed, which is independent of the 
interaction material. 
 𝑛𝜆 = ∫
𝑑𝑥
𝜆(𝑥)
𝑥2
𝑥1
 C.5 
The distance to the point of interaction, s(x), given by the product of nλ and λ(x), can be 
sampled with a random number (η) uniformly distributed in the range (0,1): 
 𝑛𝜆 = −log (𝜂) C.6 
This sampling is performed for all possible particle interactions. The process which returns 
the smallest distance is selected and its post step action is executed. If this is an interaction or 
decay, the particle is “killed” and secondary particles are generated and tracked. If not, the 
particle gets another chance to interact. The number of mean free paths for each unselected 
process is decremented by an amount corresponding to the length of the current step and the 
whole algorithm is repeated. An illustration of reducing the photon interaction lengths during 
Monte Carlo simulation is given in Figure C.1. 
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Figure C.1: Process of reducing photon interaction lengths during Monte Carlo simulation of 
particle interactions in matter. 
In the case when the CDF is not invertible or when the inverse method is computationally 
slow, other sampling techniques may be employed. One such method is the accept-reject 
algorithm, first introduced by von Neumann (Neumann 1951). The acceptance-rejection 
approach is based on the observation that random variable selection is equivalent to uniformly 
sampling the area under the density function. The PDF of an arbitrary distribution f(x) is sampled 
by choosing another distribution g(x) that can be directly sampled, with the only restriction being 
f(x) < M*g(x) for a constant M greater than 1. First, sample x from g(x) and an additional random 
number, u, in the range (0,1). Then, check if u < f(x)/M*g(x). If true, accept x and if not, reject 
the sampling and repeat. This method requires generating 2 random numbers and may lead to a 
lot of unwanted samples depending on the form of the distribution function. The number of 
rejections is exacerbated at higher dimensions and other more sophisticated sampling methods 
such as adaptive rejection sampling or the Metropolis-Hastings algorithm may be more efficient 
(Hastings 1970, Rubinstein & Kroese 2011). 
The results of a Monte Carlo simulation represent an average of contributions from each 
history over the course of the entire sampling. Therefore, Monte Carlo methods are subject to 
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statistical analysis in order to establish the confidence in the results. One way to assess the 
statistical precision of the simulation tally is to estimate the relative error (R): 
 𝑅 = √
1
𝑁
(
𝑥2̅̅ ̅
?̅?2
− 1) C.7 
where N is the number of histories, the mean, ?̅?, is the average value of the scores xi, and 𝑥2̅̅ ̅ is 
the average value of the square of the scores, 𝑥𝑖
2. Equation IV.9 demonstrates that the relative 
error depends on the inverse square root of the number of histories, and in order to reduce the 
uncertainty by a factor of two, one must increase the number of samples by fourfold. It is 
important to note that this statistical analysis only evaluates the precision of the results and not 
the accuracy of how close the simulation estimates the true physical value. More details on 
estimating Monte Carlo precision and factors affecting the simulation accuracy can be found in 
Volume 1 of the MCNP manual (Sweezy et al. 2003). 
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APPENDIX D 
 
MATERIAL TYPES AND INDENTIFIERS FOR ORGANS IN VIDA 
 
Table C.1 lists the identification number and material used for each organ in VIDA. The 
density and composition of each material is defined in Table III.1. The skeleton may be defined 
as either whole bone or separated into cortical bone, red and yellow marrow as designated by the 
user in the simulation input file (Appendix E). 
Table C.1: List of organs and assigned material type in VIDA Monte Carlo simulation.
 
Organ/Region ID Material 
Body (remainder) 1 Soft tissue 
Brain 2 Soft tissue 
Cerebellum 3 Soft tissue 
Brain stem 4 Soft tissue 
Salivary glands 5 Soft tissue 
Esophagus 6 Soft tissue 
Right thyroid 7 Soft tissue 
Left thyroid 8 Soft tissue 
Thymus 9 Soft tissue 
Right eye 10 Soft tissue 
Right eye lens 11 Soft tissue 
Left eye 12 Soft tissue 
Left eye lens 13 Soft tissue 
Right lung 14 Lung tissue 
Left lung 15 Lung tissue 
Liver 16 Soft tissue 
Gall bladder 17 Soft tissue 
Right kidney 18 Soft tissue 
Left kidney 19 Soft tissue 
Right adrenal 20 Soft tissue 
Left adrenal 21 Soft tissue 
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Stomach 22 Soft tissue 
Spleen 23 Soft tissue 
Heart 24 Soft tissue 
Pancreas 25 Soft tissue 
Bladder 26 Soft tissue 
Bladder contents 27 Water 
Ascending large intestine 28 Soft tissue 
Transcending large intestine 29 Soft tissue 
Descending large intestine 30 Soft tissue 
Sigmoid 31 Soft tissue 
Rectum 32 Soft tissue 
Small intestine 33 Soft tissue 
GI contents  34 Soft tissue 
Prostate (male only) 35 Soft tissue 
Right testicle (male only) 36 Soft tissue 
Left testicle (male only) 37 Soft tissue 
Uterus (female only) 38 Soft tissue 
Right ovary (female only) 39 Soft tissue 
Left ovary (female only) 40 Soft tissue 
Right breast 41 50% mammary / 50% adipose tissue 
Left breast 42 50% mammary / 50% adipose tissue 
Air 44 Air 
Skeleton (omitting skull/mandible) 46-74 Whole bone or cortical bone 
Skull 75 Whole skull or cortical bone 
Mandible 76 Whole skull or cortical bone 
Yellow marrow 77 Yellow marrow 
Red marrow 78-108 Red marrow 
Adipose 109 Adipose tissue 
Tumors 111-120 Soft tissue 
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APPENDIX E 
 
SAMPLE INPUT FILE FOR VIDA MONTE CARLO SIMULATION 
 
The following is an example input file (data.dat) used for input to VIDA MC. The file 
indicates the location and names of the organ and activity maps and their dimensions. The user 
defines the source organs for primary events. This may be an individual organ (see Appendix D) 
or an identifier to run the whole body (999) or all organs (555). The user also specifies the 
atomic and mass numbers of the radionuclide and the type of material for the skeleton. The bone 
and marrow IDs can be defined as a single whole bone material (WB) or as distinct cortical bone, 
red and yellow marrow (RM). 
----------------------------------------------------------------- 
Sample data.dat file. The order of inputs is important. 
----------------------------------------------------------------- 
 
./organ_map.txt : 3D organ map file name 
./activity_map.txt : 3D activity map file name 
213 : number of columns 
142 : number of rows 
78 : number of slices 
1.9531 1.9531 5.0 : voxel dimensions, in mm (col, row, slice) 
999 : source organ (999 = body, 555 = organs) 
53 : radionuclide atomic number 
131 : radionuclide mass number 
WB : marrow type (WB = mixture, RM = marrow) 
exit : indicates end of input file 
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